In vitro Metabolic Studies of Dopamine Synthesis and the Toxicity of L-DOPA in Human Cells by Delcambre, Sylvie
  
 
PhD-FSTC-2016-29 
The Faculty of Sciences, Technology and Communication 
 
 
DISSERTATION 
 
Defense held on 15/07/2016 in Luxembourg  
 
to obtain the degree of 
  
 
DOCTEUR DE L’UNIVERSITÉ DU LUXEMBOURG 
 
EN BIOLOGIE 
 
by 
 
Sylvie DELCAMBRE 
Born on 08th of March 1989 in Messancy (Belgium) 
 
IN VITRO METABOLIC STUDIES OF DOPAMINE 
SYNTHESIS AND THE TOXICITY OF L-DOPA IN HUMAN 
CELLS 
 
 
Dissertation defense committee 
Dr Karsten Hiller, dissertation supervisor 
Associate Professor, Université du Luxembourg 
 
Dr Serge Haan, Chairman 
Professor, Université du Luxembourg 
 
Dr Marcel Leist, Vice Chairman 
Professor, University of Konstanz, Germany 
 
Dr Katrin Marcus 
Professor, Ruhr University Bochum, Germany 
 
Dr Carole Linster 
PhD, Université du Luxembourg 
 
 

UNIVERSITY OF LUXEMBOURG
DOCTORAL THESIS
In vitro Metabolic Studies of Dopamine
Synthesis and the Toxicity of L-DOPA in
Human Cells
Author:
Sylvie DELCAMBRE
Supervisor:
Dr. Karsten HILLER
A thesis submitted in fulfilment of the requirements
for the degree of Doctor of Philosophy
in the
Metabolomics Group
Luxembourg Centre for Systems Biomedicine
July 15, 2016

Declaration of Authorship
I, Sylvie DELCAMBRE, declare that this thesis titled, “In vitro Metabolic Studies of
Dopamine Synthesis and the Toxicity of L-DOPA in Human Cells” and the work
presented in it are my own. I confirm that:
• This work was done wholly while in candidature for a research degree at this
University.
• Where any part of this thesis has previously been submitted for a degree or any
other qualification at this University or any other institution, this has been clearly
stated.
• Where I have consulted the published work of others, this is always clearly at-
tributed.
• Where I have quoted from the work of others, the source is always given. With
the exception of such quotations, this thesis is entirely my own work.
• I have acknowledged all main sources of help.
• Where the thesis is based on work done by myself jointly with others, I have
made clear exactly what was done by others and what I have contributed myself.
Signed:
Date:
iii

“One of the deep secrets of life is that all that is really worth the doing is what we do for others”
Lewis Carroll
v

Abstract
In vitro Metabolic Studies of Dopamine Synthesis and the Toxicity of L-DOPA in
Human Cells
by Sylvie DELCAMBRE
This work is divided in two parts. In the first, I investigated the effects of 2,3-
dihydroxy-L-phenylalanine (L-DOPA) on the metabolism of human tyrosine hydrox-
ylase (TH)-positive neuronal LUHMES cells. L-DOPA is the gold standard treatment
for Parkinson’s disease (PD) and its effects on cellular metabolism are controversial.
It induced a re-routing of intracellular carbon supplies. While glutamine contribution
to tricarboxylic acid (TCA) cycle intermediates increased, glucose contribution to the
same metabolites decreased. Carbon contribution from glucose was decreased in lac-
tate and was compensated by an increased pyruvate contribution. Pyruvate reacted
with hydrogen peroxide generated during the auto-oxidation of L-DOPA and lead to
an increase of acetate in the medium. In the presence of L-DOPA, this acetate was taken
up by the cells. In combination with an increased glutamate secretion, all these results
seem to point towards a mitochondrial complex II inhibition.
In the second part of this work, I studied and compared dopamine (DA)-producing
in vitro systems. First, I compared gene and protein expression of catecholamine (CA)-
related genes. Then, I performed molecular engineering to increase TH expression in
LUHMES and SH-SY5Y cells. This was sufficient to induce DA production in SH-SY5Y,
but not in LUHMES cells, indicating that TH expression is not sufficient to character-
ize dopaminergic neurons. Therefore I used SH-SY5Y cells overexpressing TH to study
substrates for DA production. Upon overexpression of aromatic amino acid decarboxy-
lase (AADC), LUHMES cells produced DA after L-DOPA supplementation. This model
was useful to study L-DOPA uptake in LUHMES cells and I showed that L-DOPA is
imported via large amino acid transporter (LAT). In conclusion, the expression of TH
is not sufficient to obtain a DA-producing cell system and this work opened many and
answered some questions about DA metabolism.
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1
Introduction
In this section, I introduce the scientific background and state of the art related to
my PhD project. After a description of Parkinson’s disease (PD) etiology and state of
the art treatment, I focus on dopaminergic systems. This latter part includes a short
historic overview, a brief description of dopamine-producing cells in the body, a more
detailed introduction of dopaminergic neurons in the substantia nigra pars compacta and
finally, a description of the models currently available.
Then, I describe in more detail the biochemistry around dopamine: its synthesis
and degradation as well as its action in synaptic clefts. 2,3-dihydroxy-L-phenylalanine
(L-DOPA) is the direct precursor of dopamine (DA) and is used as a drug to manage
the symptoms of PD. Since L-DOPA is a compound of high interest in the context of
my PhD thesis, I shortly introduce its history together with its toxic effects on cells.
Finally, I introduce the analytical methods used in this work: gas chromatography
- mass spectrometry as well as stable isotope-assisted metabolomics.
1.1 Parkinson’s disease
1.1.1 Etiology of Parkinson’s disease
PD is a common neurodegenerative disease affecting 1-2% of the worldwide pop-
ulation with an age above 65 years [1] and about 5% of the population over 85 years old
in Western Europe [2]. The disease was first reported by James Parkinson in his "Es-
say on the shaking palsy" [3] in which he described, through 6 cases, the main motor
symptoms of the disease: bradykinesia (slowness of movements), rigidity, tremor and
1
2 Chapter 1. Introduction
postural instability. These motor symptoms are associated with the death of dopamin-
ergic neurons within the substantia nigra pars compacta located in the midbrain as well as
with the presence of Lewy bodies [2]. These neurons project their axons to the striatum
where they release a neurotransmitter responsible for movement control: DA [4]. Lewy
bodies are cytoplasmic inclusions formed by the aggregation of ubiquitinated proteins
[5] as well as full length and truncated forms of the protein synuclein α (SNCA) [6]. By
the time of death, 50 to 70% of these neurons degraded leading to a depletion of about
80 to 85% of the DA content in the striatum [7].
Motor symptoms are not the only manifestation of PD. Indeed, other symptoms
such as sleep disorder, loss of taste and smell, constipation and depression can occur
before the start of motor symptoms [8]. The longitudinal course of PD can be followed
using the Unified Parkinson’s Disease Rating Scale (UPDRS), which was developed
in the 1980s. In 2008, a revised version sponsored by the Movement Disorder Society
(MSD) was published. It was designed to be more comprehensive, clearer and more
detailed. It comprises four parts, namely (1) non-motor experiences of daily living, (2)
motor experiences of daily living, (3) motor examination and (4) motor complications.
Some parts are filled by the patient, and a 30-minutes interview with a practitioner is
sufficient to complete the survey [9]. The results of this test help the practitioner to
define treatment options.
The etiology of PD is not fully understood, although it seems clear that genetic and
environmental factors can be involved. A genetic component is thought to be causative
of the disease in approximately 5 to 10% of cases [2]. About 28 chromosomal regions
are known to be linked to PD. From those, only six of these regions are linked to muta-
tions in genes that can individually cause the disease. These genes are SNCA/PARK1,
leucine-rich repeat kinase 2 (LRRK2)/PARK8, Parkin/PARK2, PTEN-induced putative
kinase 1 (PINK1)/PARK6, DJ1/PARK7 and ATPase type 13A2 (ATP13A2)/PARK9 [10].
Interestingly, many of these genes are coding for mitochondrial proteins or for proteins
associated with mitochondria and a mutation in their sequence disrupts mitochondrial
function [11]. PINK1 has a putative serine-threonine kinase domain and is able to re-
cruit Parkin. Parkin has an E3 ubiquitin ligase activity and is recruited to damaged
mitochondria where it promotes mitochondrial fission and mitophagy by ubiquitinat-
ing mitofusin proteins [12]. Moreover, PINK1 has been directly linked to mitochondrial
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complex I activity [13]. Loss of function of PINK1 correlated with a loss of phosphoryla-
tion of a subunit of complex I. This impaired reduction of ubiquinone lead to decreased
mitchondrial potential and to mitochondrial dysfunction [13].
DJ1 is an oncogene and when over-expressed, protects cells from oxidative stress.
When causing PD, however, the mutation induces a loss of function, which increases
intracellular oxidative stress and promotes cell death [14]. An overexpression of α-
synuclein, the main component of Lewy bodies, was also found to alter mitochondrial
function and increase the levels of oxidative stress [15].
Environmental factors include pesticides such as paraquat or rotenone. The for-
mer is a herbicide, which can poorly cross the blood brain barrier (BBB) and its mode
of action is thought to be via the generation of superoxide radicals [16]. Rotenone,
however, is a fish poison and insecticide, which is highly lipophylic and can reach all
organs. It inhibits complex I of the mitochondrial respiratory chain in all cells of the
brain, but only dopaminergic neurons are sensitive and selectively die upon rotenone
intoxication [17]. It binds to the quinone-binding site of complex I [18]. The conse-
quences of this binding are an interruption of movement of electrons leading to a drop
in the availability of adenosine triphosphate (ATP) and an accumulation of superoxide
radicals [19]. Another drug that induces PD-like symptoms is 1-methyl-4-phenyl-
1,2,3,6-tetrahydroxypyridine (MPTP). It was first discovered in 1982 when young drug
users developed parkinsonian symptoms. It appeared that MPTP was a contami-
nation obtained during the synthesis of 1-methyl-4-phenyl-4-propionoxypiperidine
(MPPP), a synthetic opioid drug. Once in the brain, MPTP is oxidized to 1-methyl-4-
phenyl-2,3-dihydropyridinium (MPDP+) by the isoform B of the monoamine oxidase
(MAO) in glial cells or serotonergic neurons, which are the only cell types expressing
this enzyme. Then, MPDP+ spontaneously oxidizes to 1-methyl-4-phenylpyridinium
(MPP+). MPP+ can be taken up by dopaminergic neurons via the dopamine trans-
porter (DAT) where it inhibits complex I of the mitochondrial respiratory chain [20].
1.1.2 State of the art treatment
To date, there is no cure for PD. The available treatments aim at improving the
quality of life of the patients, but their benefits are limited in time and most of them
present major side effects.
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The "gold standard" treatment is L-DOPA, the precursor of DA. Due to its amino
acid-like structure, it has the ability to replenish the neurotransmitter pool by cross-
ing the BBB while DA cannot [21]. The half-life of L-DOPA in plasma is only 60 to 90
minutes [22], but can be improved using several adjunct therapies. One of them is to
use a decarboxylase inhibitor such as carbidopa which will prevent decarboxylation in
the periphery [23]. Aromatic amino acid decarboxylase (AADC) is expressed in the
gastrointestinal tract, blood vessels and liver, which together decarboxylate 90% of the
orally administered dose of L-DOPA [24]. Treatment can be further improved by us-
ing inhibitors of catechol-o-methyl transferase (COMT), one of the enzymes involved in
L-DOPA and DA degradation. It is administered together with L-DOPA and carbidopa
and prevents the conversion of L-DOPA to 3-O-methyldopa by COMT in the gastroin-
testinal tract [25]. Another way to improve L-DOPA half-life is by inhibiting the action
of MAO-B, another enzyme responsible of DA degradation in the brain. Rasagiline and
selegiline lead to an increased synaptic concentration of DA reducing motor fluctua-
tions in PD patients [25]. DA receptor agonists can be used in early PD and delay the
need for L-DOPA treatment. The action of pramipexole and ropimirole is based on the
fact that they stimulate the DA receptors and thus mimic the action of DA. Among the
five DA receptors known, D1 and D2 regulate voluntary movements. Thus, DA recep-
tor agonists act through these receptors and regulate the activity of neurons in the basal
ganglia [25].
Aside from pharmacological interventions, surgical methods are also available to
cope with the symptoms of PD. They include pallidotomy. It consists of the destruction
of cells in the globus pallidus responsible for dyskinesia. However, this intervention has
minor effects on bradykinesia and rigidity. Other interventions include thalamotomy
and thalamic stimulations. The former involves removal of the thalamus, while the
latter consists of the introduction of an electrode into the thalamus, which stimulates
the gland and allows management of tremors [26].
Stem cell transplantation has been studied in order to replenish the dopaminergic
neuron pool in the putamen [27]. Li et al. reported that graft-derived dopaminergic
innervation can be maintained for 24 years [28]. The patient was engrafted unilater-
ally in the putamen with ventral mesencephalic tissue issued from four abortions [28].
The patient showed substantial benefits for up to 12 years with L-DOPA withdrawal
from year 5 to 6 post-transplantation [28]. However, after 12 years, L-DOPA doses
were increased to those used before transplantation and by 18 years after grafting, no
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graft-related improvement remained [28]. Autopsy revealed that the putamen was still
strongly innervated and that 76% of neuromelanin (NM)-containing neurons from the
graft were tyrosine hydroxylase (TH)-positive, while the nontransplanted putamen did
not contain any TH-positive neurons. Interestingly, the transplanted neurons contained
Lewy bodies, suggesting that the disease could be transferred to the transplant [28].
The most promising procedure is currently deep brain stimulation (DBS). A thin
electrode is implanted into the brain, which generates high frequency waves. They
simulate the effects of a lesion without damaging the brain and prevent the transmis-
sion of impulses responsible for involuntary movements [26]. However, this treatment
is only available for 5 to 10% of PD patients. The selection is based on: response to
L-DOPA therapy, age, mental health and predominant symptoms [26]. The most effec-
tive DBS is obtained through stimulation of the subthalamic nucleus or pars interna of
the globus pallidus. Stimulation of both regions lead to significant motor benefits as well
as reduced dyskinesia and motor fluctuation in patients with advanced PD (Figure 1.1)
[29].
FIGURE 1.1: Deep brain stimulation areas. Oblique section at the level of the basal ganglia. The
substantia nigra is circled in black. Under deep brain stimulation, stimulation of the subthalamic
nucleus and the pars interna of the globus pallidus have shown the best improvement of motor
symptoms in patients with PD. These reagions are circled in red (adapted from [30]).
Gene therapy has also been considered for treatment of PD. So far, nine clini-
cal trials using gene therapy for patients with advanced PD have been completed.
60% of them used adeno-associated virus (AAV)-NRTN, a gene coding for the neu-
rotrophic factor neurturin. Neurotrophic factors might protect against neurodegenera-
tion and improve neuronal function. For example, neurturin has been shown to protect
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dopaminergic neurons in animal models of PD [31]. Although this could not help to
restore DA production in the substantia nigra pars compacta of advanced PD patients, the
analysis of post-mortem brains enabled important discoveries [32]. (1) Viral vectors can
be delivered safely using stereotactic surgical procedures and the proteins transduced
are expressed and active on the long term. (2) Another major finding of these clinical
trials was that gene therapy might be most profitable for patients with early PD: these
patients still possess some TH-positive neurons and the stimulation with NRTN can
increase DA production. However, in patients with advanced PD, the dopaminergic
neuron loss is too important to observe any benefits [32].
1.2 Dopaminergic systems
1.2.1 Short history of dopamine research
It is nowadays clear that DA is a neurotransmitter and many of its roles in the
human body have been revealed. However, this was not always the case: for a long
time, DA was considered to be a precursor of norepinephrine and epinephrine, without
any biological effects. Arvid Carlsson had to strongly argue in order to prove that DA
can act as a neurotransmitter on its own. This section gives a short overview on the
discovery of DA and its role in signal transduction.
DA was first synthesized by Mannich and Jacobsohn as well as by Barger and
Ewins in 1910 as a by-product in an effort to synthesize other compounds. In 1938,
Holtz, Heise and Lüdtke isolated AADC, the enzyme responsible for conversion of
L-DOPA to DA, in human kidney. The following year, Holtz and Blaschko identified
L-DOPA and DA as intermediates of norepinephrine and epinephrine synthesis. From
this time, DA was accepted as a neurotransmitter precursor. In 1942, Holtz confirmed
the presence of DA in the human body by demonstrating that DA is a normal con-
stituent of human urine [33].
In 1957, the work of Carlsson revolutionized research on DA. At that time, he was
investigating the effects of reserpine, an antipsychotic drug, on the depletion of seroto-
nine and norepinephrine. Together with Lindqvist and Magnusson, they hypothesized
that if reserpine is really depleting serotonine and norepinephrine stores, administer-
ing these amines should counteract its effects. Since these amines do not cross the
BBB, they used the precursors 5-hydroxytryptophan (5-HTP) and L-DOPA. Interest-
ingly, the supplementation with 5-HTP did not rescue the effects of the drug, while
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L-DOPA counteracted its effects [33]. They concluded that the lack of norepinephrine,
but not serotonine is responsible for reserpine’s sedative effects. However, they could
not observe any noticeable increase in norepinephrine. Therefore they decided to focus
on the study of the role of DA. In 1958, Carlsson and Waldeck developed a staining
technique allowing for specific coloration of DA in tissue and bodily fluids. This flu-
orimetric characterization showed a different localization of norepinephrine and DA.
In 1959, Bertler and Rosengren, both students of Carlsson, studied the localization of
DA in the brain and other tissues. They found that (1) DA was present in all studied
species, (2) that the basal ganglia contained the highest levels of DA and (3) that 80%
of the brain DA is located in the caudate nucleus [33]. In 1960, Hornykiewicz anal-
ysed the coloration of brain of PD and control patients and found no coloration in the
corpus striatum, indicating the absence of DA in this region in PD patients only. His
observations were accepted only in 1964: the main argument used to discredit these
findings was that DA is unstable, it was possible that his observations resulted from
a factor unique to PD patients such as medication or cause of death, which could ac-
celerate the degradation of DA. However, in 1964, Bernheimer showed the same trend
in levels of homovanillic acid (HVA), which is a more stable degradation product of
DA. This lead to the conclusion that DA is involved in PD. Finally, in 1966, Poirier and
Sourkes demonstrated the existence of the nigrostriatal DA system and its importance
in normal movement. This was linked to the motor control issues in PD and it was hy-
pothesized that the death of dopaminergic neurons in that brain regions is responsible
for motor impairments [33].
For his work on DA, Arvind Carlsson received the Nobel Prize in Physiology in
2000. The prize was shared with Paul Greengard and Eric Kandel for "their discoveries
concerning signal transduction in the nervous system" [33].
1.2.2 Where is dopamine produced and what is its role in the human body?
DA is a neurotransmitter belonging to the catecholamines (CAs). CA refers to
organic compounds containing a catechol nucleus and an amine group. The catechol
nucleus is composed of a benzene group with two adjacent hydroxyl groups. Aside
from DA, norepinephrine and epinephrine are the other CA found in vivo, and both
of them are synthesized from DA [34]. DA is synthesized from tyrosine and plays two
important roles in the body: first, it is the precursor of norepinephrine and epinephrine.
Second, it is an important neurotransmitter. This section highlights the regions where
DA is produced as well as its role in these particular regions.
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In the brain. Dopaminergic neurons represent less than 1% of the cell population
in the brain [35]. In mammalian brain, there exists nine dopamine-containing neuronal
cell groups. The localization of these groups varies between mammals, but the nomen-
clature used to define them allows cross-species comparisons [36]. These areas are
called A8 to A16. In primates, A8 is located in the retrorubral field, A9 in the substantia
nigra pars compacta and A10 in the ventral tegmental area (VTA). These three groups
project to the forebrain and contain 400,000 to 600,000 TH-positive cells in human com-
pared to 20,000 to 30,000 in mouse [37]. Among those, 70% are located in the substantia
nigra [36]. A11-13 are located in the hypothalamus, A14 near the preoptic periventricu-
lar nucleus and A15 is distributed between the paraventricular hypothalamic nucleus
and supraoptic nucleus. Finally, A16 is located in the olfactory bulb [38].
To illustrate the different functions of DA, the role of some regions producing this
neurotransmitter is further developed hereafter. Dopaminergic neurons from the sub-
stantia nigra pars compacta form the nigrostriatal pathway by projecting to the dorsal
striatum (caudate and putamen). Their major role is to control motor planning and ex-
ecution of movement, but they also play a role in cognition [39]. Dopaminergic neu-
rons located in the VTA give rise to two distinct signalling pathways. The first is the
meso-cortic pathway where the neurons project to the frontal and temporal cortices.
This pathway plays an important role in concentration and executive functions such
as working memory [39]. The second pathway arising from neurons from the VTA is
the meso-limbic pathway. The neurons project to the nucleus accubens, hyppocampus,
amygdala and septum [39]. This pathway plays an important role for motivation, ex-
perience of pleasure and reward [39] (Figure 1.2). DA can also act on hormone release:
neurons from A12 innervate the median eminence of the hypothalamus and inhibit the
secretion of prolactin [39]. Finally, the neurons from A13 project to the amygdaloid and
hypothalamic nuclei and are involved in sexual behaviour [39].
The DA system is involved in movement control, motor learning, reward-seeking,
motivation, memory and cognition. If DA signalling is compromised, it can lead to
PD (hypodopaminergic activity), schizophrenia (hyperdopaminergic activity), Hunt-
ington’s disease, drug addiction, obsessive-compulsive disorder, depression or atten-
tion deficit and hyperactivity disorder (ADHD) [41]. In PD, 5 to 10% of patients suffer
of severe depression and an additional 10 to 30% experience depressive symptoms [39].
In the gastrointestinal tract. DA is also produced in the gastrointestinal tract, spleen
and pancreas, where TH, the rate-limiting enzyme in the synthesis of DA, is present
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FIGURE 1.2: Dopaminergic pathways. Dopaminergic neurons from the substantia nigra pars
compacta (SNc) project to the dorsal stiatum and form the nigrostriatal pathway (in red).
Dopaminergic neurons from the ventral tegmental area (VTA) project either to the cortex via
the meso-cortic pathway (in blue) or to the nucleus accubens via the meso-limbic pathway (in
green) (adapted from [40]).
and active. About 46% of the DA synthesized in the body is synthesized by the gas-
trointestinal tract, the spleen and the pancreas and has various roles. DA stimulates
exocrine secretions, inhibits gut motility, modulates sodium absorption and mucosal
blood flow and has been shown to be protective against gastroduodenal ulcer disease
[42]. PD is associated with gastrointestinal dysfunctions such as weight loss, dysphagia
(difficulty in swallowing), gastroparesis (impaired gastric emptying) or defecatory dys-
function. The origin of most of these non-motor symptoms is unknown. Weight loss
is common in PD and affects 52% of the patients. It could be explained by the fact that
DA regulates appetite, thus the loss of dopaminergic neurons in the brain could lead to
lower appetite in PD patients. Moreover, DBS and DA agonists induced weight gain in
PD patients [43]. Interestingly, treatment with dopamine receptor antagonists, which
do not cross the BBB, accelerates gastric emptying, therefore providing a treatment for
gastroparesis, presumably via effects on gastric dopamine receptors [43].
In renal cells. Epithelial cells of the proximal convoluted renal tubules synthesize
DA from circulating L-DOPA [44]. DA is secreted towards the tubule lumen where
it induces sodium excretion by inhibiting its reabsorption through activation of DA
receptor. DA controls about 50% of sodium excretion. Dysfunctions in the renal DA
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system lead to sodium retention and hypertension. This happens through two distinct
mechanisms: either the expression of AADC, responsible for the decarboxylation of
L-DOPA to DA, is decreased or the signal transmission through the DA receptor is
ineffective [45].
In immune cells. Lymphocytes, neutrophils and macrophages possess DA recep-
tors, DA transport system and are able to synthesize DA [46]. In these cells, DA ex-
erts immunosuppressive functions by down-regulating proliferation and differentia-
tion and increasing apoptosis [47]. In regulatory T-cells, DA has an autocrine function
that leads to inhibition of cytokine production and capacity to suppress effector T cells
[47]. Altered dopaminergic signalling is associated with autoimmune diseases such as
multiple sclerosis [47]: one of the inhibitory DA receptors is downregulated in T cells of
patients with multiple sclerosis leading to a hyper-responsiveness of these cells, char-
acteristic of the disease [47].
In the bone marrow. DA is present in bone marrow and originates from nerve end-
ings and bone marrow cells. Interestingly, the amounts of DA follow the circadian ry-
thm, with peak values occurring during the night [46]. The role of DA in hematopoiesis
is to stimulate erythropoiesis and platelet production [46].
In retinal cells. A subset of amacrine cells are able to synthesize DA as a chem-
ical messenger for light adaptation. The daily frequency of DA production depends
on interaction between dopaminergic cells and photoreceptors. DA and melatonin fol-
low the circadian rhythm: melatonin levels are high at night while DA levels are high
during the day. Each compound can act to inhibit secretion of the other [48].
1.2.3 Dopaminergic neurons in the substantia nigra pars compacta and their
development
It has been postulated that during the course of PD, dopaminergic cell death oc-
curs through apoptosis, but data rely on morphological analysis, which do not provide
conclusive evidence [49]. The mechanisms inducing selective cell death in dopaminer-
gic neurons are not yet elucidated. They could involve energy metabolism deficiencies
(through mitochondrial complex I inhibition), inadequate control of redox state (due to
low levels of antioxidants), environmental toxins (such as rotenone or MPP+) or low
amounts of neurotrophic factors [49].
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The development of midbrain dopaminergic neurons is quite complex and not yet
fully elucidated. However, the main transcription factors involved have been identi-
fied. The developmental process can be divided into four stages: (1) pluripotent stem
cells located at the ventricular mesencephalic surface give rise to multiple cell types. (2)
Some of these cells commit to dopaminergic neuron precursor cell fate, characterized
by the expression of specific markers. (3) The precursor cells exit cell cycle and start
expressing early midbrain dopaminergic neuron characteristics. (4) The mature cells
express a specific set of markers and project axons to establish connections with target
tissues [50] (Figure 1.3). In the second step, where stem cells commit to dopaminer-
gic neuron differentiation, two factors play a major role: sonic hedgehog (SSH) and
fibroblast growth factor 8 (FGF8). Their spatio-temporal expression trigger signalling
cascades that lead to commitment to either VTA or substantia nigra dopaminergic neu-
rons [37]. The third step is the exit from cell cycle and expression of phenotypic mark-
ers such as TH in early stages and DAT at a later time. It is interesting to note that
DAT expression is specific to midbrain dopaminergic neurons and is not expressed in
other catecholaminergic cell types [50]. Important transcription factors at this stage in-
clude nuclear receptor related 1 protein (NURR1), which induces the expression of TH
and c-RET, a component of glial cell line-derived neurotrophic factor (GDNF) receptor.
GDNF is a growth factor involved in neuronal survival and arborization. LIM Home-
obox Transcription Factor 1 β (LMX1B) is initially expressed throughout the midbrain
region. Later in the development, it is specifically expressed in dopaminergic neu-
rons. It is essential for the expression of Paired-Like Homeodomain 3 (PITX3). PITX3
is essential for TH expression in the substantia nigra but not in the VTA. It is hypothe-
sized that other factors induce TH expression in VTA, but they are unknown [50]. The
functional maturation of dopaminergic neurons is characterized by axonal pathfinding,
formation of synapses and release of DA induced by depolarization. Several factors are
involved in guiding the axons: Engrail (En)-1 and -2 induce the expression of guidance
molecule receptors, while slits and nestins are involved in target recognition. The to-
pographical innervation of the striatum by midbrain dopaminergic neurons is ensured
by the ephrin ligand and receptor system. Dopaminergic cells from the VTA do not
express this ligand and thus, cannot form synapses with striatal cells. This final stage
is also characterized by a wave of apoptotic cell death. It is highly likely that the axons
compete to establish synapses and this ensures cell survival through growth factors
such as GDNF and brain-derived neurotrophic factor (BDNF) [50].
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En 1,2: guidance molecule
Nestin: target recognition
Slit: target recognition
Ephrin ligand: topographical innervation
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            Neurons from the striatum:
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             Survival of neurons producing the ephrin ligand and 
growth factor receptors
FIGURE 1.3: Development of dopaminergic neurons. (1): Pluripotent stem cells give rise to
multiple cell types. (2): The commitment to dopaminergic neurons precursor is mediated by
sonic hedgehog (SHH) and fibroblast growth factor 8 (FGF8). Their spatio-temporal expression
induce migration to the ventral tegmental area (VTA) or substantia nigra pars compacta (SNpc).
(3): The precursors exit cell cycle and start to express neuronal cell markers such as tyrosine hy-
droxylase (TH), GDNF receptor protein (cRET) and dopamine transporter (DAT). The expres-
sion of the two first is induced by nuclear receptor related protein 1 (NURR1) in both lineages
while TH expression in SNpc is also mediated by paired-like homeodomain 3 (PITX3). (4): The
mature neurons project axons to their target regions and are guided by engrail 1 and 2 (En 1,
2), nestin and slit. Neurons from the SNpc also produce ephrin ligands which is recognized
by receptors in the striatum. (5): A wave of apoptotic cells characterizes the last stage of the
maturation of dopaminergic neurons.
Deregulation in neurogenesis of dopaminergic cells can have grave consequences
on the development of DA-producing brain regions. Hegarty et al. summarized the
effects of about fifty mutations of genes involved in midbrain dopaminergic neuron
development in mice and their effects on neuronal development [37]. Most of them
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induced midbrain dopaminergic loss at various stages of neuronal development. In-
terestingly, the effects of mutations in PITX3 and En-1 were stronger in neurons from
the substantia nigra than in the VTA, correlating with the highest sensitivity to cell death
of these neurons during the course of PD.
A better understanding of dopaminergic neurogenesis is needed to develop cell
therapies in PD and to evaluate whether these factors could play a role in the develop-
ment of PD. Lower levels of development-associated factors could be associated with
a lower number of dopaminergic neurons and early neurodegeneration observed in
PD patients. It cannot be excluded that supplementation with the potentially missing
factors could prevent or decrease cell death [49].
1.2.4 Currently available cell models
The effects of PD-associated mutations or toxins are often studied in vitro using cell
models. Several cell lines are available and have been characterized. However, many of
them are originating from tumours or from non-human organisms. This induces some
drawbacks concerning their use: (1) cancer cells are proliferating and therefore do not
mirror the quiescent state of mature neurons. (2) The regulation of genes related to
DA synthesis pathway, including TH, are organism specific, thus studying the effects
of a drug or mutation in mice or rats might not reflect the results that would have been
obtained in human cells [51]. (3) Mice and rats do not produce NM, a pigment present
in the substantia nigra pars compacta [51].
I describe here five cell lines that have been used as model of dopaminergic neu-
rons. NB69 cells are human neuroblastoma cells derived from a sixteen-month old male
[52]. They are positive for TH staining and DA has been measured by electrochemical
detection [52]. These cells have been used among others to characterize the neurotox-
icity of L-DOPA [53]. Another human neuroblastoma cell line commonly used is the
SH-SY5Y cell line. These cells were isolated from a four-year old female and can be
differentiated to TH expressing cells using low concentrations of fetal bovine serum
(FBS) and retinoic acid (RA) [54]. PC-12 are pheochromocytoma cells isolated from
the adrenal gland of a male rat. These cells produce DA and norepinerphrine [55]. A
fourth model commonly used are the Neuro-2a cells, isolated from mouse neuroblas-
toma. Neuro2a cells have been reported to be more sensitive to MPP+ treatment than
PC-12 and SH-SY5Y cells [56]. Differentiation of Neuro-2a with low FBS and cyclic
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adenosine monophosphate (cAMP) leads to TH-positive cells producing DA, but with-
out expression of PITX3, indicating that they do not differentiate into the same type
of dopaminergic neurons as in the substantia nigra [57]. A last model used to study
dopaminergic neurons are the LUHMES cells. They were derived from the mesen-
cephalon of an eight-week old foetus and immortalized using a v-myc vector. This
vector is repressible using tetracycline, and these cells can be differentiated to non-
proliferative post-mitotic neurons using cAMP [58]. Although these cells are positive
for TH, no DA could be measured using our gas chromatography - mass spectrometry
(GC-MS) instruments 1.
1.3 Synthesis and degradation of dopamine
DA is synthesized from tyrosine in a two-step reaction (Figure 1.4). The first and
rate-limiting enzyme in this pathway is TH which hydroxylates tyrosine to L-DOPA,
using 6R-L-erythro-5,6,7,8-tetrahydrobiopterin (BH4) as cofactor. The second enzyme
is AADC, which decarboxylates L-DOPA to DA. The synthesized neurotransmitter can
then be packaged into vesicles via the vesicular monoamine transporter 2 (VMAT2),
be further enzymatically processed or can oxidize and polymerize to NM. Futher
enzymatic processes include synthesis of other catecholamines such as norepinephrine
and epinephrine by dopamine-β-hydroxylase (DBH) and phenylethanolamine N-
methyltransferase (PNMT), respectively. Several enzymes are involved in degradation
of DA: COMT, MAO, aldehyde dehydrogenase (ALDH) and alcohol dehydrogenase
(ADH).
This section further describes these pathways starting with a description and reg-
ulation of the enzymes responsible for DA synthesis as well as the synthesis of BH4.
Then, an overview of the fate of DA within the cells is given, including its packaging,
action and transport. Finally, the enzymatic degradation is described as well as the
auto-oxidation process and the production of NM.
1The limit of detection of these instruments is discussed in section 1.5.3
Chapter 1. Introduction 15
H2N
O
OH
HO
H2N
O
OH
HO
HO
O
OH
H2N
HO
HO
NH2
HO
HO
NH2
OH
HO
HO
NH
OH
HO
NH2O
HO
O O
HO
O OH
O
HO
OHO
HO
OH
O
HO
L-Phenylalanine
L-Tyrosine
L-DOPA
Dopamine
Norepinephrine
Epinephrine
DOPAL
3-Methoxytyramine 3-Methoxy-4-
hydroxyacetaldehyde
HVA
DOPAC
DOPET
BH4
Pterin 4-α-carbinolamine
BH4
Pterin 4-α-carbinolamine
H2O
FAD
O2
H2O2
FADH2
NH3
H2O
FAD
O2
H2O2
FADH2
NH3
SAM
SAH
SAM
SAH
H2O
NAD+ NADH + H+
H2O
NAD+
NADH + H+
HO
OHHO
PheH
TH
AADC
DBH
PNMT
COMT
MAO
MAO
ALDH
ADH
COMT
ALDH
De novo synthesis
Enzymatic degradation
Catecholamine synthesis
FIGURE 1.4: Synthesis and degradation of dopamine. Dopamine can be synthesized from
L-phenylalanine or L-tyrosine. In the first case, L-phenylalanine is hydroxylated to L-
tyrosine by phenylalanine hydroxylase (PheH). L-tyrosine is then further hydroxylated to
L-3,4-dihydroxyphenylalanine (L-DOPA) by tyrosine hydroxylase (TH). Both enzymes re-
quire tetrahydrobiopterin (BH4) as cofactor and produce pterin 4-α-carbinolamine. L-DOPA
is decarboxylated to dopamine by aromatic amino acid decarboxylase (AADC). Dopamine
can be degraded via several pathways. First, it can serve as precursor for the synthesis
of norepinephrine by dopamine β-hydroxylase (DBH), which can be further methylated to
epinephrine by the phenylethanolamine N-methyltransferase (PNMT). A second degrada-
tion pathway is via catechol-o-methyltransferase (COMT), which methylates dopamine to 3-
methoxytyramine using S-adenosyl methionine (SAM) and releasing S-adenosyl homocysteine
(SAH). 3-Methoxytyramine can be further metabolized to 3-methoxy-4-hydroxyacetaldehyde
by monoamine oxidase (MAO), therefore producing ammonia (NH3) and hydrogen peroxide
(H2O2). 3-Methoxy-4-hydroxyacetaldehyde is finally converted to homovanillic acid (HVA) by
the aldehyde dehydrogenase (ALDH). A third pathway involving the same enzymes leads to
the generation of 3,4-dihydroxyphenylacetaldehyde (DOPAL) by MAO which is converted to
3,4-dihydroxyphenylacetic acid (DOPAC) by the ALDH. Finally, DOPAC is methylated to HVA
by COMT. DOPAL can also be reduced to 3,4-dihydroxyphenylethanol (DOPET) by alcohol de-
hydrogenase (ADH).
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1.3.1 Dopamine synthesis
1.3.1.1 Tyrosine hydroxylase, a key player in dopamine synthesis
TH is the first and rate-limiting enzyme in the synthesis of DA. It belongs to the
family of iron-containing, biopterin dependent amino acid hydroxylases together with
phenylalanine hydroxylase (PheH) and tryptophan hydroxylase (TrpH). TH consists of
three domains: a regulatory (R) domain of 100 to 160 amino acids, a catalytic (C) do-
main of 330 residues and a 40 amino acids coiled-coil domain at the carboxyterminus.
TH is a tetrameric enzyme predominantly found in the cytoplasm [59]. In human, four
isoforms of the enzyme exist and they differ in the length of the regulatory domain.
This is species specific since two isoforms were found in Drosophila and one in rat. All
isoforms arise from splicing variants of a single gene [59].
TH is a tightly regulated enzyme and its activity can be regulated by transcrip-
tional and post-translational modifications [34]. Transcriptional activation involves
response to growth factor, hormones and trans-synaptic signals. The major second
messengers involved in this pathway are cAMP, diacylglycerol (DAG) and calcium.
The promoter sequence of TH contains binding sites for cAMP response element (CRE)
and 12-O-tetradecanoylphorbol-13-acetate (TPA) response element (TRE). Intracellular
levels of cAMP regulate the transcription of TH by activating cAMP response element
binding protein (CREB) [60]. Another transcription factor involved in TH regulation is
the activator protein 1 (AP-1) complex, composed of c-Fos and c-Jun, which binds to
TRE. Interestingly, oxygen plays an important role in the transcriptional regulation of
TH: low oxygen levels induce functional activation of CREB and stimulate expression
of c-Fos and AP-1 activity, and thus, increase TH transcription. Hypoxia also stabilizes
the mRNA transcript of TH through the binding of hypoxia-inducible protein (HIP), a
66 kDa cytosolic protein, to the 3’ untranslated region of TH mRNA, which prolongs
its half-life from 10 to 30 hours [61]. Interestingly, the effects of low oxygen levels seem
to be organ-specific: Hui et al. reported that exposing rats to 10% oxygen for 30 days
induced an increase in DA in the carotid bodies, but not in the sympathetic ganglia or
adrenal glands [62].
At the post-translational level, TH can be regulated by substrate or product in-
hibition, phosphorylation or cofactor availability [34]. TH regulation by tyrosine, its
substrate, occurs in vitro for concentrations higher than 50 μM and acts through an al-
losteric mechanism [63]. All three CAs (i.e. DA, norepinephrine and epinephrine) can
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induce down-regulation of TH by product inhibition. They can only exert their in-
hibitory role if the iron is oxidized. In this case, they bind to the active site at a position
that overlaps with binding of the cofactor [51]. Since BH4 is essential for TH activity,
preventing binding of BH4 inhibits TH [34]. The most widely studied post-translational
modification of TH is phosphorylation. In rat, TH can be phosphorylated at ser8, -19,
-31 and -40, while in human, position eight contains a threonine [51]. Phosphorylation
at ser40 induces an increase in TH activity by increasing its affinity for BH4 [51]. Upon
depolarization, phosphorylation at ser40 increases from 5 to 10% in situ [59]. Eight
kinases can phosphorylate this site in vivo, such as protein kinase A (PK-A), protein
kinase G (PK-G) or protein kinase C (PK-C). The two phosphatases responsible for the
dephosphorylation are protein phosphatase (PP)2A and 2C [59]. Phosphorylation at
ser31 also increases TH activity through increased affinity for BH4. It is modulated by
extracellular signal-regulated kinase (ERK)1 and 2, but the phosphatase involved in its
dephosphorylation has not been identified [59]. Phosphorylation at ser19 is carried out
by calcium/calmodulin-dependent protein kinase II (CaMPKII) and mitogen-activated
protein kinase activated protein kinase (MAPKAPK)1 and 2. Dephosphorylation is car-
ried out by PP2A and 2C. Phosphorylation at ser19 does not alter TH activity in vitro.
Binding of 14-3-3 protein to TH phosphorylated at ser19 increased TH activity in vitro.
However, this could not be validated in vivo [59]. Finally, ser8 can be phosphorylated
by proline-directed serine/threonine kinase (PDPK) and ERK1 and 2. The enzymes re-
sponsible for its dephosphorylation have not been identified. Phosphorylation at ser8
does not induce any modification in TH activity in vitro or in vivo [59]. The close prox-
imity of these phosphorylation sites within the regulatory domain raised the question
whether they could influence each other. Investigation of hierarchical phosphoryla-
tion showed that phosphorylation at ser19 by CaMPKII increased three-fold the rate of
phosphorylation of ser40 by the same kinase, while this has not been investigated for
ser31 [59].
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FIGURE 1.5: Post-translational modifications of TH. Tyrosine hydroxylase (TH) is a protein
composed of 528 amino acids. It can be activated by phophorylation at different serine residues.
Rat TH can be phosphorylated at ser8, 19, 31 and 40, while human TH contains a threonine at
position 8, and therefore can only be phosphorylated at ser19, 31 and 40. The kinases involved
in the phosphorylation differ depending on the serine position. At ser8, proline-directed ser-
ine/threonine kinase (PDPK) and extracellular signal regulated kinases 1 and 2 (ERK1, ERK2)
are responsible for the phoshporylation. At ser19, calcium/calmoduline-dependent kinase II
(CaMPKII), mitogen-activated protein kinase activated protein kinase (MAPKAPK) and pro-
tein 14-3-3 (14-3-3) phosphorylate TH. At ser31, ERK1 and ERK2 are responsible for the phos-
phorylation, while protein kinases A, C and G (PK- A, PK-C and PK-G) are involved in the
phosphorylation at ser40. Phosphatases involved in dephosphorylation of ser19 and 40 include
protein phosphatases 2A and 2C (PP2A, PP2C). The phosphatases involved in ser8 and 31 de-
phosphorylation have not yet been identified.
1.3.1.2 Synthesis of tetrahydrobiopterin
BH4 is synthesized from guanosine triphosphate (GTP) (Figure 1.6) [64]. The first
and rate limiting enzyme in this pathway is GTP cyclohydrolase 1 (GTPCH) which
catalyzes the reaction of GTP to 7,8-dihydroneopterin triphosphate. The activity of
this enzyme can be regulated by cooperative binding of GTP. BH4 and phenylalanine
also modulate GTPCH activity via GTPCH feedback regulatory protein (GFRP). It in-
hibits GTPCH by binding to it and inducing conformational changes [64]. Interest-
ingly, lipopolysaccharide (LPS) and H2O2 downregulate the expression of GFRP, ren-
dering BH4 synthesis independent of phenylalanine levels. However, in the context
of dopaminergic neurons, GFRP is not of importance: it was shown to regulate BH4
in the synthesis of serotonin, but not that of DA [64]. Mutations in GTPCH, the rate-
limiting enzyme in BH4 synthesis, is associated with impaired motor activity, charac-
teristic of low DA levels [34]. The next step in the synthesis of BH4 is the reaction of
6-pyruvoyltetrahydropterin synthase (PTPS) leading to 6-pyruvoyltetrahydropterine.
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FIGURE 1.6: Synthesis of tetrahydrobiopterin. Tetrahydrobiopterin (BH4) can be synthesized
de novo (red box) from guanosine triphosphate (GTP). GTP is metabolized by GTP cyclohy-
drolase 1 (GPTCH) to 7,8-dihydroneopterin triphosphate which serves as substrate for the 6-
pyruvoyl-tetrahydropterin synthase (PTPS) to generate 6-pyruvoyltetrahydropterine. Then,
6-pyruvoyltetrahydropterine is converted to lactoyltetrahydropterin by 6-pyruvoyl tetrahy-
dropterin 2’-keto reductase (PTPR). Finally, sepiapterin reductase (SR) converts lactoyltetrahy-
dropterin to BH4. BH4 can be used as cofactor by tyrosine hydroxylase (TH), phenylala-
nine hydroxylase (PheH) or tryptophane hydroxylase (TrpH) which then generate pterin 4-
α-carbinolamine. To regenerate BH4 (blue box), pterin 4-α-carbinolamine is dehydrated to
quinoid dehydropterin (q-BH2) by the pterin 4-α-carbinolamine dehydratase (PCD). q-BH2
can either be converted to BH4 by the quinoid dihydropteridine reductase (QDPR) or spon-
taneously converts to dihydrobiopterin (BH2). A third pathway involved in generation of BH4
is the salvage pathway (green box), where sepiapterin can be used as substrate of SR to produce
BH2. BH2 is then used by the dihydrofolate reductase (DHFR) to produce BH4.
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The last two steps are catalyzed by 6-pyruvoyltetrahydropterin 2’-keto reductase
(PTPR) and sepiapterin reductase (SR) and lead to the production of lactoyltetrahy-
dropterine and BH4 respectively, both enzymes use NADPH as cofactor. BH4 can
then be used by aromatic amino acid hydroxylases which contain non-haem iron.
BH4 donates two electrons to activate oxygen and exits the reaction as pterin 4-
α-carbinolamine. A second class of enzymes using BH4 as cofactor is nitric oxide
synthase (NOS). These enzymes contain a haem iron, and in this case, BH4 does not in-
duce oxygen activation, but rather gives one electron for each of the two-step reaction
from arginine to citrulline [64].
After reaction with either aromatic amino acid hydroxylases or NOS, pterin
4-α-carbinolamine can be recycled to BH4 in a two-step reaction via the pterin-4a-
carbinolamine dehydratase (PCD) and quinoid dihydropteridine reductase (QDPR) to
form quinoid dihydropteridine (q-BH2) and BH4, respectively. This recycling pathway
has two main roles: (1) it ensures continuous supply of reduced cofactor and (2) it
prevents accumulation of harmful metabolites produced by rearrangement of pterin
4-α-carbinolamine [64].
BH4 can also be synthesized via a salvage pathway: sepiapterin can serve as pre-
cursor for 7,8-dihydrobiopterin (BH2) synthesis by the SR. BH2 can then be metabolized
by dihydrofolate reductase (DHFR) [64]. In the case of low enzymatic activity of SR or
QDPR, both lactoyltetrahydropterine and q-BH2 can be non-enzymatically converted
to sepiapterin and BH2 respectively [64].
1.3.1.3 Aromatic L-amino acid decarboxylase
The second enzyme involved in DA synthesis is AADC previously referred to as
DOPA decarboxylase (DDC). This multimeric enzyme forms homodimers and uses
pyridoxal phosphate (PLP) as cofactor to increase its activity [65]. It catalyzes the reac-
tion of L-DOPA to DA and 5-HTP to serotonin (5-HT) as well as the formation of trace
amines from phenylalanine, tyrosine and tryptophan to phenylethylamine, p-tyramine
and tryptamine, respectively [66]. Interestingly, about 50% of AADC is membrane
bound and catalyzing the production of 5-HT, while 35% of the enzyme is found in
synaptosomes and catalyzes the production of DA [66]. It is expressed in a wide range
of cell types including neurons and glial cells.
AADC is not the rate-limiting enzyme in the DA synthesis pathway. Therefore,
it was assumed for a long time that it is not regulated. Recent evidence suggests that
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it is regulated at both the transcriptional and post-translational levels. In mammals,
genetic regulation of AADC is not well established [66]. Different promoter regions
are expressed in different tissues suggesting a tissue-specific expression of AADC [66].
Among tissues, there exist different ratios of AADC activity to L-DOPA and 5-HTP sug-
gesting that there exists several isoforms of the enzyme. Some studies have shown that
isoforms are produced by alternative splicing of exon 3 [66], although further work is
needed to confirm these data. At the post-translational level, the activity of AADC can
be modulated by phosphorylation: AADC contains recognition motifs for PK-A, PK-C
and CaMPKII. Phosphorylation can be mediated through the DA receptors: activation
of D2 receptors inhibits adenylyl cyclase (AC). AC is responsible for cAMP synthesis,
which then activates PK-A that can phosphorylate AADC. Therefore, activation of D2
receptors decreases the activity of AADC, while inhibition of D2 receptors increases the
activity of AADC [66]. PK-C activation could be modulated through the 5-HT receptor,
which is known to use PK-C as second messenger [66].
Although AADC is not involved in the etiology of PD, it plays a crucial role during
L-DOPA treatment. It might become rate-limiting upon degeneration of neurons and
L-DOPA supplementation. Glial cells also express AADC and it cannot be excluded
that they play a role in DA synthesis when only few dopaminergic neurons are left
[66].
1.3.2 Packaging, action and transport of dopamine
Upon synthesis, DA can either be packaged into vesicles via the VMAT2 or can
auto-oxidize in the cytoplasm and be incorporated into NM granules (Figure 1.7).
Upon depolarization stimuli, DA-containing vesicles are released into the synaptic
cleft where it activates DA receptors. This reaction can be stopped by DA reuptake via
the DAT in either neurons or astrocytes. This section describes the role of the different
receptors and transporters involved in these processes.
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FIGURE 1.7: Packaging, action and transport of dopamine. Upon synthesis, dopamine (DA)
is either (1) packaged into vesicles via vesicular monoamine transporter 2 (VMAT2) or (2) can
oxidize and polymerize to melanin which gathers in neuromelanin (NM) granules. (3) Influx
of calcium triggers the release of vesicular DA which (4) can activate the membrane bound
dopamine receptors (D1-5). (5) The neurotransmition is controlled by the dopamine transporter
(DAT) which can stop it by transporting DA back into the cells. Both neuronal and astrocytic
cells possess DAT. (6) Finally, DA can be enzymatically degraded.
1.3.2.1 Vesicular monoamine transporter 2
Vesicular monoamine transporters (VMATs) are H+-ATPase antiporters which
package monoamines into vesicles [67]. These transporters evolved from a bacterial
antiporter that excretes toxins. The function of VMATs inside the cell is very similar:
they sequester molecules that otherwise would be toxic to the cells if left free in the
cytoplasm [68]. The vesicle concentrates monoamines about 10,000 fold and possesses
a pH of 5.5, which prevents auto-oxidation inside the vesicle [68]. There exists two
transporters: vesicular monoamine transporter 1 (VMAT1) and VMAT2. The for-
mer is located in peripheral neuroendocrine cells and absent in the central nervous
system (CNS) while the latter is present in the central and peripheral sympathetic
nervous systems [68]. VMAT2 is present in all neurons in the brain that produce DA,
5-HT, norepinephrine, epinephrine, histamine and trace amines such as tyramine and
phenylethylamine [68]. Complete knockout of VMAT2 is lethal, while a 95% reduction
of VMAT2 in mice leads to a dramatic decrease in the amounts of monoamines in the
brain. Interestingly, the amounts of VMAT2 are decreased in patients with advanced
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PD. In patients under L-DOPA medication, VMAT2 levels further decreased shortly
after administration of the treatment [68]. It was thus hypothesized that increasing
VMAT2 expression in PD patients could protect them from oxidative stress due to auto-
oxidation of DA products, improve the efficacy of L-DOPA treatment and increase DA
neurotransmission from the remaining neurons [67]. Moreover, mice overexpressing
VMAT2 showed a beneficial outcome on depression and anxiety behaviours, both
mediated by monoamines [67].
1.3.2.2 Dopamine receptor
The DA released into the synaptic cleft upon depolarization can activate DA re-
ceptors. These can be divided into two families: the D1-like receptors containing D1 and
D5 variants and the D2-like receptors containing D2, D3 and D4 variants. The major dif-
ference is that D1-like receptors are coupled to AC and thus, exert their activity through
cAMP accumulation, while D2-like receptors are cAMP-independent [69]. The two fami-
lies possess distinct pharmacological, biochemical and physiological properties as well
as distinct anatomical distribution [70]. The affinity to DA is also receptor-specific: DA
has a ten times higher affinity for D5 than for D1 receptors and a twenty times higher
affinity for D3 than D2 receptors [70]. The signal transduction of these receptors is quite
complex and displayed in Figure 1.8 A. As mentioned, D1-like receptors can activate AC
via activation of the Gsα subunit of the G-protein and AC catalyses the production of
cAMP from ATP. cAMP activates PK-A which phosphorylates dopamine- and cAMP-
regulated neuronal phosphoprotein (DARRP-32). DARRP-32 activates ERK through
inhibition of protein phosphatase 1 (PP1), an activator of striatal-enriched protein ty-
rosine phosphatase (STEP), which negatively regulates ERK [70]. PK-A also plays an-
other role following the activation of D1-like receptors activation: it induces an increase
in cytoplasmic calcium concentration by increasing calcium uptake from the extracel-
lular space and by increasing calcium release from the intracellular storage of the en-
doplasmic reticulum (ER) lumen. D2-like receptors, on the other hand, decrease the ac-
tivity of AC, PK-A and calcium uptake from the extracellular space [70]. The increase
of intracellular calcium levels can also be mediated by activation of phospholipase C
(PLC) which catalyzes the degradation of phosphaditylinositol-4,5-biphosphate (PIP2)
to DAG and inositol triphosphate (IP3). IP3 then binds to calcium channels of the ER
and triggers calcium release [70] .
D1-like and D2-like receptors also act on other ion channels: potassium channels,
sodium/proton exchange and sodium-potassium-ATPase [70]. The effect of D1-like on
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potassium channels is not well documented, but D2-like receptors increase the outward
of potassium leading to cell hyperpolarization. This causes prolactin secretion in the
pituitary and DA release inhibition by autoreceptors [70]. D1-like receptors agonists
inhibit sodium/proton exchange while D2-like agonists activate this transporter. It is
responsible for pH and cell volume regulations [70]. Finally, both D1-like and D2-like re-
ceptor agonists inhibit sodium-potassium-ATPases, which maintain the electrochemi-
cal gradient and are responsible for excitability. It has also been suggested that D2-like
receptors play a role in neuronal differentiation, although their roles remain to be clar-
ified [70].
1.3.2.3 Dopamine transporter
DAT is responsible for reuptake of DA from the synaptic cleft into presynaptic neu-
rons. Therefore, it controls the spatio-temporal dynamic of DA neurotransmission [71].
Reuptake is driven by a concentration gradient generated by the sodium-potassium-
ATPase allowing co-transport of DA together with 2 sodium ions and 1 chloride ion
through the DAT [72]. In mammalian brains, DAT expression is restricted to dopamin-
ergic (DAergic) neurons and astrocytes [73] and the directionality of the flux depends
on cellular concentrations. DA can be bidirectionally transported, but at normal mem-
brane potential and sodium gradient, the inward transport is favoured [74]. Regulation
of the activity of the DAT can be mediated via several pathways (Figure 1.8 B). First,
DAT can be negatively regulated via PK-C: upon extended activation of PK-C, DAT
is internalized and targeted for lysosomal degradation, thus this is a long term regu-
lation. PK-C also exerts its effects by increasing efflux of DA through the DAT or by
phophorylating ser7, leading to a decrease in DA uptake. Positive regulation of DAT
is mediated by D2-like receptors in two ways: activation of ERK by D2-like receptors in-
duces phosphorylation of thr53 of the DAT and thus, increasing DA influx. The second
role of D2-like receptors is by G protein-mediated promotion of DAT surface expression,
therefore increasing the uptake capacity of the cell [71].
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FIGURE 1.8: The role of dopamine receptor and dopamine transporter. (A): Activation of D1-2
receptors. (1) Upon binding of DA, DA receptors regulate ion transport channels. D1-like (D1) re-
ceptors inhibit both Na+/H+ exchange and Na+-K+-ATPase. D2-like (D2) receptors inhibit Na+-
K+-ATPase and K+ channels and activate Na+/H+ exchange. (2) D1-like and D2-like receptors
activate phospholipase C (PLC) through Gαq and Gβ, respectively. PLC catalyzes the degra-
dation of phosphatidylinositol-4,5-bisphosphate (PIP2) to diacylglycerol (DAG) and inositol
triphosphate (IP3). IP3 can then trigger the release of intracellular stores of calcium from the
endoplasmic reticulum (ER) lumen. (3) D1-like can also activate adenylyl cyclase (AC) through
Gαs. AC catalyzes the production of cAMP, which in turn activates protein kinase A (PK-A).
PK-A phosphorylates dopamine- and cAMP-regulated neuronal phosphoprotein (DARRP-32),
which inhibits protein phosphatase 1 (PP1). PP1 activates striatal-enriched protein tyrosine
phosphatase (STEP), which inhibits ERK. Thus, activation of DARRP-32 activates ERK. (B):
Regulation of DAT. Dopamine transporter (DAT) can be negatively regulated in several ways by
protein kinase C (PK-C). (1): The bioavailability of the transporter can be modified by PK-C by
targeting it for lysosomal degradation. (2): PK-C can also stimulate the reverse transport of DA
from the intracellular matrix to the synaptic cleft, thus increasing the synaptic concentration of
DA. (3): Finally, PK-C can decrease the influx of DA by phosphorylation of serine 7 (Ser7). DAT
can be positively regulated by D2 in two ways. (4): The binding of DA to the receptor induces
activation of extracellular-signal-regulated kinase (ERK) which phosphorylates threonine 53
(Thr53) of DAT. (5): DAT can also be activated via G-protein βγ (Gβγ) to increase DA influx.
1.3.3 Dopamine degradation
After reuptake by DAT, DA can either be packaged into synaptic vesicles via
VMAT2 to be reused or it can be degraded either enzymatically or non-enzymatically.
The former involves MAO, COMT and ALDH, while the latter occurs spontaneously
in the cytoplasm by auto-oxidation. This section describes the degradation pathways
of DA as well as the formation of melanin.
26 Chapter 1. Introduction
1.3.3.1 Monoamine oxidase, catecholamine-o-methyl transferase and aldehyde de-
hydrogenase
Degradation of DA occurs via several pathways (Figure 1.4). The first pathway
involves methylation of DA to 3-methoxytyramine by COMT. S-adenosyl methio-
nine (SAM) is used as a methyl donor in this reaction leading to the formation of
S-adenosyl homocysteine (SAH). Then, 3-methoxytyramine is oxidized by MAO to
3-methoxy-4-hydroxyacetaldehyde. This reaction consumes oxygen, water and FAD
and produces H2O2, ammonia and FADH2. Finally, ALDH oxidizes 3-methoxy-
4-hydroxyacetaldehyde to HVA using water and NAD+ and releasing NADH. An
alternative pathway uses the same enzymes and cofactors, but in a different order.
MAO can oxidize DA to 3,4-dihydroxyphenylacetaldehyde (DOPAL), which is then
either oxidized to 3,4-dihydroxyphenylacetic acid (DOPAC) by ALDH or reduced to
3,4-dihydroxyphenylethanol (DOPET) by ADH. DOPAC is then further methylated by
COMT to HVA.
Monoamine oxidase. MAO are flavoenzymes located at the outer mitochondrial
membrane [75]. There exists two forms of MAO: A and B. Their localization is cell-type
specific: noradrenergic neurons of the locus coruleus stain for MAO-A, serotoninergic
neurons of the raphe nuclei stain for MAO-B, while the staining of dopaminergic neu-
rons from the substantia nigra for both isoforms of MAO is extremely low [76]. This
low expression of the enzyme does not prevent an increase in DA levels upon selec-
tive MAO inhibition. Neurons are not the only cells expressing MAO: microglial cells
express predominantly MAO-B, whereas astrocytes contain both forms of the enzyme
[76]. Metabolism of MAO generates H2O2, which can lead to defects in the mitochon-
drial electron transport chain. H2O2 is naturally formed during respiration: around
1 to 2% of the oxygen consumed is diverted to superoxide, which dismutes to H2O2.
However, the activity of MAO leads to H2O2 production largely exceeding that pro-
duced during electron flow [75]. Glutathione peroxidase (GPx) detoxifies H2O2 using
reduced L-glutathione (GSH). The products of this reaction are glutathione disulfide
(GSSG) and water. If H2O2 production exceeds the rate of detoxification by GPx, it
can be toxic to the mitochondrial electron transport chain in particular by inhibiting
complex I and II [77].
Catechol-o-methyl transferase. COMT catalyzes the methylation of one of the hy-
droxyl groups of a catechol substrates. It can thus methylate DA and DOPAC as well as
L-DOPA. Methylation of L-DOPA leads to the production of 3-o-methyldopa (3-OMD)
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[78]. COMT exists in two forms: soluble and membrane-bound. In human, the solu-
ble form is more abundant in peripheral tissues, whereas the membrane-bound form
is more prevalent in the brain and is predominantly associated with methylation of
dopamine and norepinephrine [79]. In all areas of the brain, COMT expression is low
in astrocytes and microglial cells express the highest levels [80]. The expression of
COMT is the highest in the striatum and substantia nigra pars compacta [79]. The cells
expressing this enzyme differ between brain regions: in the striatum, GABAergic neu-
rons express COMT [80], while in the substantia nigra pars compacta, it is not expressed
in dopaminergic neurons, but in microglia and astrocytes [79].
Aldehyde dehydrogenase. ALDH catalyzes the reaction of 3-methoxy-4-hydroxy-
acetaldehyde to HVA and from DOPAL to DOPAC. DOPAL can also be metabolized
by ADH to DOPET. Inhibition of ALDH leads to an accumulation of toxic aldehydes
and dopaminergic neuron loss in vitro and in vivo [81].
1.3.3.2 Dopamine auto-oxidation and neuromelanin
In the cytosol, L-DOPA, DA, norepinephrine and epinephrine can undergo non-
enzymatic oxidation or auto-oxidation (Figure 1.9 A). This pathway includes quinones,
leukochromes and chrome intermediates, which can polymerize and be included into
NM vesicles. These intermediates are highly reactive and induce cell death via protein
inactivation, mitochondrial dysfunction or depletion of antioxidants. The effects of
quinones will be further discussed in section 1.4.2.1.
Melanins are cytoplasmic dark coloured granules that can be found in the skin or
in the brain. Because of its location, melanin in the brain is referred to as NM. Melanins
can be classified into four groups: (1) eumelanin (formed from L-DOPA), (2) pheome-
lanin (formed from 5-S-cysteinyl-DOPA), (3) neuromelanin (formed by oxidative poly-
merization of DA or norepinephrine and a mixture of eumelanin and pheomelanin)
and (4) allomelanin (formed from polyphenols) [82]. The brain region containing the
highest levels of NM is the substantia nigra pars compacta, but no correlation was found
between degree of pigmentation and TH immunoreactivity. Knowledge about NM is
limited, partly because the most common animal models including rodents do not pos-
sess this pigment [82]. In the scope of PD, there is an inverse relationship between the
amount of NM contained in the neurons and their vulnerability to cell death [82]. The
current hypothesis concerning the role of NM is that it has a protective role through
scavenging of toxic phenols, which can be integrated into the polymer. NM also binds
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FIGURE 1.9: Auto-oxidation of catecholamines. (A): The synthesis of epinephrine from ty-
rosine enzymatically occurs as described in Figure 1.4. Each of the metabolites of the cate-
cholamine synthesis pathway can auto-oxidize and form the respective quinones. Quinones
then cyclize into leukochrome intermediates, which further oxidize into chrome intermediates.
The next step in the pathway is the formation of dihydroxyindole, which oxidizes to form in-
dolquinone. These can polymerize to form neuromelanin. Depending on the precursor, R1
represents either H or OH and R2 represents H or CH3. (B): The superoxide radicals (O2.-)
generated during the auto-oxidation can react with proton (H+) to generate hydrogen peroxide
(H2O2).
toxic cations such as iron, zinc, copper or manganese as well as hydroxyl radicals [82].
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It has also been proposed that NM plays a role in iron homeostasis: NM is only par-
tially saturated with iron, and thus binds excess and prevents its toxicity [82]. NM also
contains protein and lipids.
1.4 L-DOPA
1.4.1 Short history on L-DOPA as a treatment
L-DOPA was first synthesized by Funk in 1911. Two years later, Guggenheim iso-
lated the compound from the legume Vicia fabra. Both considered L-DOPA to be related
to epinephrine and biologically inactive, although Guggenheim noticed that it had a
very strong emetic capacity after ingesting 2.5 g. This reaction was later associated
with the fact that DA acts on the emetic center of the medulla oblongata. In 1939, Holtz
discovered that AADC catalyzes the decarboxylation of L-DOPA to DA. In 1942, the
same investigator showed that treatment of animals with L-DOPA leads to excretion
of DA in urine. The first link between L-DOPA administration and DA replenishment
in the brain was established by Raab and Gigee in 1951. They treated rats with a large
range of compounds and found that only L-DOPA could increase DA concentration
in the brain. In 1959, Bertler, Rosengren and Sano demonstrated that brain DA was
located mostly in the basal ganglia. They also observed that upon reserpine treatment,
a molecule depleting catecholamine stores and causing parkinsonism-like symptoms,
there was a drop in DA in the basal ganglia, therefore linking DA and motor control
activity [83].
The missing link between L-DOPA and PD was established in 1960 when Erhin-
gen and Hornykiewicz analyzed brains of healthy individuals and PD patients and
observed that PD patients suffered from a severe loss of DA in the corpus striatum. In
1961, Hornykiewicz and Birkmayer launched a clinical trial and observed that L-DOPA
treatment in PD patients improved motor symptoms for at least several hours. The ma-
jor breakthrough that allowed the use of L-DOPA as treatment for PD is attributable to
Colzia: instead of using a single high dose treatment which made the patients sick, he
started with low L-DOPA concentrations and steadily increased them over time. The
dose was thus adjusted for each patient to maximize motor improvements and mini-
mize side effects [84].
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However, the role of L-DOPA in mediating symptoms of PD stayed matter of de-
bate until 1975 when Lloyd published the results of a study in the striatum of PD pa-
tients treated with L-DOPA and showed that: (1) DA levels were nine to fifteen-fold
higher in patients treated with L-DOPA than in non-treated patients, (2) DA levels were
depending on the duration between the last L-DOPA dose and the time of death and
(3) DA content was higher in good responders to the treatment than in poor responders
[85]
1.4.2 L-DOPA toxicity
Reactive oxygen species (ROS) are by-products of DA metabolism that are either
enzymatically or non-enzymatically produced. The main source of toxicity depends
on the intracellular concentration of DA: under low concentrations, the toxicity is me-
diated by activity of MAO. Increasing concentrations of DA lead to non-enzymatic
toxicity caused by the auto-oxidation of L-DOPA and DA [86]. This section describes
the sources of ROS issued from L-DOPA and DA metabolism as well as the means of
detoxification.
1.4.2.1 Via auto-oxidation
At cytosolic pH, protons of the hydroxyl groups of catechol rings dissociate. This
promotes oxidation of CA, including L-DOPA, DA, norepinephrine and epinephrine,
to their respective quinones (see Figure 1.9 A) [87]. This auto-oxidation step can ei-
ther occur via a one- or two- electron oxidation. Both reactions lead to production of
quinones, but the former has an intermediate semiquinone radical [87]. Semiquinones
rapidly oxidize in the presence of oxygen to form quinones and superoxide radicals
[88]. Quinone residues are not stable at cytosolic pH and their amino chain cyclizes to
form leukoaminochrome, which can further oxidize to aminochromes. Aminochromes
can oxidize to dihydroxyindoles and indolquinones, which can polymerize and be in-
tegrated to NM [87]. Quinones are highly reactive compounds and each oxidation step
causes release of superoxide radicals (O ·–2 ) causing GSH depletion and enzymatic in-
activation further discussed in section 1.4.2.3. Furthermore, O ·–2 reacts with protons to
form H2O2 (Figure 1.9 B)
Auto-oxidation can be enhanced by high concentrations of metal ions such as man-
ganese, iron or copper [87]. ROS and reactive nitric oxide species (RNS) such as H2O2,
hydroxyl radicals (·OH), peroxynitrite (ONOO) or nitrite (NO ·–2 ) can also increase ox-
idation rates [87]. RNS are generated by the activity of neuronal nitric oxide synthase
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(nNOS), which synthesizes nitric oxide (NO) as mediator of response to excitatory
amino acids [89].
1.4.2.2 Via enzymatic degradation
As mentioned in section 1.3.3.1, MAO is one of the main enzymes involved in
DA degradation. This protein, located at the outer membrane of the mitochondrium,
increases cellular H2O2 production 100 times when activated [90]. H2O2 can then re-
act with iron via the Fenton reaction and generate hydroxyl radicals [91]. These com-
pounds have several cellular targets and induce DNA mutations, lipid peroxidation or
amino acid modifications [91]. Due to the loss of DAergic neurons during the course of
PD, the turnover of DA is increased, leading to higher expression of MAO and there-
fore increased oxidative stress levels [92]. H2O2 can be detoxified via reaction with 2
GSH by the GPx to form GSSG and 2 H2O. However, GSSG can react with sulfydryl
residues of proteins leading to their inactivation. This can be avoided by recycling of
GSSG to GSH using NADPH via glutathione reductase (GR).
DA can be enzymatically oxidized to DA-quinone by flavoenzymes such as
prostaglandin H synthase, lipoxygenase or xhantine oxidase [93]. Aminochromes
can also be enzymatically reduced back to leukaminochromes by NAD(P)H:quinone
oxidoreductase (DT-diaphorase) or via NADPH cytochrome P450. DT-diaphorase cat-
alyzes a two-electron reduction of aminochrome to leukoaminochrome, while NADPH
cytochrome P450 catalyzes a one-electron reduction of aminochrome to the corre-
sponding semiquinone radical, which is not generated upon two-electron reduction
[87].
1.4.2.3 Consequences
DA-quinones and DOPA-quinones are electron deficient compounds that react
with nucleophiles such as cysteine, GSH or cysteinyl residues of proteins to form 5-
cysteinyl-dopamine and 5-cysteinyl-DOPA, respectively [93]. If cysteine residues are
located in the active site of an enzyme, the reaction with the quinone leads to its in-
activation. Affected proteins include enzymes involved in energy metabolism such
as succinate dehydrogenase (SDH), NADH dehydrogenase, ATPase, isocitrate dehy-
drogenase (IDH), pyruvate dehydrogenase complex (PDH), α-ketoglutarate dehydro-
genase (α-KGDH) or aconitase (Aco), which leads to inhibition of tricarboxylic acid
(TCA) cycle and mitochondrial electron transport chain.
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A second class of proteins affected by quinones include enzymes of the cate-
cholamine synthesis pathway: TH, DAT, QDPR and COMT. They are involved in
L-DOPA synthesis, DA reuptake from the synaptic cleft, recycling of the BH4 cofactor
and degradation of L-DOPA and DA, respectively. Inhibition of the three first enzymes
is beneficial because it reduces the amount of L-DOPA and DA produced and limits
the amount of quinones produced. Inhibition of COMT is detrimental since it prevents
degradation of L-DOPA and DA [93, 94].
A third class of proteins affected by quinones are permeability transition pores
(PTPs). These proteins, located at the inner membrane of mitochondrium, are involved
in the transport of solutes smaller than 1500 kDa. Quinones and oxidants cause an
increase in PTP permeability, which induce swelling of the mitochondria, proton leak
and subsequent depolarization [95]. The direct consequence of this process is a loss of
oxidative phophorylation and uncoupling of ATP synthesis [95].
The activity of DT-diaphorase and NADPH cytochrome P450 also have deleterious
effects on the cells: the NADPH used by DT-diaphorase depletes the pool of electron
donors for GSSG reduction and the NADH used by both enzymes exhausts the electron
donors needed for ATP synthesis in the mitochondria [87].
Quinones have detrimental effects on another important cellular process: au-
tophagy. This includes recycling of cytoplasmic proteins and organelles, which are
transported to lysosomes. Quinones can bind to different proteins and inhibit their
activity: (1) Quinones can form adducts with SNCA, which subsequently forms fibrils.
This complex inhibits chaperone-mediated autophagy (CMA). (2) Quinones can bind
to ubiquitin C-terminal hydrolase I (UCH-LI) which also inhibits CMA. (3) Adduct
formation between quinones and DJ-1 indirectly alters autophagy by disrupting reg-
ulation of oxidative stress. (4) Finally, by binding to β-tubulin, quinones disrupt the
cytoskeleton and prevent fusion of autophagosomes with lysosomes by accumulation
of microtubules [87].
1.4.2.4 Detoxification
Antioxidants are playing a crucial role in quinone detoxification. GSH and ascor-
bic acid (AA) can exert their antioxidant effects via enzymatic reaction with GPx and
AA peroxidase respectively (although AA peroxidase is expressed only in plants) [96]
and via non-enzymatic reaction [97]. Besides the fact that AA and GSH can scavenge
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free radicals [98, 99], they can also directly interact with quinone derivatives (Fig-
ure 1.10). AA can react with quinones to generate hydroquinones and dehydroascorbic
acid (Figure 1.10 A) [100]. Dehydroascorbic acid can be recycled back to AA via a
two-electron reduction by glutaredoxin, a GSH-dependent enzyme [101]. In the case of
DOPA-o-quinone, the hydroquinone formed by the reaction with AA is L-DOPA itself
(Figure 1.10 B) [102, 103], and thus, stabilizes this compound.
Astrocytes possess a great antioxidant capacity [104] and their interaction with
neurons is important to assure protection of the neurons against oxidative stress. In
the brain, astrocytes are responsible for the recycling of AA [105]. For that, they import
dehydroascorbic acid through dedicated transporters, reduce it to AA and export it
back to the extracellular space where it can be used to protect neurons [106].
GSH is the most abundant antioxidant in the body [107] and its concentration can
reach concentrations of 10 mM inside the cells [108]. Astrocytes also support neurons
for GSH synthesis, but the compound cannot be transported across cell membranes
[109]. Thus, in vivo, astrocytes provide precursor for GSH synthesis to the neurons in
the form of the dipeptide CysGly [110]. In co-culture systems of neurons and astro-
cytes, L-DOPA treatment stimulates the production of GSH by astrocytes [111]. GSH
plays an important role in the cellular redox cycle, free radical reactions, thio-transfer
reactions and conjugation [99]. It can be conjugated to DA-quinone, DOPA-quinone or
aminochrome either non-enzymatically or enzymatically by glutathione S-transferase
M2-2 (GST M2-2) to form 5-glutathionyl-dopamine, 4-S-5,6-dihydroxyindoline and 5-
glutathionyl DOPA (Figure 1.10 C) [112], respectively. These products are stable in
the presence of oxidizing agents suggesting that they are final elimination products.
All GSH conjugates can be degraded to glutamate, glycine and 5-cysteinyl-DA or 5-
cysteinyl-DOPA. In vivo 5-S-cysteinyl DOPA has been found in melanoma cells [112],
in cerebrospinal fluid and in brain regions containing high amounts of DA such as the
substantia nigra or the putamen [87]. 5-S-cysteinyl DOPA can also be directly formed via
interaction of DOPA-quinone with the thiol group of cysteine or cysteinyl residues in
proteins. This leads to the protein inactivation if the residue is located within the active
site of the enzyme [113].
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FIGURE 1.10: Mechanism of action of antioxidants on DOPA-o-quinone. (A): Ascorbic acid
(AA) reacts with quinones to form hydroquinones and dehydroascorbic acid. (B): In the case
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cysteine and acetate upon entry into the cells and the cysteine residue can be used for GSH
synthesis.
Chapter 1. Introduction 35
The third antioxidant considered is N-acetyl-L-cysteine (NAC). It prevents the tox-
icity of L-DOPA in two ways: as a synthetic compound, NAC can enter the cell where
it is deacetylated to cysteine, (Figure 1.10 D) [109] and thus, promotes GSH synthesis.
Secondly, like GSH and cysteine, NAC contains a thiol group which directly reacts with
the quinones to stabilize them.
Reactive quinones are inactivated by conjugation via methylation by COMT or
transfer of sulfo group by sulfotransferase [114]. Superoxide dismutase (SOD) and
catalase also possess a protective role by limiting the amount of H2O2 and free superox-
ide radicals in the cytosol [115]. Metallothioneins are a last class of enzymes important
for the prevention of quinone toxicity: they are responsible for metal homeostasis by
binding to heavy metals. These proteins are rich in cysteine residues, which can make
up to 40% of the protein content. Therefore, they can sequester quinones and prevent
further oxidation [93].
Antioxidant systems are important when considering cell viability in the context
of ageing. Levels of GSH, SOD and catalase specifically decrease in the substantia nigra
pars compacta with increasing age rendering these neurons more sensitive to oxidative
stress and neurotoxic insults over time [116]. In PD patients, it has been shown that the
levels of GSH are further reduced in the substantia nigra compared to healthy individu-
als [117] and a correlation has been established between the extent of neuronal loss and
the depletion of GSH [118]. The decrease in GSH levels has been linked to an altered
remethylation of homocysteine to methionine and transsulfuration to cysteine [119]
(Figure 1.11). This mechanism was identified through elevated levels of homocysteine
in the plasma of PD patients. Plasma levels of homocysteine were further increased in
patients under L-DOPA medication, indicating a further decrease in antioxidant levels
[120].
The increased levels of homocysteine can be routed back to L-DOPA and DA
degradation by COMT, the methyltransferase that uses SAM as cofactor and produces
SAH [79]. SAH can be hydrolyzed to homocysteine which can be remethylated to me-
thionine as mentioned above and finally coupled to an adenosyl group to form back
SAM [121]. It is therefore possible that the further increase in homocysteine plasma
levels observed in PD patients under L-DOPA treatment is due to an increased activity
of COMT coupled to an altered remethylation of homocysteine.
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FIGURE 1.11: Transsulfuration of S-adenosyl-homocysteine and glutathione biosynthesis.
Degradation of dopamine via catechol-o-methyltransferase (COMT) is dependent on the use
of S-adenosyl-methionine (SAM) for methylation (in red). S-adenosyl-homocysteine (SAH)
is produced by this reaction and can be recycled. First, SAH is metabolized to homocysteine
by S-adenosyl hydrolase (SAHase) which can either be converted to methionine by methio-
nine synthase (MS) or to cystathionine by cystathionine β-synthase (CBS) by addition of ser-
ine. Methionine can finally be recycled to SAM by methionine adenosyltransferase (MAT).
The second pathway involved is the transsulfuation pathway (in green) where cystathionine
enters the glutathione synthesis pathway (in blue) via cystathionine γ-lyase (CGL) to form
cysteine. γ-glutamylcysteine is formed by addition of glutamate to cysteine by glutamate-
cysteine ligase (GCL). Finally, glutahione (GSH) is synthesized by further addition of glycine
by glutathione synthase (GSS). GSH can be degraded into the three original amino acids by γ-
glutamyl transpeptidase (γGT) which releases glutamate and produces the dipeptide cysteinyl-
glycine. This compound can finally be cleaved by dipeptidase (Dip) to release glycine and
cysteine.
1.5 Metabolomics
After describing the biological background, these last sections focus on the an-
alytical methods applied in this work. I will start with a general introduction on
metabolomic studies followed by a more detailed description of GC-MS studies. Fi-
nally, I will give an overview of stable isotope-assisted metabolomics and its applica-
tion in the context of this work.
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1.5.1 Metabolomics studies
Metabolites are small molecules that can serve as substrate for enzymatic reactions
[122]. Therefore, metabolomics is the study of metabolites within cells, body fluids,
tissues or organisms. Metabolites are considered as the direct signature of biochemical
activity since they are the final products of epigenetic regulation of genes and post-
translational modification of proteins [122].
Depending on the goal and design of the experiment, metabolomics studies can be
divided into two classes: targeted and untargeted approaches. In targeted metabolo-
mics, the interest is focused on a selected subset of metabolites. These experiments are
designed to answer a specific question directed towards a particular pathway. In un-
targeted metabolomics, the approach is slightly different: instead of being interested in
a subset of compounds, the goal is to detect as many metabolites as possible to obtain a
broad overview of metabolic adaptation upon treatment for example [122]. Given the
different approaches, the obtained data sets are really different and require different
pipelines for data processing and analysis.
In metabolomics studies, sample preparation is critical: the metabolite composi-
tion can quickly change due to enzymatic activity, thermo-sensitivity, high reactivity or
breakdown of metabolites [123]. To increase reproducibility, extractions are performed
using solvents under cold conditions to denature enzymes and preserve metabolites
[123]. Once the samples are extracted, they are dried under vacuum and stored under
cold temperature to prevent metabolite degradation [123].
Several metabolomics platforms are available for measurements of biological sam-
ples. The most commonly used being nuclear magnetic resonance (NMR), GC-MS and
liquid chromatography coupled to mass spectrometry (LC-MS) [123]. Each of them
presents advantages and disadvantages: NMR requires minimal sample preparation.
However, NMR is less sensitive than mass spectrometry [123]. GC-MS and LC-MS are
more suitable techniques for measuring and quantifying a broad range of molecules.
None of the aforementioned methods is powerful enough to cover the full metabolome.
The best approach so far is to use a combination of techniques [123]. GC-MS was the
technique of choice during my PhD thesis. Therefore, I will further discuss this tech-
nique using DA as example.
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1.5.2 Gas chromatography - mass spectrometry
GC-MS can be divided into two parts: the gas chromatograph and the mass spec-
trometer. The chromatography consists of a column composed of a specific stationary
phase. The sample is transferred to the gas phase and loaded on the column, where
a temperature gradient is applied to induce migration of metabolites on the column
depending on their affinity with the stationary phase. Therefore, the chromatography
allows for compound separation based on retention.
The second component of GC-MS is the mass spectrometer. This can be divided
into three parts: (1) an ionization step by electron ionization (EI), (2) a ion selection step
by quadrupole and (3) finally, the detector records all ions reaching it. The role of EI is
to fragment the metabolites eluting from the column: the metabolites are bombarded
with electrons generated from a filament and are fragmented in highly reproducible
ion patterns. It is therefore the most commonly used mode of ionization [123]. Upon
fragmentation, the ions travel through the quadrupole, which allows either all ions to
migrate to the detector or selects for specific ions. Finally, the detector records the ions
reaching it as well as their intensity. A detector is characterized by its scan rate, which
is how fast it scans a mass spectrum: the faster it is, the more data points are recorded
and available for analysis.
The complexity of a sample can be visualized by the total ion current (TIC) chro-
matogram. This is obtained by summing up the intensity of all ions detected at each
recording point. The TIC of DA 4TMS 2 is displayed in Figure 1.12 A.
In optimal conditions, one peak represents one metabolite, which can be further
visualized by its mass spectrum. This is the plot of intensity against mass over charge
ratio (m/z). The patterns obtained in the mass spectra are compound specific and
can be used for metabolite identification along with the retention time. Identification
is performed by comparison of obtained spectra and retention times with compound
libraries. The compound libraries used in this work were built in house.
2Sample derivatization is further discussed in section 1.5.4
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FIGURE 1.12: Chromatogram and spectrum of dopamine. (A): The sum of all ions recorded
at a given time point can be visualized by the total ion current (TIC) chromatogram, plotting
signal intensity in function of the time. A compound can first be characterized by its retention
time: in this temperature gradient, the retention time for dopamine is 28.16 min. (B): A second
characteristic of a compound is its spectrum obtained by fragmentation in the ion source. The
spectrum of dopamine is displayed. Specific ions of dopamine include 174.1 and 426.2.
Figure 1.12 B represents the mass spectrum of DA. This plot displays the intensity
of the signal in function of the m/z. Ion m/z 426.2 represents the fragment of DA 4TMS
in which the full carbon backbone of the metabolite is present. Ions m/z 427.2 and 428.2
are the isotopic peaks of this molecule. Upon fragmentation in the ion source, other
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fragments are formed: ion m/z 174.1 can also be used to identify DA and this molecule
contains only a fragment of the original DA. Isotopic peaks are m/z 175.1 and 176.1.
The isotopic peaks obtained in the mass spectrum are due to natural occurrence
of stable isotopes. Isotopes are obtained upon addition of neutron within the nucleus
of an atom. For example, 98.9% of the naturally occurring carbon contains six protons
and six neutrons, called 12C. Around 1.1% of carbon atoms are formed by six protons
and seven neutrons, giving rise to 13C. For hydrogen, 99.99% of the atoms contain only
one proton and are called 1H. The second possible isotope contains one proton and
one neutron and is called 2H or deuterium. The presence of this extra neutron can be
visualized on GC-MS mass spectrum due to a shift of one mass unit.
The spectrum in Figure 1.12 B was obtained in full SCAN mode, meaning that all
the ions hitting the detector are recorded. The detector can also be operated in selected
ion monitoring (SIM) mode: specific ions can be selected and only those are recorded.
This increases the sensitivity of the measurement and allows to detect low amounts of
metabolites [124]. In the case of DA, specific ions used for SIM measurement are 174.1
and 426.2.
1.5.3 Limit of detection
Limit of detection (LOD) is the lowest quantity of analyte that can be distinguished
from the background signal. This value is instrument specific, analyte dependent and
can be calculated from the signal-to-noise ratio (S/N) [125]. I calculated this value
for ion 426.2 of DA in SIM mode. The LOD is 234.3 fmol (30 μL in vial), which is
equivalent to 7.8 fmol on column (1 μL injected). Given the fact that 1 μL is injected, this
corresponds to a LOD of 7.8 nM. Using electrochemical detection, Kim et al. estimated
the LOD of DA to be 2.64 μM [126]. Using nanoparticles and modified electrodes,
Guo et al. reported an LOD of 30 nM [127]. The addition of a microfluidic device can
decrease the LOD to 3.5 nM [128]. Therefore, the LOD obtained using GC-MS is in
the range of LOD obtained with other methods. The advantage of GC-MS is that the
spectrum allows for specific identification, while using electrochemical detection, this
identification is based on elution profile [129].
Chapter 1. Introduction 41
1.5.4 Sample preparation: derivatization
To perform GC-MS analysis, samples need to be transferred to the gas phase. Most
compounds containing polar functional groups are thermally labile or not volatile at all
[123]. This can be circumvented by the use of chemical derivatization.
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FIGURE 1.13: Derivatization of functional groups in GC-MS. Derivatization is necessary in
order to bring metabolites to the gas phase. (A): Methoxyamine prevents keto-enol tautomer-
ization of aldehydes and ketones. (B): MSTFA or MTBSTFA can be used for alkylsilylation on a
wide range of functional groups.
Common derivatization methods in GC-MS are based on oximation followed
by silylation [123]. Oximation can be performed by methoxyamine which modi-
fies aldehyde and ketone groups (Figure 1.13 A). This allows for example to keep
sugars in open chain form. Methoxyamine can exist in two different configu-
ration (E/Z), which give two derivatives. Silylation can be performed with N-
methyl-N-(trimethylsilyl)trifluoroacetamide (MSTFA) or N-tert-butyldimethylsilyl-
N-methyltrifluoroacetamide (MTBSTFA), both modifying amine, amide, alcohol, thiol
and carboxylic acid groups (Figure 1.13 B) and give rise to trimethylsylil (TMS) or
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tert-butyl dimethylsilyl (TBDMS) derivatives, respectively. In order to perform a com-
plete silylation, the samples must be completely dry: silylation reagents are extremely
sensitive to hydrolysis and the presence of water can use up to twenty times its volume
in derivatization reagent.
1.6 Stable isotope-assisted metabolomics
Results from non-targeted metabolomics experiments give indication about intra-
cellular or extracellular metabolite levels. In addition, information about consumption,
secretion and transport reactions are obtained. This does not provide any information
on metabolic fluxes nor which carbon source is preferably used for specific pathways
and how this could change upon stimulation. These can be investigated using sta-
ble isotope labeled nutrients [130]. The most commonly used isotope is 13C. In this
work, the tracers used were fully labeled glucose ([U-13C6]-glucose), fully labeled glu-
tamine ([U-13C5]-glutamine), fully labeled pyruvate ([U-13C3]-pyruvate), glucose la-
beled at positions 1 and 2 ([1,2-13C2]-glucose), fully labeled phenylalanine ([U-13C9]-
phenylalanine) and fully labeled tyrosine ([U-13C9]-tyrosine).
1.6.1 Isotopic steady state
In order to perform stable isotope-assisted metabolomics, the cells need to be at
metabolic and isotopic steady state. When a tracer is supplemented to cells, intracel-
lular enrichment of downstream metabolites increases over time until it reaches a sta-
ble level, which is the isotopic steady state. Using [U-13C6]-glucose as tracer, isotopic
steady state within glycolysis is reached within minutes while it takes up to several
hours to reach this point in TCA cycle intermediates [130]. To assess the isotopic steady
state precondition in LUHMES cells, I incubated these cells with [U-13C6]-glucose or
[U-13C5]-glutamine for 2 min, 15 min, 30 min, 1 h, 6 h, 18 h, 24 h and 48 h. I established
that cells were at isotopic steady state after 24 hours for both tracers (Appendix A).
1.6.2 Mass isotopomer distribution
The use of stable isotope tracers leads to the formation of labeling patterns in target
metabolites. Metabolites only differing in their isotopic compositions are called isotopo-
logues or mass isotopomer. As isotopologues have different masses, they can be separated
on a mass spectrum [130]. On the other hand, isotopomers are positional isomers with
the same isotopic composition, therefore, they have the same mass. These cannot be
resolved by GC-MS, which does not provide any positional information [130].
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Adapted from [131].
Mass isotopomer distributions (MIDs) vector can be determined and describe the
fractional abundance of each isotopologue normalized to the sum of all possible iso-
topologues [130]. Therefore, the sum of all MIDs of a metabolite is always 1 or 100%.
An example is given in Figure 1.14. In Figure 1.14 A, different isotopologues give rise
to different spectra, with shift of one m/z unit for each heavy isotope added to the
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metabolite. A sample is usually constituted of a mixture of isotopologues which gives
rise to complex MID pattern (Figure 1.14 B). This can be computationally solved using
linear equation systems. In the resolution of these equations, the natural abundance of
isotopes needs to be taken into account and corrected for. The results can then be dis-
played in the form of barplots for example (Figure 1.14 C), where M0 is the non-labeled
fraction of metabolites, M1 represents the fraction of metabolites containing one atom
labeled and M2 represents the fraction of metabolites containing two labeled atoms.
1.6.3 Compartmentalization
Stable isotope assisted-metabolomics can be used to evaluate compartmentaliza-
tion of metabolites. For example, pyruvate can be found in the cytosol and in the
mitochondrium. Upon extraction and calculation of pyruvate MIDs, it is not possi-
ble to evaluate from which compartment they derive. However, this can be estimated
by proxy: lactate dehydrogenase (LDH), the enzyme converting pyruvate to lactate is
strictly cytosolic while the expression of alanine aminotransferase (ALT) appears to be
mainly mitochondrial in some cell lines [130]. Indeed, knock down of the pyruvate
mitochondrial transporter in cultured myoblasts leads to a strong decrease in alanine
levels, suggesting a strong contribution of the mitochondrial ALT in alanine synthesis
in these cells [132]. Therefore, the labeling of lactate reflects the cytosolic pool of pyru-
vate labeling, while the labeling of alanine reflects the mitochondrial pyruvate pool
[130].
1.6.4 Fractional contribution
MIDs are also informative on nutrient contribution to a certain metabolite. This
can be calculated by a weighted average of all isotopologues, as follows:
1
n
×
n∑
i=1
Mi × i
Where n is the number of carbon atom of the molecule and Mi is the ith mass iso-
topomer. This gives information on fractional contribution of a substrate to a metabo-
lite and allows to determine whether a treatment or conditions induce metabolic
switches [130].
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Finally, stable isotope-assisted metabolomics experiments give information on
pathway activity. This can be inferred by the ratio of two alternative and converg-
ing pathways. This implies that a specific pathway can be identified by a specific
isotopologue and that a metabolite of the targeted pathway can be measured [130].

Aim of the thesis
Although described for the first time in 1817 by James Parkinson, the mechanisms
underlying the development of Parkinson’s disease (PD) are still unknown. This neu-
rodegenerative disease primarily affects dopaminergic neurons within the substantia
nigra pars compacta. The death of dopaminergic neurons causes a drop in the amounts
of dopamine (DA) in the striatum, leading to impaired movement control. Genetic
and environmental factors are involved in some cases and molecular mechanisms in-
clude increased oxidative stress, mitochondrial dysfunction or disruption of proteaso-
mal degradation. So far, there exists no cure for PD, but symptoms can be managed for
several years using 2,3-dihydroxy-L-phenylalanine (L-DOPA), the precursor of DA, as
a treatment.
In vitro models for PD include cell lines derived from different organisms (hu-
man, mouse, rat), different organs (brain, adrenal gland) or different cell types (neu-
roblastoma, pheochromocytoma, immortalized mesencephalon cells). The most com-
monly used in vivo models include mice and rats unilaterally treated with PD-inducing
drugs, such as 1-methyl-4-phenylpyridinium (MPP+), 6-hydroxydopamine (6-OHDA)
or rotenone. Both in vitro and in vivo models present some disadvantages: most of the
cell lines used are of cancer origin and therefore proliferate in culture. Proliferating and
resting cells have distinct metabolism. Therefore, the use of cancer cells to study neu-
rons under cell cycle arrest is not ideal. Concerning in vivo studies, it is important to
bear in mind that enzymatic regulation of tyrosine hydroxylase (TH), the rate-limiting
enzyme in the DA synthesis pathway, is organism-specific. Moreover, mouse and rat
do not produce neuromelanin (NM), a pigment typical for DA producing cells.
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Given cell type and organism specificity of central carbon metabolism as well as
regulation of DA synthesis, it is of crucial importance to have a study model that
reflects the human dopaminergic neurons from the substantia nigra as best as pos-
sible. A second important point to address is the interplay between the different
enzymes involved in DA synthesis. Therefore, I decided to focus this work on the
human LUHMES immortalized mesencephalon cells. These cells can be differenti-
ated into post-mitotic TH-expressing neurons, but they do not produce DA in amounts
detectable by gas chromatography - mass spectrometry (GC-MS).
In the first part of my PhD, I investigated the effects of L-DOPA on the metabo-
lism of LUHMES cells. LUHMES cells were treated with L-DOPA for 24 hours and
metabolites were extracted for GC-MS measurement. I used a non-targeted approach
to assess the overall changes in the metabolism as well as stable isotope-assisted me-
tabolomics in order to follow the fate of carbon sources throughout central carbon
metabolism.
In the second part, I focused on the generation of a human DA-producing cell
system that would not be of cancer origin. After comparing gene and protein expres-
sion of available systems, I used lentiviral-mediated systems to increase expression of
genes involved in DA synthesis. In the course of this project, I also evaluated the role
of enzymes involved in the synthesis of DA.
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2.1 Cell culture
2.1.1 LUHMES cell line
LUnd Human Mesencephalon (LUHMES) cells [58] were kindly provided by
Professor Marcel Leist (University of Konstanz, Germany). They are issued from a
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8-week old foetus and were conditionally immortalized using a v-myc vector. Thus the
cells are proliferating. Upon addition of tetracycline, the cells stop proliferating and
differentiation can be initiated.
The cells are always cultivated in flasks and plates coated with 5 µg/mL poly-L-
ornithine (PLO) (Sigma Aldrich, P4957) and 1 µg/mL fibronectine (Sigma Aldrich,
F1141) for minimum 3 hours and dried before use.
Proliferating cells were cultivated in Advanced Dubelcco’s Modified Eagle’s
Medium (DMEM)/F-12 (Life Technologies, 12634) supplemented with 2 mM L-
Glutamine (Sigma Aldrich, G7513), 1x N2 (Life Technologies, 17502-048) and 40
ng/mL fibroblast growth factor (FGF) (R&D Systems Europe, 4114-TC). Cells were
passaged twice a week. They were dissociated with 0.05% Trypsin-EDTA (1X) (Life
Technologies, 25300) for 5 min, 500.000 cells were centrifuged for 5 min at 200 x g and
resuspended in 10 mL of fresh proliferation medium in a coated T75 flask.
For differentiation, 8 million cells were transferred to a T175 flask and medium
was exchanged to differentiation medium on the next day. This medium consists of
Advanced DMEM/F-12 supplemented with 1 mM L-Glutamine, 1X N2, 1 mM dibu-
tyryl cAMP (db-cAMP) (Sigma Aldrich, D0627), 1 µg/mL tetracycline (Sigma Aldrich,
T7660) and 2 ng/mL glial cell line-derived neurotrophic factor (GDNF) (R&D Systems
Europe, 212-GD-050). 48 h later, cells are seeded in plates, unless otherwise stated, with
the following densities: 1 million cells per well in 6-well plates, 500.000 cells per well
in 12-well plates, 250.000 cells per well in 24-well plates and 125.000 cells per well in
48-well plates. Cells were kept in culture for additional 4 days (day 6 of differentiation)
or 8 days (day 10 of differentiation) prior to experiments.
2.1.2 IMA2.1 cell line
The mouse immortalized astrocyte IMA2.1 cell line [133] was kindly provided
by Professor Marcel Leist (University of Konstanz, Germany). They were culti-
vated in DMEM low glucose (Sigma Aldrich, D6046) supplemented with 10% heat
inactivated fetal bovine serum (FBS) (Gibco, 10500-064, Lot #1096628K) and 1% Peni-
cillin/Streptomycin (P/S) (Sigma Aldrich, P0781). They were passaged twice a week
and dissociated using 0.05% Trypsin-EDTA (1X) (Life Technologies, 25300).
For experiments, the cells were seeded at a density of 50.000 cells per well in
48-well plates for cell viability assay and 100.000 cells per well in 12-well plates for
metabolite extraction 24 hours before the start of the treatment.
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2.1.3 BV2 cell line
The retroviral immortalized microglia BV2 cell line [134] was kindly provided by
Dr Wolfgang Wurst (Helmholtz Centre, Munich, Germany) were cultivated in Ad-
vanced DMEM/F-12 (Life Technologies, 12634) supplemented with 2mM L-Glutamine
(Sigma Aldrich, G7513). Cells were passaged twice a week and dissociated using a cell
scraper.
For experiments, cells were seeded 24 hours before treatment at the density of
100.000 cells per well in 24-well plates for cell viability assay and at the density of
200.000 cells per well in 12-well plates for metabolite extraction 24 h before the start of
the treatment.
2.1.4 SH-SY5Y cell line
The neuroblastoma cell line SH-SY5Y [135] was kindly provided by Dr Aleksan-
dar Rakovic (University of Luebeck, Germany). They were cultivated in DMEM high
glucose (Sigma Aldrich, D5796) supplemented with 10% FBS and 1% P/S. They were
passaged twice a week and dissociated using 0.05% Trypsin-EDTA (1X).
For experiments, the cells were seeded at a density of 50.000 cells per well in
48-well plates for cell viability assay and 100.000 cells per well in 12-well plates for
metabolite extraction 24 hours before the start of the treatment.
2.1.5 P-C12 cell line
The rat pheochromocytoma cell line PC-12 was obtained from ATCC (CRL-
1721.1 R©). They were cultivated in ATCC-formulated F-12K medium (ATCC, 30-2004)
completed with 2.5% FBS and 15% horse serum. Cells were passaged twice a week and
dissociated using a cell scraper.
For experiments, cells were seeded at a density of 50.000 cells per well in 48-well
plates for cell viability assay 24 h before the start of the treatment and 300.000 cells per
well in 12-well plates for metabolite extraction 48 hours prior to extraction.
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2.1.6 CCF-STTG1 cell line
The human astrocytoma cell line CCF-STTG1 was obtained from ATCC (CRL-
1718 R©). They were cultivated in ATCC-formulated RPMI-1640 medium (ATCC, 30-
2001) completed with 10% FBS. Cells were passaged twice a week and dissociated us-
ing 0.05% Trypsin-EDTA (1X).
For experiments, cells were seeded at a density of 150.000 cells per well in 48-well
plates for cell viability assay 24 h before the start of the treatment.
2.2 Treatments
2.2.1 L-DOPA
2,3-dihydroxy-L-phenylalanine (L-DOPA) (Sigma Aldrich, D9628) was freshly pre-
pared unless otherwise stated and reconstituted in cell culture medium. Treatments
were carried out for 24 h.
When assessing the role of anti-oxidants on the viability of LUHMES cells upon
L-DOPA treatment, ascorbic acid (AA) (Sigma Aldrich, 255564), reduced L-glutathione
(GSH) (Sigma Aldrich, G6013) and N-acetyl-L-cysteine (NAC) (Sigma Aldrich, A7250)
were reconstituted in cell culture medium and applied to the cells at the same time as
L-DOPA at the concentration of 1 mM.
When evaluating the transport of L-DOPA, cells were co-treated with 1 mM L-
leucine (Sigma Aldrich, L8912) reconstituted in cell culture medium or 5 μM GBR
12909 dihyrdrochloride (Sigma Aldrich, D052). GBR12909 was reconstituted in DMSO
(Sigma Aldrich, D2438) at the concentration of 5 mM and diluted to the final concen-
tration in cell culture medium. These compounds were used to inhibit the large amino
acid transporter (LAT) and the dopamine transporter (DAT) respectively. To evalu-
ate if the toxicity is due to enzymatic degradation products, cells were treated with
3,4-dihydroxy-D-phenylalanine (D-DOPA) (Sigma Aldrich, D9378) at the same con-
centrations as L-DOPA. superoxide dismutase (SOD) (Sigma Aldrich, S7571) was re-
constituted in cell culture medium at the concentration of 1000 U/mL and was further
diluted to 500 U/mL for treatment for 24 h.
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2.2.2 Others
LPS: BV2 cells were treated with lipopolysaccharide (LPS) from E.coli (Sigma
Aldrich, L6529) to induce inflammatory response. It was reconstituted in Phosphate
Buffer Saline (PBS) without calcium and magnesium (Sigma Aldrich, D1408) at the
stock concentration of 1 mg/mL. The final concentration used was 10 ng/mL for 6h.
When an additional L-DOPA treatment was performed, the L-DOPA was reconstituted
in cell culture medium and applied to the cells 18 h before the LPS treatment.
MPP+: LUHMES cells were treated with 1-methyl-4-phenylpyridinium (MPP+)
(Sigma Aldrich, D048) to induce mitochondrial complex I inhibition. Stock solutions of
13.5 mM were prepared in water and stored at -20 ◦C. The solution was then diluted
1:10 in cell culture medium and 5.6 μL were added in 1 mL of medium in each well
to the final concentration of 10 μM. Incubation was carried for 24 h before metabolite
extraction.
Rotenone: LUHMES cells were treated with rotenone (Sigma Aldrich, R8875) to
induce mitochondrial complex I inhibition. Stock solutions were prepared in DMSO at
the concentration of 10 mM. This solution was stored at -20 ◦C. Upon utilization, it was
diluted in cell culture medium to 1 mM and 1 μL was added in 1 mL of medium in each
well to the final concentration of 1 μM. Incubation was carried for 6 h before metabolite
extraction.
Heptelidic acid: LUHMES cells were treated with heptelidic acid (Abcam, ab144269)
to induce glyceraldehyde-3-phosphate dehydrogenase (GAPDH) inhibition. Stock so-
lutions were prepared in water at the concentration of 1 mM. This solution was stored
at -20 ◦C. Upon utilization, 3.6 μL was diluted in 1 mL of medium to the final concen-
tration of 3.6 μM. Incubation was carried for 24 h before metabolite extraction.
H2O2: LUHMES cells were treated with H2O2 (Sigma Aldrich, 216763) for cell
viability assays. Cells were treated for 24 h with concentrations ranging from 12.5 μM
to 200 μM.
Glutamate: LUHMES cells were treated with glutamate (Sigma Aldrich, G8415) for
cell viability assay. Cells were treated with concentrations ranging from 100 μM to 400
μM for 24 h.
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Acetate: LUHMES cells were treated with acetate (Sigma Aldrich, S8750) for
metabolite extraction. Cells were treated for 24 h with 800 μM acetate and 400 μM
pyruvate (instead of the usual 1 mM) before metabolite extraction. These concentra-
tions correspond to the concentrations of acetate and pyruvate measured in Advanced
DMEM/F-12 incubated without cells for 24 h with 200 μM L-DOPA.
Tyrosine hydroxylase (TH) cofactors: LUHMES AADCox cells were treated for 5 h
with 200, 400 or 600 μM sepiapterin (Sigma Aldrich, S154) before metabolites were
extracted. The same cell line was also treated with 100 μM and 200 μM 6R-L-erythro-
5,6,7,8-tetrahydrobiopterin (BH4) (Sigma Aldrich, T4425) for 30 min before metabo-
lite extraction. For both compounds, solutions were prepared freshly in cell culture
medium.
2.3 Molecular Biology
2.3.1 RNA extraction
RNA was extracted either directly from cells or from interphases after metabo-
lite extraction using the RNeasy Mini Kit1 (Qiagen, 74106) following manufacturer’s
instructions. If the RNA was extracted from the cells, they were seeded, treated and
washed once with PBS before 350 μL RLT buffer supplemented with 10 μL/mL β-
mercaptoethanol (BME) (Sigma Aldrich, M3148) was added. If the RNA was extracted
from the interphase, the interphase contained in methanol was centrifuged for 5 min at
16,000 x g at 4 ◦C. All the methanol was removed and the interphase was left to dry be-
fore 350 μL RLT/BME buffer was added. The rest of the extraction was done following
the manufacturer’s instruction and the RNA was eluted in 40 μL of RNase free water.
RNA concentration was measured using the Nanodrop. Samples were stored at -80 ◦C.
2.3.2 cDNA synthesis
cDNA was synthesized by using SuperScript III Reverse Transcriptase R© kit2
(Thermo Scientific, 18080-044) and following manufacturer’s instruction. 0.1 to 0.5 μg
of RNA were used per reaction and the final product was diluted in 180 μL of RNase
free water to obtain a final volume of 200 μL. Samples were stored at -20 ◦C.
1https://www.qiagen.com/us/shop/sample-technologies/rna/rna-preparation/
rneasy-mini-kit
2https://www.thermofisher.com/order/catalog/product/18080085
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2.3.3 qPCR using LigthCycler 480
All primers used for qPCR were designed using the NCBI Primer-BLAST tool3.
They were sent for synthesis to Eurogentec4 at a concentration of 100 μM. All human
and mouse primer sequences used in this thesis can be found in tables 2.1 and 2.2.
A master mix solution was prepared for each primer pair containing per sample in a
384-well plate: 0.25 μL of 10 μM forward and reverse primer, 5 μL of IQ SYBR Green
Supermix (Bio-Rad, 170-8885) and 3.5 μL of H2O. 9 μL of master mix and 1 μL of cDNA
were added per well. The plate was then sealed and centrifuged before being loaded
on the LightCycler 480 (Roche). The program used to run the PCR can be found in
Table 2.3.
TABLE 2.1: Sequences of human primers used for qPCR
Gene symbol Sequence
DAT
fwd 5’-GTCACCAACGGTGGCATCTA-3’
rev 5’-CTGGATGTCGTCGCTGAACT-3’
DDC
fwd 5’-CTGTCCCATGAGTTTGAGTC-3’
rev 5’-CACTTTGTTGGAACCCTTTAG-3’
GTPCH
fwd 5’-GCTGTAGCAATCACGGAAGC-3’
rev 5’-TTTGGATCCTCCCGGAACAC-3’
L27
fwd 5’-CTGGTGGCTGGAATTGAC-3’
rev 5’-ACAGAGTACCTTGTGGGC-3’
TH
fwd 5’-TGTAAGCAGAACGGGGAGGT-3’
rev 5’-CTGGATGCGTGAGGCATAGC-3’
VMAT2
fwd 5’-CCTTCTGCTGGTGGTGCTAT-3’
rev 5’-AGGGCAGTTGTGATCCATGA-3’
TABLE 2.2: Sequences of mouse primers used for qPCR
Gene symbol Sequence
IL1b
fwd 5’-TGCCACCTTTTGACAGTGATG-3’
rev 5’-TGATGTGCTGCTGCGAGATT-3’
iNOS
fwd 5’-ACATCGACCCGTCCACAGTAT-3’
rev 5’-CAGAGGGGTAGGCTTGTCTC-3’
continued . . .
3http://www.ncbi.nlm.nih.gov/tools/primer-blast/
4http://www.eurogentec.com/eu-home.html
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TABLE 2.2: (continued)
Gene symbol Sequence
L27
fwd 5’-ACATTGACGATGGCACCTC-3’
rev 5’-GCTTGGCGATCTTCTTCTTG-3’
TNFa
fwd 5’-GGTTCTGTCCCTTTCACTCAC-3’
rev 5’-TGCCTCTTCTGCCAGTTCC-3’
TABLE 2.3: Run protocol for qPCR on the LightCycler 480
Step Temperature Duration Repetition
Denaturation 95 ◦C 5 min
Amplification
95 ◦C 30 sec
60 ◦C 30 sec x 45
72 ◦C 30 sec
Melting curve
95 ◦C 15 sec
40 ◦C 90 sec
95 ◦C continuous
Cooling 40 ◦C 30 min
2.3.4 Western Blot
2.3.5 Protein extraction
Proteins were extracted using mammalian protein extraction reagent (M-PER)
(Thermo Fischer Scientific, 78501) supplemented with cOmplete Mini EDTA-free pro-
tease inhibitor (Roche, 11836170001, 1 tablet diluted in 10 mL of M-PER). Cells in
6-well plates were extracted with 120 μL of M-PER-cOmplete and cells from 12-well
plates were extracted with 60 μL. The extract was transferred to a tube and vortexed
for 10 min at 4 ◦C and 1400 rpm on a Thermomixer (Eppendorf). The extract was
centrifuged for 10 min at 4 ◦C and 16,000 x g. The supernatant was finally transferred
to a new tube and the samples were stored at -80 ◦C. Before loading on a sodium
dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel, the samples were
quantified using the spectrophotometer Nanodrop 2000C UV-V15 (Thermo).
Chapter 2. Material and Methods 57
2.3.5.1 SDS-PAGE
The protein extracts were denaturated by dilution in self-made 5X Laemmli buffer
and heated at 95 ◦C for 5 min. Then, 10 or 20 μg were loaded on self-made 10% acry-
lamide gels. The precision plus protein kaleidoscope standard (Bio-Rad, 161-0375)
served as marker. Gels were run for 20 min at 90V, then at 120V until the Laemmli
buffer reached the end of the gel.
2.3.5.2 Transfer
The proteins were transferred to a 0.45 μm polyvinylidene fluoride (PVDF) mem-
brane (Merck Millipore, IPFL00010) at 80V for 1 h. The membranes were then blocked
in 5% skim milk (Fluka, 70166) (w/v) for 1 h at room temperature or overnight at 4 ◦C.
2.3.5.3 Antibodies and detection
The list of antibodies and their respective dilutions can be found in table 2.4.
TABLE 2.4: Antibodies and dilution used.
Antibody Supplier Dilution
Primary
mouse anti-TH Millipore MAB318 1:5000 in 5% Milk
rabbit anti-DDC Cell Signaling 13531 1:1000 in 5% BSA
mouse anti-V5 HRP Invitrogen 46-0708 1:5000 in 5% Milk
mouse anti-GAPDH HRP Sigma G9295-25UL 1:1000 in 5% Milk
mouse anti-beta actin Sigma A5451 1:3000 in 5% Milk
Secondary
anti-mouse HRP Cell Signaling 7076P2 1:10.000 in 5% Milk
anti-rabbit HRP Cell Signaling 7074P2 1:10.000 in 5% Milk
Antibodies were incubated for 1 h at room temperature or overnight at 4 ◦C. They
were diluted either in 5% skim milk or in 5% bovine serum albumine (BSA) (VWR,
A6588,0100), following the recommendation from the antibodies provider. After in-
cubation with primary antibodies, the membranes were washed three times for 5 min
with TBS-Tween. Then the secondary antibody was added and the membranes were
incubated for 1 h at room temperature or overnight at 4 ◦C. After three additional wash-
ing steps, detection was done using the Odyssey Fc Imager (LI-COR), the standard was
detected at 700 nm for 30 sec and the horseradish peroxidase (HRP)-conjugated anti-
bodies were detected with the chemiluminescence channel for 10 min, after a 1-min
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incubation in self-made pCA-ECL detection reagent. Data were analysed using Image
Studio software (LI-COR).
2.4 Cell viability assay
Cell viability was assayed using resazurin (Sigma Aldrich, R7017). Resazurin, a
blue and non-fluorescent dye, can be reduced to resorufin, which is pink and fluores-
cent, proportionally to the cell density [136]. Stock solutions of 1 mg/mL were pre-
pared, filtered with a 0.22 μm filter and stored at 4 ◦C protected from light. Cells were
then treated for 1 h with a final concentration of 5 μg/mL. Fluorescence was measured
with excitation wavelength of 570 nm and emission wavelength of 590 nm using Syn-
ergy Mx microplate reader (BIOTEK).
2.5 Cloning
The plasmids used for cloning were purchased from Harvard Medical School Plas-
mid5. Plasmids used:
• THox: clone HsCD00378692
• Aromatic amino acid decarboxylase (AADC)ox: clone HsCD00003768.
2.5.1 Bacterial growth
All bacterial plasmid amplifications were carried using the One Shot R© MAX
Efficiency R© DH5αTM-T1 R© competent cells (Invitrogen, 12297016). Culture plates were
prepared with LB agar (Sigma, L2897) and supplemented with the corresponding
antibiotic. Liquid cultures were carried out in LB broth (Sigma L3022) supplemented
with antibiotics. A single colony was picked from the plate and transferred to 5 mL
culture for minimum 10 hours before being transferred to 200 mL liquid culture for an
overnight incubation. Liquid cultures were incubated at 37 ◦C with constant shaking
(200rpm). Liquid cultures were incubated at the same temperature with constant shak-
ing (200rpm). Before purification of the plasmids by maxiprep, glycerol stocks were
made: 700 μL of bacteria were mixed with 300 μL of glycerol (Sigma Aldrich, G6279)
and stored at -80 ◦C.
5https://plasmid.med.harvard.edu/PLASMID/Home.xhtml
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2.5.1.1 Transformation
25 μL of DH5αTMbacteria were transformed with 1 μL of plasmid and incubated on
ice for 30 min. Heat shock was performed for 30 sec at 42 ◦C. 125 μL of SOC medium
(Invitrogen, PIN 46-0700) were then added and the bacteria were incubated for 1 h at
37 ◦C with constant shaking (900rpm). 100 μL of the transformation were plated on
agar plates and incubated overnight at 37 ◦C.
2.5.1.2 Plasmid purification
Plasmids were purified using the NucleoBond Xtra Midi/Maxi kit6 (Macherey
Nagel, 740414.50) following manufacturer’s instructions. Plasmids were reconstituted
in 400 μL water.
2.5.2 Gateway cloning
2.5.2.1 Attachment sites addition
For the AADC plasmid that was not compatible with the Gateway system, attB
sites needed to be added to the gene of interest. This was done by PCR. The run proto-
col can be found in table 2.5. A description of the master mix follows.
TABLE 2.5: Run protocol for to attach attB sites
Step Temperature Duration Repetition
Denaturation 95 ◦C 3 min
Amplification
95 ◦C 30 sec
60 ◦C 45 sec x 45
68 ◦C 1 min 30 sec
Final elongation
68 ◦C 10 min
10 ◦C pause
A master mix was prepared containing 2.5 μL of 10X Pfx AccuPrimeTMReaction
mix (Invitrogen, 55013), 0.5 μL of AccuPrimeTMPfx DNA Polymerase (Invitrogen,
12344-02A), 0.5 μL of 50 mM MgSO4, 0.5 μL of DNA template diluted 1:200, 1.5 μL of
10 μM attB1 primer (5’-GGG GAC AAG TTT GTA CAA AAA AGC AGG CTG GAT
6http://www.mn-net.com/ProductsBioanalysis/DNAandRNApurification/
PlasmidDNApurificationeasyfastreliable/NucleoBondXtraplasmidMidiprepMaxiprepkits/
tabid/1479/language/en-US/Default.aspx
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GAA CGC AAG TGA ATT CCGA-3’), 1.5 μL of 10 μM attB2 primer (5’-GGG GAC CAC
TTT GTA CAA GAA AGC TGG GTA CAA CTC CCT CTC TGC TCGC-3’) and 18 μL
of water.
2.5.2.2 PCR product isolation and purification
PCR products were isolated by agarose gel. 0.8 % agarose (Sigma Aldrich, A9539)
gel containing 1:10.000 SYBR R©Safe DNA Gel Stain (Thermo Fisher, S33102) (v:v, i.e: 5
μL in 50 mL) was prepared. The 20 μL of PCR products were mixed with 4 μL of 6X
MassRuler DNA Loading Dye (Thermo Fisher, R0621). The mix was loaded on the gel
together with GeneRuler 1kb Plus DNA Ladder (Thermo Fisher, SM1331). The gel was
run 1 h at 100 V in Tris-acetate-EDTA (TAE) buffer. A picture of the gel was taken using
UV light and the PCR product was cut out of the gel. The DNA was then purified
using the QIAquick Gel Extraction Kit7 (Quiagen, 28704) following the manufacturer’s
instructions. The DNA was eluted in 20 μL of water and the samples were stored at -20
◦C.
2.5.2.3 BP reaction
BP reaction was performed using an attB-flanked DNA fragment and an attP-
containing donor vector (pDONR207) to generate an attL-containing entry vector.
In a microcentrifuge tube, the reaction was started by mixing 1 μL to 7 μL of attB-PCR
product (15-150 ng), 1 μL of pDONR207 (150 ng/μL) and TE buffer pH 8 up to 8 μL.
Then, 2 μL of Gateway R© BP clonaseTMII Enzyme mix (Invitrogen, 56481) were added
and the reaction was incubated for 1 h at 25 ◦C. The reaction was terminated by adding
1 μL of proteinase K (Invitrogen, 59895) and incubated for 10 min at 37 ◦C. The product
was amplified using E.coli DH5α and purified by maxiprep.
2.5.2.4 LR reaction
LR reaction was performed using an attL-containing entry clone and an attR-
containing destination vector to generate an expression vector.
In a microcentrifuge tube, reaction was started by mixing 1 μL to 7 μL of entry clone
(15-150 ng), 1 μL of pLenti6.3/TO/V5-DEST or pLenti6/UbC/V5-DEST (150 ng/μL)
and TE buffer pH 8 up to 8 μL. Then, 2 μL of Gateway R© LR clonaseTMII Enzyme
mix (Invitrogen, 56484) were added and the reaction was incubated for 1 h at 25 ◦C.
7https://www.qiagen.com/us/shop/sample-technologies/dna/dna-clean-up/
qiaquick-gel-extraction-kit
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The reaction was terminated by adding 1 μL of proteinase K (Invitrogen, 59895) and
incubating for 10 min at 37 ◦C.
The maps for the pDONR207, pLenti6.3/TO/V5-DEST and pLenti6/UbC/V5-
DEST are available in Appendix B.
2.5.2.5 Sequencing
To ensure proper gene insertion, plasmids were sent to Eurofins Genomics8.
Primers were designed to cover the plasmid before and after the attachment sites. The
primers used for the sequencing can be found in table 2.6
TABLE 2.6: Sequences of the mouse primers used for qPCR
Gene symbol Position Sequence
DDC
plamsid fwd 5’-CGCGTTAACGCTAGCATGGA-3’
on gene fwd 5’-GCTCACACAGGCCGCTATCA-3’
on plasmid rev 5’-ATTTTGAGACACGGGCCAGA-3’
TH
plamsid fwd 5’- CGACGGCCAGTCTTAAGCTCG-3’
on gene fwd 5’-GTGATGACACTTGTCCAGCTCTG-3’
on plasmid rev 5’- GAGCTGCCAGGAAACAGCTATG-3’
2.5.3 Virus production
Viruses were produced using the ViraPowerTMLentiviral Gateway R© Expression
kit9 (Thermo Fisher, K4960-00) using the reverse transfection procedure following man-
ufacturer’s instruction in a volume of 10 mL. After filtration with a 0.45 μm cellulose
acetate membrane filter (VWR International, 28145-481), the viruses were concentrated.
First, 1/5 of the final volume of 40% poly-ethylene glycol (PEG)10.000 (Fluka, 81280)
was added to the filtered viruses and incubated overnight. Then, the samples were
centrifuged for 30 min at 1500 x g, 4 ◦C. The supernatant was discarded and the sam-
ples were centrifuged once again for 5 min at the same speed and temperature. The
remaining supernatant was discarded and the viruses were resuspended in 100 μL of
PBS, aliquoted by 10 μL and stored at -80 ◦C.
8https://eurofinsgenomics.eu/?countryCode=LU
9https://www.thermofisher.com/order/catalog/product/K497500
62 Chapter 2. Material and Methods
2.5.4 Cell transduction
For viral transduction, cells were seeded in a 12-well plate at the density of 50.000
cells per well. 10 μL of virus were added to the cells at the same time. On the next day,
cell culture media were exchanged. Two days later, the antibiotic selection was started.
2.5.5 Antibiotic selection
pLenti6.3/TO/V5-DEST and pLenti6/UbC/V5-DEST carry a blasticidine resis-
tance gene. To assess the concentration needed for selection, 50.000 cells were seeded
per well in a 24-well plate. On the next day, blasticidin was applied with a concentra-
tion range from 0 to 5 μg/mL. The concentration that kills the cells within 5 days was
used. For the LUHMES cells, this corresponds to 2 μg/mL.
2.6 Metabolite extraction and measurements
2.6.1 Stable isotope labeled compounds
TABLE 2.7: Stable isotope labeled compounds and internal standards used
Tracer Supplier
U-13C6 D-Glucose Cambridge Isotope Laboratories, CLM-2250-0,25
1,2-13C2 D-Glucose Sigma Aldrich, 453188
U-13C5 L-Glutamine Cambridge Isotope Laboratories,CS01-183-434
U-13C9 L-Phenylalanine Cambridge Isotope Laboratories,CLM-2250-0,25
U-13C3 Sodium pyruvate Cambridge Isotope Laboratories, CLM-2440-0,5
U-13C9 L-Tyrosine Cambridge Isotope Laboratories, CLM-2263-0,1
Internal Standard Supplier
Pentanedioic D6 acid CDN Isotopes, D-5227
2-(3,4-dihydroxyphenyl)ethyl-
1,1,2,2-D4-amine HCl
CDN Isotopes, D1540
U-13C5 Ribitol Omiron Biochemicl Inc., ALD062
2-Ethylbutyric acid Sigma Aldrich, 109959
Advanced DMEM/F-12 for experiments using labeled glucose, glutamine or pyru-
vate was prepared in house, omitting these metabolites 10. Glucose, glutamine and
10Formulation of the complete medium can be found here: http://www.thermofisher.com/lu/
en/home/technical-resources/media-formulation.227.html
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pyruvate were then supplemented at the concentrations of 17.5, 2 and 1 mM respec-
tively, either as tracers or as unlabled compounds.
Advanced DMEM/F-12 for experiments using labeled phenylalanine and tyrosine
was prepared in house, omitting these metabolites as well as glucose, glutamine and
pyruvate. Glucose, glutamine and pyruvate were then supplemented at the concentra-
tions of 17.5, 2 and 1 mM respectively as unlabled compounds. Labeled or unlabeled
tyrosine and phenylalanine were supplemented at the concentrations of 213 and 215
μM respectively.
After adjustment of the pH to 7.4, all media were filtered with a 0.22 μm pore size
filter and supplemented with necessary additives (depending on the cell lines).
2.6.2 Non-targeted approach
2.6.2.1 Metabolite extraction
Metabolites were extracted from 12-well plates. First, the cells were washed using
room temperature 0.9% NaCl (Sigma Aldrich, S5886) solution (w:v), then metabolism
was quenched with 200 μL of ice-cold methanol (Sigma Aldrich, 34860). The plate was
transferred to an ice plate (CoolSink R© XT 96F, Biocision) and 200 μL of 4 ◦C water con-
taining 1 μg/mL pentanedioic D6 acid were added. Cells were scraped and transferred
to a reaction tube containing 200 μL of chloroform (Sigma Aldrich, 650498). Samples
were vortexed for 20 min at 4 ◦C, 1400 rpm on a Thermomixer (Eppendorf). They were
then centrifuged for 5 min at 4 ◦C, 16,000 x g. 150 μL of the upper phase were trans-
ferred to a 1.8 mL glass vial with 5-250 μL micro-insert (further referred to as GC glass
vials) and dried in a refrigerated rotary vacuum evaporator (Labconco) at -4 ◦C. The
samples were finally capped and stored at -80 ◦C until measurement. If the interphases
were kept for RNA extraction, the rest of the upper phase as well as the lower phase
were removed, methanol was added and the samples were centrifuged once more to
pellet the interphases. Supernatant was removed and replaced with fresh methanol.
Samples were transferred to -80 ◦C until further sample processing.
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2.6.2.2 Sample derivatization
The dried samples were derivatized using a multipurpose sampler (Gerstel) for
1 hour at 40 ◦C under constant shaking using 15 μL pyridine (Sigma 270970) con-
taining 20 μg/mL methoxyamine (Sigma Aldrich 226904). Then 15 μL N-methyl-N-
(trimethylsilyl)trifluoroacetamide (MSTFA) (Macherey-Nagel 701270.110) were added
for 30 min at 40 ◦C under constant shaking.
2.6.2.3 GC-MS measurement
Gas chromatography - mass spectrometry (GC-MS) analysis was performed using
an Agilent 7890A GC equipped with a 30 m DB-35MS capillary column (Agilent 122-
3832). The GC was connected to an Agilent 5975C mass selective detector operating
under electron ionization (EI) at 70 eV. The MS source was held at 230 ◦C and the
quadrupole at 150 ◦C. A sample volume of 1 μL was injected into a split/splitless inlet
in splitless mode. Helium was used as carrier gas at a constant flow rate of 1 mL/min.
The GC oven temperature was held on 80 ◦C for 6 min and increased to 300 ◦C at 6
◦C/min. After 10 min, the temperature was increased to 325 ◦C at 10 ◦C/min for 4 min.
The detector was operated in scan mode with a mass over charge ratio (m/z) of 70 to
800. The run time of one sample was 59 min.
2.6.3 Stable isotope-assisted metabolomics
2.6.3.1 Metabolite extraction
Metabolites were extracted following the same procedure as in section 2.6.2.1.
2.6.3.2 Sample derivatization
Sample that were incubated with tracers were derivatized for 90 min with
methoxyamine at 55 ◦C, and silylation was performed with 15 μL N-tert-butyldimethylsilyl-
N-methyltrifluoroacetamide (MTBSTFA) (Restek) for 1 hour at 55 ◦C under constant
shaking.
2.6.3.3 GC-MS measurement
For samples incubated with a tracer and derivatized with MTBSTFA, the GC oven
temperature was held on 100 ◦C for 2 min and increased to 300 ◦C at 10 ◦C /min and
held at this temperature for 4 min. The run time of one sample was 26 min. Labeled
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samples were measured in selected ion monitoring (SIM) mode, the fragment ions used
are displayed in table 2.8. Data were acquired using the Agilent MassHunter Software.
TABLE 2.8: SIM method settings for TBDMS derivatives of intermediates of central carbon
metabolism
Metabolite Ions Dwell time (ms) Formula
Pyruvate 174-180 15 C6H12O3NSi
Lactate 261-267 15 C11H25O3Si2
Alanine 260-266 15 C11H26NO2Si2
Glycine 246-252 15 C10H24NO2Si2
GABA 274-281 15 C12H28NO2Si2
Succinate 289-296 15 C12H25O4Si2
Fumarate 287-294 15 C12H23O4Si2
Pentanedioic D6 acid 235,309,351 15
Serine 390-396 15 C17H40NO3Si3
Methionine 320-328 10 C13H30NO2SSi2
α-Ketoglutarate 346-354 15 C14H28NO5Si2
Malate 419-426 15 C18H39O5Si3
Aspartate 418-425 15 C18H40NO4Si3
Cysteine 406-413 15 C17H40NO2SSi3
Glutamate 432-440 10 C19H42NO4Si3
Glutamine 431-439 10 C19H43N2O3Si3
Citrate 591-600 10 C26H55O7Si4
2.6.4 Dopamine extraction
2.6.4.1 Metabolite extraction
Metabolites were extracted following the procedure as described in section 2.6.2.1,
with slight adaptations. The water was replaced by 0.1 M HCl and the internal standard
was replaced by 0.5 μM 2-(3,4-dihydroxyphenyl)ethyl-1,1,2,2-D4-amine HCl. 200 μL of
the polar phase were transferred to GC glass vials.
This extraction procedure was also used upon labeling with [U-13C9]tyrosine and
[U-13C9]phenylalanine.
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2.6.4.2 Sample derivatization
The samples were derivatized following procedure described in section 2.6.2.2.
2.6.4.3 GC-MS measurement
Measurements were performed using the same temperature profile as in section
2.6.2.3. The samples were measured in SIM mode with the following target ions within
the same measurement window: 176.1 and 430.2 for the internal standard and 174.1
and 426.2 for dopamine (DA) with dwell times of 20 ms.
Upon labeling with [U-13C9]tyrosine and [U-13C9]phenylalanine, samples were
measured in SIM mode, the fragment ions used are displayed in table 2.9.
TABLE 2.9: SIM method settings for TMS derivatives of intermediates of central carbon meta-
bolism
Metabolite Ions Dwell time (ms) Formula
Phenylalanine 217-223 30 C15H17NO2Si2
Tyrosine 217-223 30 C18H35NO3Si3
Dopamine 425-437 15 C20H43NO2Si4
2.6.5 Medium extraction
Metabolites from medium were obtained from LUHMES cells cultivated in 400 μL
of medium in 24-well plates. Control samples were prepared with the same volume of
medium and incubated in wells without cells. The media were transferred to a reaction
tube. The cells were washed once with PBS before trypsinization with 100 μL of trypsin.
After 7 min of incubation, 400 μL of medium was added and two wells were pooled for
cell counting using the Vi-CELL XR 2.03 (Beckman Coulter, Inc.).
The media were filtered with a 0.2 μm pore size 4 mm regenerated cellulose filter
(Phenomenex, AF0-3203-52) to remove cells and cell debris. Quantification was per-
formed using a calibration curve prepared in Advanced DMEM/F-12. It was supple-
mented with 8 mM L-Lactate (Sigma Aldrich, L7022) and 450 μM L-Glutamate (Sigma
Aldrich, G8415) to obtain a final concentration of 500 μM L-Glutamate. Concentra-
tion in the original medium of L-Pyruvate was 1 mM, D-Glucose: 17.5 mM and L-
Glutamine: 2 mM. The initial stock was diluted 1:2, 1:4, 1:8, 1:16 and 1:32 to obtain a
five-point calibration curve.
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2.6.5.1 Metabolite extraction for GC-MS measurement
20 μL of medium were extracted with 180 μL of extraction fluid composed of 5:1
methanol:water (v:v) containing 50 μg/mL of 13C5 Ribitol and 20 μg/mL Pentanedioic
D6 acid. Samples were incubated for 10 min at 4
◦C, 1400 rpm on a Thermomixer. They
were then centrifuged for 5 min at 4 ◦C, 16,000 g. 50 μL were transferred to a GC glass
vial dried in a refrigerated rotary vacuum evaporator at -4 ◦C.
2.6.5.2 Sample derivatization
Samples were derivatized following the procedure in section 2.6.3.2.
2.6.5.3 GC-MS measurement
Medium samples were derivatized with MTBSTFA and measured with a split ratio
of 10:1. The GC oven temperature was held on 100 ◦C for 2 min and increased to 300
◦C at 10 ◦C /min and held at this temperature for 4 min. The run time of one sample
was 26 min. Samples were measured in SIM mode, the fragments ions are displayed in
table 2.10.
TABLE 2.10: SIM method settings for TBDMS derivatives of metabolites extracted from cell
culture medium
Metabolite Quant ion Qual ion Qual ion Dwell time (ms) Formula
Pyruvate 174.1 89 115 50 C6H12NO3Si
Lactate 261.1 189.1 233.1 50 C11H25O3Si2
Alanine 260.2 158.1 232.1 70 C11H26NO2Si2
Glycine 246.1 189.1 218.1 50 C10H24NO2Si2
Valine 288.6 186.1 260.2 70 C13H30NO2Si2
Leucine 302.2 200.2 274.2 70 C14H32NO2Si2
Isoleucine 302.2 200.2 274.2 70 C14H32NO2Si2
Threonine 290.2 159.1 303.2 50 C12H28NO3Si2
Proline 286.2 184.1 258.2 50 C13H28NO2Si2
Succinate 289.1 215.1 331.2 50 C12H25O4Si2
Pentanedioic D6 309.2 235.2 351.3 70
Phosphoric acid 383.2 425.1 440.2 50 C14H36O4PSi3
Serine 390.2 302.2 362.2 50 C17H40NO3Si3
Threonine 404.2 376.3 417.3 70 C18H42NO3Si3
Methionine 320.2 218.1 292.2 50 C13H30NO2SSi2
continued . . .
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TABLE 2.10: (continued)
Metabolite Quant ion Qual ion Qual ion Dwell time (ms) Formula
Malate 419.2 287.1 403.2 50 C18H39O5Si3
Phenylalanine 336.2 308.2 50 C17H30NO2Si2
Aspartate 418.2 316.2 C18H40NO4Si3
Cysteine 406.2 304.2 378.2 50 C17H40NO2SSi3
Ornithine 474.4 184.1 286.2 50 C23H54N2O2Si3
Glutamate 432.3 330.2 404.3 50 C19H42NO4Si3
Lysine 431.3 300.2 488.4 70 C20H47N2O2Si3
Glutamine 431.3 329.2 473.3 50 C19H43N2O3Si3
Arginine 442,3 169.2 340.3 50 C20H44N3O2Si3
Tyrosine 466.3 302.2 438.3 50 C23H44NO3Si3
Histidine 440.3 338.3 196.1 70 C20H42N3O2Si3
2.6.5.4 Medium quantification using YSI Bioanalyzer
120 μL of filtered medium were loaded on a 96-well plate and measured with
a 2950D Biochemistry Analyzer (YSI). Membranes for quantification of glucose (YSI,
2365), lactate (YIS, 2329), glutamine (YSI, 2735) and glutamate (YSI, 2754) were used.
Quantification was performed using an external calibration curve prepared in the Ad-
vanced DMEM/F-12 containing 17.5 mM D-Glucose, 2 mM L-Glutamine, 500 μM L-
Glutamate and 8 mM L-Lactate.
2.6.5.5 Determination of uptake and secretion rates
Uptake rates for glucose and glutamine as well as secretion rates for glutamate and
lactate were calculated. First, concentrations in each sample were determined using
an external calibration curve. Second, the concentration of metabolites obtained in
media incubated without cells were subtracted from the samples in order to control for
temperature-associated metabolite degradation. Third, this difference was divided by
the respective cell number at the beginning of the experiment and by 24 h to obtain
rates in mol/cell/hour.
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2.6.6 Short chain fatty acid extraction
2.6.6.1 Metabolite extraction
Quantification of short chain fatty acid (SCFA) was performed using a volatile
acid standard mix (Supelco, 46975-U). Each compound is present in the mix at the
concentration of 10 mM. For extraction, the standard mix was diluted 1:10 to a final
concentration of 1 mM. A calibration curve of concentrations 0, 0.2, 0.4, 0.6, 0.8 and
1 mM were used for extraction. 95 μL of filtered medium were transferred to a new
tube. 5 μL of 200 mM 2-Ethylbutyric acid (internal standard), 5 μL of 1 M HCl and
500 μL of diethyl ether (VWR, 1.00921.1000) were added to each sample. Samples were
vortexed for 10 min at room temperature, 1400 rpm on a Thermomixer. They were then
centrifuged for 5 min at 4 ◦C, 16,000 x g. 450 μL were transferred to a new tube and 500
μL of diethyl ether were added a second time to the first tubes. Samples were vortexed
for 10 min at room temperature, 1400 rpm. They were then centrifuged for 5 min at 4 ◦C,
16,000 x g and 450 μL were transferred to the second tube. 250 μL of the second reaction
tube were transferred to a GC glass vial and the samples were derivatized by adding
25 μL of MTBSTFA and incubated for 1 h at room temperature before measurement.
2.6.6.2 GC-MS measurement
GC-MS analysis was performed using an Agilent 7890A GC equipped with a 20
m DB-1MS capillary column (Agilent, 121-0122). Samples were measured with a split
ratio of 20:1. The GC oven temperature was held on 80 ◦C for 0.75 min and increased
to 150 ◦C at 15 ◦C /min and held at this temperature for 2 min, then temperature was
increased to 280 ◦C at 50 ◦C /min and held at this temperature for 2 min. The run time
of one sample was 12 min. Samples were measured in SIM mode, the fragments used
are displayed in table 2.11. The detector was switched off between 2.2 and 2.6 min,
corresponding to the elution of MTBSTFA.
TABLE 2.11: SIM method settings for MTBSTFA derivatives of SCFA extracted from cell culture
medium
Metabolite Quant ion Qual ion Qual ion Dwell time (ms) Formula
Formate 103 75 99 20 C3H7O2Si
Acetate 117 75 99 20 C4H9O2Si
Propionate 131 75 115.1 20 C5H12O2Si
Butyrate 145.1 75 115.1 20 C6H14O2Si
continued . . .
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TABLE 2.11: (continued)
Metabolite Quant ion Qual ion Qual ion Dwell time (ms) Formula
Isobutyrate 145.1 75 115.1 20 C6H14O2Si
Valerate 159.1 75 201.1 20 C7H16O2Si
2-Ethylbutyrate 173.1 75 115.1 20 C8H18O2Si
4-Methylvalerate 173.1 75 215.1 20 C8H18O2Si
Hexanoate 173.1 75 131 20 C8H18O2Si
Heptanoate 187.1 75 131 20 C9H20O2Si
Lactate 261.1 233.1 189.1 20 C11H25O3Si2
Succinate 289.1 331.2 331.2 20 C12H25O4Si2
2.6.7 Limit of detection calculation
Limit of detection (LOD) of DA was determined following the procedure de-
scribed by Wells et al. [125]. Briefly, a concentration curve of fresh DA was measured
to determine which concentration of DA would give a signal between 5 and 10 times
above background signal for ion 426.2. This concentration was 4.63 ng/mL. Then, a
fresh solution of DA with this concentration was prepared and 200 μL were transferred
to an eppendorf tube and dried under vacuum at -4 ◦C. The sample was derivatized
for 90 min with 150 μL of 20 mg/mL methoxyamine dissolved in pyridine followed by
a 30-min derivatization with MSTFA. Finally, 30 μL of sample were aliquoted in 8 GC
glass vials and measured in SIM mode as described in section 2.6.4.3.
The LOD was calculated using the following formula:
tα × SX¯ ×A
X¯
Where tα is 2.998, equivalent to the test statistic for 7 degrees of freedom and a 99%
confidence interval. X¯ and SX¯ are the average and standard deviation of the eight peak
areas, respectively. A is the concentration of standard in the vial (1.19 ng/mL).
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2.6.8 Data analysis
Acquired data were processed using the MetaboliteDetector [137] software pack-
age. Deconvolution settings for SCAN and SIM measurement are displayed in Ta-
ble 2.12. Setting for batch quantification and mass isotopomer distribution (MID) cal-
culations are displayed in Table 2.13.
TABLE 2.12: Deconvolution settings for SCAN and SIM measurement
Settings SCAN SIM
Peak Threshold 5 1
Mininum Peak Height 5 1
Bins/Scan 10 10
Deconvolution width 5 7
TABLE 2.13: Batch quantification and MID settings for SCAN and SIM measurement
Settings
Batch quantification MID calculation
Non-targeted
SIM medium
SIM TCA
DA, SCFA
Δ RI 50 3 3
Pure/Impure 0.50 0.50 0.50
Scoring Method RI + Seq RI + Seq RI + Seq
Req. score 0.85 0.85 0.60
Compound Reproducibility 0.75 1 1
Req S/N 0.0 0.0 0.0
Max. peak discr. index 100 100 100
Min. # ions 15 1 1
The data can be visualized by integrating the carbon contributions from each tracer
in the metabolites of interest. This is a weighted average of the MIDs calculated as
follows:
1
n
×
n∑
i=1
Mi × i
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Where n is the number of carbon atoms of the molecule and Mi is the ith mass
isotopomer.
2.7 Statistics
Experiments were performed in biological triplicates. Each replicate contained
technical triplicates. The data displayed in this work display a representative exper-
iment. Figures were created using LibreOffice Calc, QtiPlot and Inkscape. Statisti-
cal analysis were performed using LibreOffice Calc and the R statistical environment
[138].
3
Results and discussion
This chapter is divided in two sections which correspond to the main research
projects I participated in|. The first section focuses on the effects of 2,3-dihydroxy-
L-phenylalanine (L-DOPA) on the metabolism of tyrosine hydroxylase (TH)-positive
neuronal cells, LUHMES. First of all, we assayed cell viability to assess the sensitivity
of neuronal cells against L-DOPA and determined the rescuing effect of antioxidants.
Furthermore, we compared its toxicity in neurons to that in cell lines of other cell types.
Then, I performed a metabolic study of these neurons to evaluate their response to L-
DOPA using non-targeted, targeted and stable isotope-assisted metabolomics.
In the second part of this work, I focused on the engineering of a human
dopamine-producing cell system which is not of cancer origin. First, we performed
a comparison of catecholamine (CA) metabolism in LUHMES cells with that in other
models (induced pluripotent stem cells (iPSC) and SH-SY5Y) to evaluate the strengths
and weaknesses of the LUHMES cell model. Second, we used a genome-engineering
approach to increase catecholamine-related gene expression.
3.1 Effects of L-DOPA on the metabolism of TH-positive neu-
rons
3.1.1 The effects of L-DOPA on cell viability
Although it is the most widely used treatment for Parkinson’s disease (PD), L-
DOPA has been shown to be toxic in vitro [53, 107, 139–142]. Dopaminergic neurons are
the most sensitive cells, but other cell types such as melanoma cells [140] were sensitive
to high L-DOPA concentrations (500 μM), while fibroblasts or ovarian cancer cells [142]
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died upon long term L-DOPA treatment at lower concentrations (10 μM for 6 days). In
order to compare the response to L-DOPA in different cell types, we performed a cell
viability assay for different concentrations in a 24 h-treatment (Figure 3.1). The two
first assays (Figure 3.1 A and B) were performed with the support of Xiangyi Dong and
Jenny Ghelfi. In the first assay (Figure 3.1 A), we compared the effects of L-DOPA on
three cells lines derived from neuronal cells and one human cell line which was not
derived from the central nervous system (CNS): rat PC-12 pheochromocytoma cells,
human SH-SY5Y neuroblastoma cells, human LUHMES immortalized mesencephalon
cells and human A549 lung cancer cells. Overall, the LUHMES cells were the most
sensitive to the treatment and the viability already dropped at 25 μM. It should be noted
that LUHMES cells are the only cell type studied which is in a cell cycle arrest state. The
three other cell types are of cancer origin and are proliferative. At 200 μM L-DOPA, SH-
SY5Y cells started to be affected and their viability dropped to 20%, the same level as
LUHMES cells. A549 were sensitive to 100 μM and higher concentrations of L-DOPA,
with a drop in viability to 50%, but their viability did not further decrease for higher
concentrations. PC-12 cells were not affected at all by the applied concentrations of
L-DOPA. At this stage, we could not rule out an organism-specific effect of L-DOPA
in which human-derived cells would be more sensitive than cells derived from other
organisms.
In order to test other cell types of CNS origin, the same assay was performed with
mouse IMA2.1 immortalized astrocytes, mouse BV2 immortalized microglia and hu-
man CCF-STTG1 astrocytoma cells (Figure 3.1 B). LUHMES cells were plotted again
for comparison. We observed that IMA2.1 and BV2 cells were sensitive to high (250
μM) concentrations of L-DOPA and that CFF-STTG1 were not sensitive to the applied
L-DOPA treatment.
L-DOPA quickly auto-oxidizes in cell culture media. The auto-oxidation path-
way involves generation of free radicals and mixtures of quinones and semi-quinones
[140, 143]. Antioxidants have been shown to protect cells against oxidation products
of L-DOPA [107]. Their mechanism of action was described in section 1.4.2.4. I tested
whether providing LUHMES cells with antioxidants would prevent L-DOPA toxicity.
Ascorbic acid (AA) and reduced L-glutathione (GSH) were tested as well as N-acetyl-
L-cysteine (NAC). Unlike GSH, NAC passively enters the cells where it is cleaved to
generate cysteine, which can then be used for GSH synthesis [109]. Figure 3.1 C shows
that all three antioxidants tested rescued cell viability upon L-DOPA treatment.
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FIGURE 3.1: Cell viability upon L-DOPA treatment. (A): Human A549 lung cancer, rat PC-
12 pheochromocytoma, human SH-SY5Y neuroblastoma and human LUHMES immortalized
mesencephalon cells were treated for 24 h with different L-DOPA concentrations. (B): Hu-
man CCF-STTG1 astrocytoma, mouse IMA2.1 immortalized astrocytes, mouse BV2 immortal-
ized microglia and human LUHMES immortalized mesencephalon cells were treated for 24 h
with different L-DOPA concentrations. (C): LUHMES cells were treated for 24 h with differ-
ent concentrations of L-DOPA and 1 mM of ascorbic acid (AA), N-acetyl-L-cysteine (NAC) or
L-glutathione reduced (GSH). (D): LUHMES cells were treated for 24 h with different concen-
trations of L-DOPA, D-DOPA, L-DOPA previously oxidized for 7 days (DOPAox) or L-DOPA
supplemented with 500 units per mL of superoxide dismutase (SOD).
Impaired serine metabolism has also been associated with decreased GSH levels in
the cell: loss of DJ-1 in LUHMES cells induced a decrease in serine synthesis from gly-
colysis and an increase in serine uptake from the extracellular space. It also induced an
increase in glutathione disulfide (GSSG) to GSH ratio, indicative of impaired GSH re-
generation or increased reactive oxygen species (ROS).Therefore, serine was proposed
to be used for transsulfuration to cysteine which can then be used for GSH synthesis
[144]1.
I performed a final assay to ensure that the observed toxicity is mediated by inter-
mediates of L-DOPA auto-oxidation in the extracellular space and not via its intracel-
lular enzymatic degradation. Therefore, I incubated LUHMES cells in the presence of
1More details on this subject in the manuscript I co-authored in Appendix D
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superoxide dismutase (SOD), 3,4-dihydroxy-D-phenylalanine (D-DOPA) or L-DOPA
oxidized for seven days. First, L-DOPA was incubated with SOD, an enzyme respon-
sible for superoxide detoxification (Figure 3.1 D). The presence of this enzyme rescued
the cell loss induced by L-DOPA. In this case, the protection was entirely at the extra-
cellular level since SOD cannot cross the cell membrane as such [145]. Secondly, replac-
ing L-DOPA by its stereoisomer D-DOPA did not modify the cell viability pattern. D-
DOPA auto-oxidizes in a similar fashion than L-DOPA and Shindo et al. reported that it
cannot be enzymatically metabolized [146]. In this publication, they studied the trans-
port and metabolism of D- and L-DOPA in rat intestine. Upon treatment of the animals
with radio isotopically labeled D-DOPA, they could not observe any labeled dopamine
(DA), 3-methoxytyramine (3-MT), nor 3,4-dihydroxyphenylacetic acid (DOPAC) (prod-
ucts of the activity of aromatic amino acid decarboxylase (AADC), catechol-o-methyl
transferase (COMT) and aldehyde dehydrogenase (ALDH), respectively). These three
metabolites could all be detected upon L-DOPA stimulation [146]. Finally, viability of
cells was not affected when I treated them with L-DOPA that was left to oxidize for
seven days prior to supplementation to the cells, indicating that the final products of
the oxidation pathway are not toxic.
Further evidence points to an extracellular effect of L-DOPA oxidation indepen-
dent of DA synthesis. Basma et al. reported that L-DOPA is toxic to PC-12 in culture
due to its auto-oxidation, independently of DA formation since addition of carbidopa,
an inhibitor of AADC, did not affect cell viability. On the other hand, toxicity was
not mediated by enzymatically generated oxidative products of DA metabolism since
inhibition of both isoforms of monoamine oxidase (MAO) (MAO-A and -B) by pargy-
line did not change cell viability. Cytotoxicity was decreased by supplementation of
catalase and SOD indicating that the toxicity comes from auto-oxidation products of
L-DOPA [139].
In summary, we demonstrated that LUHMES cells are the most sensitive to L-
DOPA treatment among all cell lines tested. Moreover, we showed that the toxicity
generated by L-DOPA treatment could be prevented by using antioxidants. Neurons
possess less antioxidant capacity than astrocytes [110] and microglia [147] and thus
are more sensitive to oxidative stress [110]. Given the fact that antioxidant levels are
already decreased in PD patients [117], they have been suggested as potential co-drugs
before [148] or during L-DOPA treatment [149].
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The higher resistance against L-DOPA in BV2 and IMA2.1 cell lines can be ex-
plained by the increased antioxidant capacities of astrocytes and microglia. The other
cell lines, A549, PC-12, SH-SY5Y and CFF-STCG1 are of various cancer origin, thus are
prone to proliferation. It has been reported by Miller et al. that the expression of the
oncogene ras induces oxidative stress resistance without involving the GSH pathway
[150], indicating that cancer cells are able to adapt to stress conditions.
Finally, the toxic effects induced by L-DOPA treatment were due to its auto-
oxidation which could be prevented by SOD, AA, GSH and NAC. We demonstrated
that this process mainly occurred in the extracellular space, by the use of D-DOPA as
negative control [146]. Eumelanin itself, as final product of the oxidation pathway of
L-DOPA was not toxic to the cells.
3.1.2 The effects of L-DOPA on the metabolism of LUHMES cells
After evaluating the effects of L-DOPA on the viability of human TH-positive neu-
rons LUHMES, I investigated the effects of L-DOPA on the metabolism of these neu-
rons, focusing primarily on the central carbon metabolism.
3.1.2.1 Non-targeted metabolomics approach
It has been reported that the concentration of L-DOPA in the plasma of PD pa-
tients under treatment ranges between 5 and 50 μM [151]. Therefore, in this section,
I used concentrations ranging from 0 to 100 μM. LUHMES cells were treated for 24
h with 0, 25, 50 or 100 μM of L-DOPA before quenching of metabolism and metabo-
lite extraction. Significantly altered metabolites (one-way ANOVA, p-value < 0.05) are
displayed in Figure 3.2. This heatmap shows profound changes in the levels of many
metabolites. L-DOPA treatment induced increased levels of essential amino acids such
as valine, leucine, isoleucine, phenylalanine and lysine (Figure 3.3 A-E) and decreased
levels of non-essential amino acids such as alanine, serine and glycine (Figure 3.3 F-H).
Another interesting compound in the context of neuronal cells is N-acetyl-aspartate
(NAA), which levels decreased (Figure 3.3 I). The levels of tricarboxylic acid (TCA) cy-
cle intermediates, citrate, glutamate, fumarate, malate and aspartate decreased with in-
creasing L-DOPA concentrations, while the level of succinate increased upon treatment
(Figure 3.4 B-G). Citrate and succinate are not included in the heatmap (Figure 3.2) be-
cause these data were obtained using a targeted metabolomics approach.
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FIGURE 3.2: Effects of L-DOPA treatment on the metabolism of LUHMES cells. LUHMES
cells were treated for 24 h with 0, 25, 50 or 100 μM L-DOPA. This heatmap displays the metabo-
lites that show a significance level below 0.05 by one-way ANOVA. Signal intensities were
normalized using the summed sample signal and row mean.
The increase of free essential amino acids could indicate a decrease in protein syn-
thesis. In opposite, I observed a significant decrease of serine, glycine and alanine
levels, which are non-essential amino acids synthesized from glycolytic intermediates.
Most of the intermediates of the TCA cycle showed lower abundance upon L-DOPA
treatments, except for succinate, which increased. Interestingly, increased succinate
levels have been associated with succinate dehydrogenase (SDH) inhibition, which acts
as complex II of the mitochondrial electron transport chain [152].
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FIGURE 3.3: Effects of L-DOPA treatment on the levels of amino acids. LUHMES cells were
treated for 24 h with 0, 25, 50 or 100 μM L-DOPA. Levels of valine (A), isoleucine (B), leucine
(C), phenylalanine (D), lysine (E), alanine (F), serine (G), glycine (H) and N-acetyl-aspartate (I)
are displayed. Signal intensities were normalized using the sum sample signal normalization.
All changes were significant by one-way ANOVA, p-value <0.05.
In cancer, inhibition of SDH leads to accumulation of succinate which can stabilize
hypoxia-inducible factor (HIF)-1α expression by inhibiting prolyl hydroxylase (PHD)
through a product inhibition feedback. Stabilization of HIF-1α leads to its translocation
to the nucleus where it promotes expression of tumor survival-associated genes [152].
On the other hand, inhibition of SDH decreases the activity of coenzyme Q10, which
can act as antioxidant by scavenging ROS. Upon inactivation of coenzyme Q10 and in-
creased ROS levels, p53 is activated and has two major impacts on central carbon meta-
bolism. First, it leads to the activation of the glycolysis inhibiting gene TP53-induced
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FIGURE 3.4: Effects of L-DOPA treatment on the levels of intermediates of the TCA cycle
and associated metabolites. (A): Scheme of the TCA cycle. LUHMES cells were treated for
24 h with 0, 25, 50 or 100 μM L-DOPA. Levels of citrate (B), glutamate (C), succinate (D), fu-
marate (E), malate (F) and aspartate (G) are displayed. Signal intensities were normalized using
the sum sample signal normalization. LDH: lactate dehydrogenase, PDH: pyruvate dehydro-
genase complex, CS: citrate synthase, Aco: aconitase, IDH: isocitrate dehydrogenase, GDH:
glutamate dehydrogenase, α-KDH: α-ketoglutarate dehydrogenase, SCS: succinyl-CoA syn-
thetase, SDH: succinate dehydrogenase, FUM: fumarase, MDH: malate dehydrogenase, AAT:
aspartate aminotransferase. All changes were significant by one-way ANOVA, p-value <0.05.
glycolysis regulator (TIGAR) by lowering the levels of fructose-2,6-biphosphate, a reg-
ulator of glycolysis [153]. Second, it leads to inhibition of oxidative phosphorylation
by inducing gene expression of cytochrome c oxidase 2 (SCO2).
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These events induce a decrease in glycolytic and oxidative phophorylation fluxes
preventing tumor survival and progression. In the light of L-DOPA treatment, an ac-
tivation of these enzymes in response to oxidative stress could explain the decrease in
TCA cycle intermediates as well as glycolysis-derived amino acids.
Mutations or decreased activity of SDH have also been associated with several
neurodegenerative diseases such as Leigh’s syndrome, Huntington’s disease or Down
syndrome [152]. Huntington’s disease is characterized by the death of striatal GABAer-
gic neurons which causes a loss of coordination, dystonia and decline in cognitive
functions [152]. Patients with Huntington’s disease show decreased levels of SDHA
and SDHB, two of the four subunits composing SDH. In addition, treatment of animals
with specific complex II inhibitors such as 3-nitropropionic acid (3-NP) or malonate
induced the same phenotype [152]. These two compounds have been shown to be cy-
totoxic in vitro and in vivo. 3-NP is an irreversible inhibitor while the action of malonate
is reversible [154] and both compounds induce decreased ATP levels, increased gluta-
mate secretion and oxidative damage [155]. The toxicity could be prevented by using
antioxidants and free radical scavengers, preventing ROS accumulation downstream
of the mitochondrial complex II inhibition [156]. In the case of L-DOPA treatment, it
is interesting to note that, similar to complex II inhibition, succinate accumulated and
the toxicity could be prevented by antioxidants. Moreover, as observed for complex II
inhibition, I observed an increased glutamate secretion (see section 3.1.4).
Another important metabolite in the context of the CNS is NAA. It is synthesized
from aspartate and acetyl-CoA by the N-acetylaspartate synthetase. Arun et al. re-
ported that in SH-SY5Y, NAA can be synthesized in both the cytoplasm and the mito-
chondria with its majority being synthesized in the mitochondria [157]. In the CNS, it
has several functions: 1) NAA is a precursor for N-acetylaspartylglutamate, the most
concentrated neurotransmitter. 2) NAA has also been correlated to ATP levels and neu-
ronal energy metabolism, although no direct connection between the two components
has been found, 3) NAA is a source of acetate for fatty acid (such as myelin) and steroid
synthesis in oligodendrocytes [158]. Demougeat et al. reported that upon 3-NP treat-
ment, NAA levels decreased in the striatum before observation of any cell death and
was associated with motor symptoms [159]. Treating rat striatal cells with the same
compound, Lee et al. firstly observed an increased acetate level [160]. Three hours after
the start of the treatment, they observed a decrease in acetate concentrations suggesting
that it was used as acetyl donor for membrane repair in neuronal injuries [160]. 3-NP
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caused a disruption of cell membranes leading to the release of NAA which could be
hydrolyzed to acetate and aspartate. The toxin also induced an increase in free fatty
acids which can be metabolized to acetate as well. Interestingly, L-DOPA treatment
induced a degradation of the neurite network (suggesting a disruption of cell mem-
branes) as well as an increase in acetate uptake (see section 3.1.4).
To summarize, I showed that L-DOPA treatment caused profound changes in the
metabolic profile of LUHMES cells, demonstrated by a decrease in the levels of non-
essential amino acids such as alanine, serine and glycine and an increase in the levels
of essential amino acids such as valine, leucine, isoleucine, phenylalanine and lysine.
This suggests a decreased protein synthesis. Levels of NAA also decreased. The lev-
els of TCA cycle intermediates decreased, except for succinate which increased upon
treatment. This indicates that auto-oxidation products of L-DOPA induced a complex
II inhibition and lead to decreased glycolytic and TCA cycle activity.
3.1.2.2 Stable isotope-assisted metabolomics
Stable isotopes are a powerful tool in metabolomics and fluxomics studies. They
allow to study the utilization of specific substrates by cells or organisms. In order
to study the metabolic adaptations of LUHMES cells during L-DOPA treatment, I
incubated these cells for 24 h with either [U-13C6]glucose, [U-13C5]glutamine or [U-
13C3]pyruvate, the main carbon sources of these cells. To obtain a higher percentage
of labeling, Advanced DMEM/F12 free of glucose-, glutamine- and pyruvate was
prepared in-house. After incubation of the cells in the presence of the tracer, I extracted
intracellular metabolites and measured the polar extracts in selected ion monitoring
(SIM) mode to precisely determine mass isotopomer distributions (MIDs). For all
experiments described in this section, I cultivated one million cells per well instead
of five hundred thousand and increased L-DOPA concentrations to 200 μM. The in-
crease in cell number allowed an increase in signal intensity for compounds of low
abundance, such as citrate and succinate, and to better quantify medium uptake and
secretion rates. Since LUHMES cells do not proliferate when they are differentiated,
their substrate use is really low and precise quantification was not possible over the
duration of the treatment with the original cell density. Increased cell number allowed
to increase the amount of metabolites consumed and secreted, and thus lead to a more
precise quantification. However, when the cells at this density were treated with 50
or 100 μL-DOPA, the morphological changes (neurite degradation) and apparition of
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eumelanin in the medium did not occur any more. This is why the concentration of
L-DOPA was increased for consistency.
Figure 3.5 depicts the relative carbon contributions from glucose, glutamine and
pyruvate to the glycolysis-derived metabolites serine, glycine, alanine and lactate (Fig-
ure 3.5 A-D) as well as to the TCA cycle-derived metabolites citrate, succinate, malate
and fumarate (Figure 3.5 E-H). "Other" represents other carbon sources that were not
labeled by the applied tracers as, for example, carbon derived from protein degradation
or β-oxidation of fatty acids.
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FIGURE 3.5: Effects of L-DOPA treatment on carbon contribution. (A): LUHMES cells
were treated for 24 h with 200 μM L-DOPA and incubated with [U-13C6]glucose (Glc), [U-
13C5]glutamine (Gln) or [U-13C3]pyruvate (Pyr), for the same amount of time. Carbon contri-
butions were calculated by a weighted average of the individual mass isotopomer distribution.
Other denotes carbon contribution from other sources. Carbon contributions to serine (A) and
glycine (B) only consider glucose since none other applied tracer was detected. Carbon con-
tributions to alanine (C), lactate (D) and the TCA cycle intermediates citrate (E), succinate (F),
malate (G) and fumarate (H) are displayed. *: p-value <0.05 by Student t-test.
Serine and glycine are derived from 3-phosphoglycerate and are exclusively la-
beled from glucose (Figure 3.5 A and B). Neither pyruvate nor glutamine contributed
to their labeling pattern. Upon L-DOPA treatment, the carbon contribution from glu-
cose significantly decreased for both amino acids.
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Alanine and lactate are derived from pyruvate. For both metabolites, carbon
contribution from glucose decreased upon L-DOPA treatment, and the decrease was
stronger for alanine (Figure 3.5 C and D). In parallel, carbon contribution from pyru-
vate increased in both metabolites, but only compensated for the decrease of glucose
contribution in the case of lactate. For alanine, however, the carbon contribution from
other sources increased, potentially from protein degradation. It is also interesting to
note that although no carbon from glutamine was detected in lactate, its contribution
to alanine increased upon L-DOPA treatment.
Concerning the TCA cycle intermediates, in all metabolites displayed, glucose con-
tribution decreased upon L-DOPA treatment (Figure 3.5 E-F). There was no significant
change in pyruvate contribution to citrate and malate, but a significant decrease in
its contribution to succinate and fumarate. Glutamine contribution increased in all
metabolites of the TCA cycle upon L-DOPA treatment.
MIDs also provide information on enzymatic activities (Figure 3.6). Glucose-
derived carbons enter the TCA cycle via two distinct routes: via pyruvate dehydro-
genase complex (PDH) or pyruvate carboxylase (PC) (Figure 3.6 A). In the first case,
pyruvate is decarboxylated to acetyl-CoA and is condensed with oxaloacetate to form
citrate. Thus, two labeled carbons originating from glucose end up in citrate. The ratio
of M2 citrate over M3 lactate gives information on the activity of PDH. The second
route glucose can undertake to enter the TCA cycle is via PC. This enzyme carboxylates
pyruvate to oxaloacetate, thus three carbons from glucose end up in citrate. The ratio
of M3 citrate over M3 lactate gives an overview of the flux through PC. The relative
fluxes through both enzymes are depicted in Figure 3.6 B and C. The activity of both
enzymes significantly decreased under treatment with L-DOPA and the decrease in PC
activity was stronger than that of PDH.
Glutamine is another important carbon source contributing to the TCA cycle. It en-
ters the cycle after deamidation to glutamate and conversion to α-ketoglutarate. Thus,
glutamine-derived carbons enter the TCA cycle as fully labeled α-ketoglutarate, which
can be further metabolized through two distinct routes (Figure 3.6 D): (1) in the oxida-
tive glutamine metabolism, α-ketoglutarate is decarboxylated to succinyl-CoA, which
is further oxidized to oxaloacetate and then condensed with an unlabeled acetyl-CoA
to form M4 citrate. Thus, the ratio of M4 citrate over M5 glutamate gives an estimation
of the oxidative metabolism of glutamine. (2) The second metabolic route of glutamine
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is the reductive glutamine metabolism in which α-ketoglutarate is reductively carboxy-
lated to isocitrate, finally giving M5 citrate. The ratio used to estimate this flux is M5
citrate over M5 glutamate. Since two decarboxylations occur through one complete cy-
cle, the ratio of M2 over M4 citrate indicates the TCA cycling activity. Finally, the ratio
of reductive to oxidative glutamine metabolism can be determined using the ratio of
M5 over M4 citrate. Upon L-DOPA treatment, the TCA cycle turnover, (figure 3.6 E),
as well as the oxidative (figure 3.6 F) and the reductive (Figure 3.6 G) glutamine meta-
bolism decreased. Moreover, the ratio of reductive to oxidative glutamine metabolism
decreased (Figure 3.6 H).
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FIGURE 3.6: Effects of L-DOPA treatment on metabolic fluxes. LUHMES cells were treated for
24 h with 200 μM L-DOPA and incubated with [U-13C6]glucose or [U-13C5]glutamine. (A): The
fluxes through pyruvate dehydrogenase complex (PDH) and pyruvate carboxylase (PC) can be
determined from [U-13C6]glucose labeling. M2 isotopomers in citrate are derived through PDH
activity (orange) while PC activity induces M3 isotopomers of citrate (blue). (B): The ratio of
M2 citrate/M3 lactate gives an estimation of PDH activity. (C): The ratio of M3 citrate/M3 lac-
tate gives an estimation of PC activity. (D): Upon its entry into the TCA cycle, glutamine can be
metabolized through two different pathways: on the one hand, glutamine can be metabolized
oxidatively (red), giving rise to M4 labeled citrate. On the other hand, the reaction to isocitrate
being reversible, glutamine can be metabolized in a reductive way and gives rise to M5 citrate
(green). (E): Since a complete cycling through the TCA cycle leads to two decarboxylations, the
cycling rate of the TCA cycle can be evaluated by using the ratio of M2 citrate/M4 citrate from
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of the reductive glutamine metabolism. (H): The ratio of M5 citrate/M4 citrate gives an esti-
mate of the ratio of reductive to oxidative glutamine metabolism. All changes were significant
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As pointed out in section 3.1.2.1, ROS can inhibit glycolysis through the action of
p53. The decrease of glucose contribution to glycolytic intermediates could indicate an
inhibition of glycolysis, although uptake and secretion rates of glucose and lactate are
necessary to finally draw that conclusion. Inhibition of glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) is commonly used to assess metabolic effects of inhibition of
glycolysis [161]. In order to assess the effects of glycolysis inhibition and to compare
these to the effects of the L-DOPA treatment in LUHMES cells, I treated them for 24 h
with 3.6 μM heptelidic acid, a compound binding to the Cys149 residue in the catalytic
site of GAPDH [162]. Interestingly, the effects of the GAPDH inhibitor were different
to those observed upon L-DOPA treatment. Upon treatment of LUHMES cells with
heptelidic acid, the contribution of glucose to serine, glycine, alanine, lactate and TCA
cycle intermediates decreased (Figure 3.7 A-G), as seen upon L-DOPA treatment. How-
ever, upon [U-13C3]pyruvate labeling, carbon contribution increased not only in lactate
and alanine, as seen upon L-DOPA treatment, but also in the TCA cycle intermediates,
which was not observed under L-DOPA treatment (Figure 3.7 C-G). This indicates that
a decrease in glucose contribution to the TCA cycle is compensated by contribution
from pyruvate. I can therefore rule out a complete GAPDH inhibition as only mecha-
nism of L-DOPA-induced metabolic changes.
Przedborski et al. showed that chronic L-DOPA treatment in rats induced a de-
crease of mitochondrial complex I activity without affecting the activity of mitochon-
drial complexes II and IV [163]. To compare the profile of LUHMES cells treated with
L-DOPA with the effects of a complex I inhibitor, I treated the LUHMES cells with
rotenone or 1-methyl-4-phenylpyridinium (MPP+). Using [U-13C6]glucose, the contri-
bution of glucose to alanine and lactate as well as the fraction of M3 isotopomer of
malate and aspartate increased upon complex I inhibition (Figure 3.7 H-J), which was
not observed upon L-DOPA treatment. Moreover, Worth et al. showed that rotenone
treatment induced an increase in reductive glutamine metabolism [164], which was not
observed upon L-DOPA treatment (see Figure 3.6 G). Taken together, these data indi-
cate that L-DOPA did not induce a mitochondrial complex I inhibition in LUHMES
cells.
Tretter et al. used guinea pig synaptosomes (isolated nerve endings) to show that
concentrations of H2O2 below 50 μM block the activity of aconitase, the enzyme that
interconverts citrate and isocitrate. To compensate this inhibition, glutamate intake in-
creased to fuel the TCA cycle. This lead to an unaltered NADH production. However,
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FIGURE 3.7: Effects of heptelidic acid, rotenone and MPP+ treatment on carbon contribution.
LUHMES cells were treated for 24 h with 3.6 μM heptelidic acid (Hept), 10 μM MPP+ or for 6 h
with 1 μM rotenone (Rot) and incubated with [U-13C6]glucose (Glc) or [U-13C3]pyruvate (Pyr).
Carbon contributions of serine (A), glycine (B), alanine (C), lactate (D), citrate (E), malate (F)
and aspartate (G) were calculated under glucose and pyruvate tracers after heptelidic acid treat-
ment. Carbon contribution from glucose to alanine (H) and lactate (I) upon MPP+ and rotenone
treatments. (J): M3 isotopologue of malate under glucose tracer and MPP+ and rotenone treat-
ment. All were significant by Student t-test, p-value <0.05.
in the case of concentrations of H2O2 higher than 100 μM, the α-ketoglutarate dehy-
drogenase was also inhibited, leading to a limited NADH generation which caused
impaired respiratory capacities [165]. In their study, Tretter et al. also observed an in-
hibition of SDH by H2O2, although this was not further discussed [165]. The inhibition
of aconitase by H2O2 lead to a truncated TCA cycle. In that case, the aspartate amino-
transferase becomes important to keep the cycle running. This enzyme is responsible
for the conversion of oxaloacetate to aspartate, thereby using glutamate and producing
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α-ketoglutarate. Yudkoff et al. used rat synaptosome and radioactive tracers to show
that aspartate aminotransferase is active in those particles and that the malate-aspartate
shuttle is functional, but to a considerately lower rate than aspartate aminotransferase
[166]. Moreover, Oikawa et al. used substantia nigra tissue from monkeys to show that
ROS induced carbonylation of various proteins including aconitase, glutamate dehy-
drogenase and aspartate aminotransferase [167]. Protein carbonylation is a modifica-
tion induced by ROS during which carbonyl amino acid side chains of proteins are
oxidized to reactive ketones or aldehydes. It has been linked to several dysfunctions
and targets the side chains of lysine, arginine, proline and threonine residues [168]. The
inactivation of these enzymes could explain the decreased activity of the TCA cycle.
Another interesting pathway of central carbon metabolism is the pentose phos-
phate pathway (PPP). On the one hand, it provides precursors for nucleotide biosyn-
thesis from glucose-6-phosphate. On the other hand, it produces the reduced form of
the cofactor NADP+, NADPH. The regeneration of this cofactor plays an important role
in the context of oxidative stress: oxidants cause an increase in the NADP+/NADPH
ratio. NADPH is an important cofactor of the glutathione reductase (GR), the enzyme
recycling GSSG to GSH. This increase in the NADP+/NADPH ratio leads to the in-
hibition of GAPDH and pyruvate kinase (PK), redirecting the glycolytic flux towards
the PPP to reduce more NADP+, thereby supporting the stress response and the syn-
thesis of ribose-5-phosphate needed for the repair of DNA damaged upon stress [169,
170]. Ralser et al. reported that inhibition of GAPDH in S. cerevisiae and C. elegans
induced a rerouting of carbon fluxes towards the PPP. Upon GAPDH inhibition, this
pathway was essential for survival under oxidative stress in order to maintain the cy-
toplasmic NADPH/NADP+ ratio [170]. Using stable isotopte tracing, the activity of
the PPP can be monitored using a [1,2-13C2]glucose tracer. The third reaction of the
pathway leads to the decarboxylation of the first carbon of glucose-6-phosphate, thus
M1 isotopologues of lactate can be traced back to the activity of the oxidative part of
the PPP. On the other hand, M2 isotopologues of lactate are indicative for glycolytic
activity (Figure 3.8 A). The ratio of M1 over (M1 + M2) lactate gives an estimation of
the flux through the PPP. To test whether L-DOPA treatment affects the activity of the
oxidative part of the PPP, I seeded LUHMES cells at the density used in section 3.1.2.1
and treated for 24 h with 0, 25, 50 and 100 μM L-DOPA in the presence of the [1,2-
13C2]glucose. I observed an increase in this ratio, indicating an increased activity of the
oxidative PPP, and thus a linked increased NADPH production (Figure 3.8 B).
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FIGURE 3.8: Effects of L-DOPA treatment on the pentose phosphate pathway. LUHMES
cells (seeded at the density used in section 3.1.2.1) were treated for 24 h with 0, 25, 50 or 100
μM L-DOPA and incubated with [1,2-13C2]glucose. (A): A scheme of the pentose phosphate
pathway (PPP) is represented: the two times labeled glucose-6-phosphate is decarboxylated
upon entry in the PPP, thus only non-labeled or one time labeled fructose-6-phosphate will
enter back the glycolysis and M1 of lactate represents the fraction of metabolites that went
through the PPP. If glucose goes through glycolysis, lactate is two times labeled. (B): Upon
L-DOPA treatment the fraction of carbons that went through the PPP was calculated using
the ratio of M1 over (M1 + M2) lactate. G6PDH: glucose-6-phosphate dehydrogenase; GNL:
gluconolactonase; 6PGD: 6-phophogluconate dehydrogenase; RPE: ribulose-5-phosphate-3-
epimerase; RPI: ribose-5-phosphate isomerase; TKT: transketolase; TAL: transaldolase; TIM:
triose-phosphate isomerase. p-value <0.05 by One-way ANOVA.
In summary, I observed that L-DOPA treatment induced (1) a decreased carbon
contribution from glucose to glycolysis and TCA-derived metabolites. (2) In alanine
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and lactate, carbon contribution from pyruvate increased while in TCA cycle inter-
mediates, glutamine-derived carbon contribution increased. (3) L-DOPA caused a de-
crease in PDH and PC activity as well as a decrease in TCA cycling, oxidative and re-
ductive glutamine metabolism. (4) Although the glycolytic flux might be reduced, an
inhibition of glycolysis cannot account for all these changes observed upon L-DOPA
treatment as observed by comparing L-DOPA and heptelidic acid treatments. (5) L-
DOPA induced changes in TCA cycle activity, but not through a mitochondrial complex
I inhibition as shown by comparison of L-DOPA, rotenone and MPP+ treatments. (6)
The glutamine contribution to TCA cycle intermediates correlates with data obtained
by Tretter et al. who showed that ROS inhibits aconitase and SDH and induces gluta-
mate utilization to fuel the TCA cycle [165]. Inhibition of aconitase would thus lead
to the observed decreased activities of PDH and PC. (7) Finally, L-DOPA treatment
induced an increase in the activity of the oxidative part of the PPP.
The decreased TCA cycling, reduction of the oxidative and reductive glutamine
metabolism as well as the increased activity through the PPP upon treatment indicates
an imbalance in the NAD(P)+ /NAD(P)H ratio.
3.1.3 Does pyruvate play a crucial role for cell survival?
As demonstrated in the previous section, L-DOPA treatment induced a signifi-
cant increase in the contribution of pyruvate carbon to lactate and alanine. Wang et al.
showed that upon H2O2-induced oxidative stress, pyruvate was essential for survival
of human SK-N-SH neuroblastoma cells [171]. They also observed (1) that pyruvate
helped to maintain the membrane potential of the mitochondria and (2) that pyruvate
rescued the decrease in ATP production induced by oxidative stress. They concluded
from these facts that pyruvate could provide protection by being oxidized and be used
as substrate for energy production to maintain cellular functions under stress condi-
tions [171]. I therefore investigated whether pyruvate could play a role in neuronal
survival upon L-DOPA treatment (Figure 3.9). First, I treated LUHMES cells with dif-
ferent concentrations of H2O2 for 24 h in the presence or absence of pyruvate (Fig-
ure 3.9 A). Pyruvate was essential for cell survival for all concentrations of H2O2 above
10 μM. However, when I treated LUHMES cells with L-DOPA, the presence or absence
of pyruvate did not play any role in cell survival (Figure 3.9 B). This is in contradiction
with a further article published by Wang et al. where they found that ethyl pyruvate
could protect PC-12 cells from DA-induced toxicity by suppressing intracellular oxida-
tive stress and modulating signal pathways of apoptosis [172]. It cannot be excluded
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that the protective effect seen in PC-12 was due to the fact that ethyl pyruvate and not
pyruvate was used. Sappington et al. treated enterocytic Caco-2 cells with a mixture of
pro-inflammatory cytokines and showed that ethyl pyruvate inhibited nuclear factor
κB (NF-κB) activation, inducible nitric oxide synthase (iNOS) mRNA expression and
nitric oxide (NO) production (all being responses to inflammation). When pyruvate
was used under the same conditions, it was ineffective and did not reduce the inflam-
matory state of these cells [173].
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FIGURE 3.9: Effects of pyruvate on the viability of LUHMES cells. (A): LUHMES cells were
treated for 24 h with different concentrations of hydrogen peroxide (H2O2) in the presence or
absence of 1 mM pyruvate. (B): LUHMES cells were treated for 24 h with different concentra-
tions of L-DOPA in the presence or absence of 1 mM pyruvate. (C): Mechanism of action of
pyruvate in the scavenging of H2O2 to form acetate, carbon dioxide and water.
Pyruvate protects cells through two mechanisms: (1) by scavenging H2O2 radicals
and (2) by rescuing intracellular energy failure [174]. In the first case, pyruvate can
degrade H2O2 through a non-enzymatic oxidative decarboxylation leading to the for-
mation of acetate, water and carbon dioxide (Figure 3.9 C) [175]. O’Donnel-Tormey et
al. showed, that human and murine cancer cell lines cultured in pyruvate-free medium
secreted pyruvate to reach the extracellular concentration of 60-150 μM, which corre-
sponds to the human serum and plasma concentrations and that this pyruvate served
as extracellular antioxidant [176]. In the second case, pyruvate replenishes the TCA
cycle [177]: upon H2O2 treatment of rat brain slices, the expression of poly (ADP-
ribose) polymerase-1 (PARP-1), a nuclear enzyme expressed abundantly upon DNA
damage induced by oxidative stress, increased and lead to the depletion of NAD+. The
NAD+/NADH redox couple is highly important for energy metabolism and its deple-
tion leads to a drop in ATP production, causing cell death. Zheng et al. incubated the
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slices with mixtures of glucose and pyruvate or pyruvate alone and could conclude that
pyruvate alone was able to replenish the NAD+ pool, probably via the lactate dehydro-
genase, while only the glucose-pyruvate mixture lead to a recovery of both NAD+ and
ATP [177].
In neuronal cells, pyruvate metabolism has not been studied in detail. However,
lactate metabolism has been studied in a much greater extend and its particular use
in neuronal cells gave rise to the astrocyte-neuron lactate shuttle hypothesis (ANLSH).
This process is happening upon glutamatergic activation: neurons synthesize and re-
lease glutamate, which is a highly energy-demanding process. The oxidative phospho-
rylation is thus increased, leading to lower intracellular levels of pyruvate. Glutamate
released for neuronal signalling can also activate glycolysis in astrocytes which release
lactate for neuronal utilization. Concomitantly, neuronal use of glucose is decreased
and lactate is used as carbon source for energy production [178]. In their original work,
Pellerin et al. demonstrated that glutamate induced an increased glycolytic flux in as-
trocytes, leading to increased release of lactate. They also reported that astrocytes re-
leased pyruvate at a rate three times lower than lactate [179]. Furthermore, Wang et
al. showed that astrocytes can release pyruvate to protect neurons upon cysteine auto-
oxidation-induced toxicity [180].
Although I did not observe any protective effect of pyruvate on cell viability in
the presence of L-DOPA, I determined whether pyruvate supplementation impacts in-
tracellular fluxes. For that, I incubated LUHMES cells in the presence and absence
of pyruvate, together with L-DOPA and [U-13C6]glucose or [U-13C5]glutamine. Based
on the MIDs, I determined carbon contributions (Figure 3.10). In the following para-
graphs, I compare the carbon contributions for control conditions in the presence and
absence of pyruvate as well as the carbon contributions for L-DOPA treated cells in the
presence and absence of pyruvate. This comparison was performed for alanine, lactate,
citrate, fumarate, malate and aspartate.
As shown in section 3.1.2.2, L-DOPA treatment induced a decreased carbon contri-
bution from glucose in both alanine and lactate This is displayed in Figure 3.10 A and
B, ctrl and L-DOPA bars.
When pyruvate was omitted, the contribution of glucose-derived carbon increased
in both lactate and alanine (Figure 3.10 A and B, ctrl and wo pyr bars). This could be
94 Chapter 3. Results and discussion
explained by the fact that if one substrate (pyruvate) is omitted, the overall relative
contribution of others sources (glucose in this case) increase.
However, upon L-DOPA treatment in the absence of pyruvate, the carbon contri-
bution pattern differed for the two metabolites: while alanine carbon contribution from
glucose decreased upon treatment to the levels observed in L-DOPA treated cells in the
presence of pyruvate, the carbon contribution from glucose to lactate also significantly
decreased, but to a much lesser extend than that of alanine (Figure 3.10 A and B, wo pyr
L-DOPA bars).
Concerning carbon contribution to TCA cycle intermediates, the absence of pyru-
vate did not induce a difference in carbon contributions under control conditions for
citrate, fumarate, malate and aspartate (Figure 3.10 C-F, ctrl and wo pyr bars). Upon
L-DOPA treatment, the response in the absence of pyruvate showed similar trend as
in the presence of pyruvate and L-DOPA treatment. However, citrate, malate and as-
partate showed a significant decreased carbon contribution from glucose compared to
the condition containing pyruvate. In addition, citrate and malate showed a signifi-
cant increase in carbon contribution from glutamine compared to the L-DOPA treated
conditions with pyruvate (Figure 3.10 C, E, F, L-DOPA and wo pyr L-DOPA bars).
The absence of pyruvate did not induce any change in the TCA cycling as indicated
by the ratio of M2 citrate and M4 citrate from [U-13C6]glucose labeling in control condi-
tions. (Figure 3.10 G, ctrl and wo pyr bars). However, when the treatment was combined
with the absence of pyruvate, the cycling significantly decreased to levels lower than
those observed under treatment conditions in the presence of pyruvate (Figure 3.10 G,
L-DOPA and wo pyr L-DOPA bars).
The lower decrease in carbon contribution from glucose to lactate in comparison
to the one from glucose to alanine supports the idea that the cells are using the lac-
tate dehydrogenase (LDH) reaction to regenerate NAD+, since the absence of pyruvate
deprived the cells of alternative substrate for LDH. Ying et al. reported that astro-
cytes treated with an alkylating agent inducing DNA damage had higher expression of
PARP-1, an enzyme facilitating DNA repair. As mentioned earlier in this section, this
lead to NAD+ depletion and inhibition of glycolysis. In those cells, glucose was the pri-
mary substrate for energy metabolism, thus inhibition of glycolysis lead to mitochon-
drial dysfunction and permeability transition pore (PTP) opening, eventually leading
to cell death. The same authors could partially prevent this toxic effect by supplying
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FIGURE 3.10: Effects of pyruvate on the metabolism of LUHMES cells upon L-DOPA treat-
ment. LUHMES cells were treated for 24 h with 50 μM L-DOPA in the presence or absence (wo
pyr) of 1 mM pyruvate. Carbon contribution from glucose to lactate (A) and alanine (B). Car-
bon contribution from glucose (UGlc), glutamine (UGln) or other sources (Other) for citrate
(C), fumarate (D), malate (E) and aspartate (F). (G): TCA cycling was calculated using the ratio
of M2 over M4 citrate from UGlc tracer for each condition. *: p-value <0.05 by Student t-test.
the astrocytes with either pyruvate, glutamate or glutamine, but not lactate [181]. They
hypothesized that these three metabolites were all able to replenish the TCA cycle and
thus preserve the energy state of the cells. Since NAD+ depletion by PARP-1 did not
prevent activation of TCA cycle upon replenishment, this also suggested that the mi-
tochondrial NAD+ pool was spared from the depletion [181]. In the light of our cell
system, it is possible that I did not observe any effect on the cell viability upon pyru-
vate depletion due to the fact that the cell culture medium contains both glutamine and
glutamate.
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DNA damage via its cleavage has been linked to quinone toxicity by Wang et al.
[182]. Quinones bind to cysteinyl residues of the toposiamerase II enzymes [183]. These
enzymes generate DNA double strand break in order to remove superhelical twists and
tangles from the genetic material. Bender et al. reported that quinones interfere with
this process by covalently attaching to the protein-DNA complex and increase DNA
scission [183], which could in turn induce PARP-1 activation.
The decrease in TCA cycling upon L-DOPA treatment in the absence of pyruvate
could also be due to lower NAD+ levels: although NAD+ as such cannot cross the mito-
chondrial inner membrane, the malate-aspartate shuttle can transport aspartate to the
cytoplasm where it is converted to oxaloacetate, then to malate with the consumption
of NADH and production of NAD+. Malate can then enter the mitochondria back and
be converted to oxaloacetate, thereby consuming NAD+ and producing NADH. This
would decrease the amount of NAD+ available for the TCA cycle activity [184], but the
NADH generated could be used for oxidative phosphorylation through the electron
transport chain.
To summarize, I observed that pyruvate is not essential for cell survival upon
L-DOPA treatment as it is for H2O2, indicating that it does not play an antioxidant
role in the case of L-DOPA treatment. Its absence, however, induced an increase of
glucose-derived carbon contribution to lactate under treated conditions, which was
not observed under conditions containing pyruvate. This suggested a compensation of
pyruvate absence by glucose for NAD+ regeneration. Concerning the TCA cycle, the
absence of pyruvate induced a decrease in glucose contribution to citrate, malate and
aspartate as well as an increased glutamine contribution to citrate and malate. The TCA
cycling decreased upon L-DOPA treatment in the absence of pyruvate. This could sug-
gest that quinone induced DNA strand break by binding to the topoisomerase, which
lead to the activation of PARP-1 and depletion of the cytosolic NAD+ pool. The malate-
aspartate shuttle, together with lactate production, could contribute to restoration of
NAD+, but at the expense of the TCA cycling.
3.1.4 Effects of L-DOPA on uptake and secretion rates
In section 3.1.2.2, the effects of L-DOPA on the contributions of glucose, glutamine
and pyruvate to metabolites of central carbon metabolism were assessed. However,
these values only give a partial view of the overall picture. In order to complete it,
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uptake and secretion rates for glucose, glutamine, lactate, glutamate and pyruvate were
needed.
To measure differences in uptake and secretion rates induced by L-DOPA, I treated
LUHMES cells, seeded at the same density as in section 3.1.2.2, for 24 h with 200 μM L-
DOPA. Uptake rates for glucose and glutamine, as well as secretion rates of lactate and
glutamate are depicted in Figure 3.11 A-D. Upon L-DOPA treatment, I observed that
glucose uptake and lactate secretion decreased. Interestingly, the ratio of lactate over
glucose, indicating the proportion of glycolysis used for ATP production, increased
upon treatment (Figure 3.11 E). This also means that glucose-derived carbon is de-
viated from oxidation in the TCA cycle towards lactate secretion, thus suggesting a
decreased flux through PDH. On the other hand, glutamine uptake was not modified
by L-DOPA stimulation, while glutamate secretion highly increased. As a result, glu-
tamine anaplerosis to the TCA cycle, obtained by subtracting glutamate secretion from
glutamine uptake, decreased upon treatment (Figure 3.11 F).
The decrease in glucose uptake further pointed towards a decreased glycolytic ac-
tivity. The lesser decrease in lactate secretion compared to the decrease in glucose up-
take, manifested in an increase in the lactate over glucose ratio, confirmed the redirec-
tion of glucose carbon towards lactate production rather than towards the TCA cycle.
This increased ATP and NAD+ production through glycolysis could be advantageous
over short periods of time. Indeed, on the long term, TCA cycle is more efficient both
for energy and cofactor synthesis. However, glycolysis runs 100 times faster than TCA
cycle, therefore, an increased lactate to glucose ratio lead to rapid, short term increase
in NAD+ [185].
Glutamine and glutamate showed different profiles. The unchanged uptake rate
of glutamine with and without L-DOPA could be due to an intracellular redirection of
fluxes, away from protein synthesis to protein degradation, thus replenishing the TCA
cycle. The increased concentrations of glutamate in the medium upon L-DOPA treat-
ment could be due to an inhibition of glutamate transporters. These transporters are re-
sponsible for limiting the amounts of glutamate present in the extracellular space [186].
Large amounts of glutamate are secreted under ischemic conditions (i.e. low oxygen
and glucose availability), which lead to overexcitation of postsynaptic neurons [187].
Glutamate excitotoxicity is characterized by disrupted calcium homeostasis, mitochon-
drial dysfunction and generation of ROS [187]. Berman et al. studied rat synaptosomes
and reported an decreased glutamate uptake upon DA treatment [186]. This decrease
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FIGURE 3.11: Effects of L-DOPA on uptake of glucose and glutamine and secretion of lactate
and glutamate. LUHMES cells were treated for 24 h with 200 μM L-DOPA. Uptake and secre-
tion rates were determined. The concentration of the metabolites did not vary between control
and treated conditions in medium without cells. Uptake of glucose (A), glutamine (B) as well as
secretion of lactate (C) and glutamate (D) were calculated. (E): The ratio of lactate over glucose
indicates the proportion of glucose taken up secreted as lactate. (F): Glutamine anaplerosis can
be calculated by subtracting glutamate secretion to glutamine uptake. (G): To test whether the
secreted glutamate could be toxic to the cells, LUHMES cells were treated for 24 h with various
concentrations of glutamate. *: p-value <0.05 by Student t-test.
was due to inhibition of glutamate transporter by ROS and quinones produced during
the oxidation of DA. ROS and quinones can directly inactivate glutamate transporter by
binding to cysteinyl residues located in the active site of the protein, therefore prevent-
ing re-uptake of glutamate into the cells [186]. Transport of glutamate is bidirectional,
therefore, inhibition of the uptake should be accompanied by inhibition of release [188].
However, Rothstein et al. reported that a selective inhibition of glutamate transport in
rat spinal cord cells lead to an accumulation of glutamate in cell culture medium [189].
Glutamate transporter is a symport with sodium, and therefore its activity is linked
to the activity of the Na+/K+ ATPase and membrane potential [188]. Disruption of
membrane potential is responsible for reverse transport of glutamate, and therefore
increased extracellular concentrations of glutamate, under ischemic conditions [188].
Although I could not find evidence of membrane disruption upon L-DOPA treatment
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in the literature, Jana et al. reported that quinones issued from DA oxidation lead to
loss of mitochondrial membrane potential [190]. Interestingly, increased glutamate ex-
tracellular concentrations have been associated with SDH inhibition [155].
In order to ascertain that the toxic effects observed on LUHMES cells upon L-
DOPA treatment were not due to glutamate excitotoxicity, I performed a cell viability
assay with a range of glutamate concentrations covering the concentration measured in
medium after L-DOPA treatment (200 μM) (Figure 3.11 G). No cell death was observed,
indicating that glutamate excitotoxicity is not involved in L-DOPA toxicity.
Intriguingly, I observed that pyruvate levels decreased in media incubated with
L-DOPA, even in the absence of cells (Figure 3.12 A). One hypothesis for the observed
pyruvate depletion could be its function as antioxidant as described in section 3.1.3:
H2O2 produced from redox cycling of quinone can non-enzymatically react with pyru-
vate to form acetate [175]. In this case, I would expect a production of acetate due to
oxidative decarboxylation of pyruvate (see reaction in Figure 3.9 C). To test this hypoth-
esis, I compared the acetate levels in the medium after incubation with and without
L-DOPA, in the absence of cells. Figure 3.12 B shows that the concentration of acetate
increased if L-DOPA is present in the medium. It is however intriguing that the concen-
tration of acetate measured is about one and a half times higher than the concentration
of pyruvate consumed during the same time period. H2O2 can also react with other α-
ketoacids to form the respective carboxylic acid [175]. It is therefore possible that other
compounds from the medium react with H2O2 to form acetate.
Taking into account the degradation of pyruvate as well as acetate production in
medium containing L-DOPA, I calculated uptake rates of pyruvate and acetate in both
treated and untreated conditions (Figure 3.12 C). The consumption of pyruvate was sig-
nificantly decreased upon L-DOPA treatment. In the case of acetate, the cells secreted
it in the absence of treatment, while upon L-DOPA treatment, the uptake of acetate
increased.
Since the presence of acetate in the medium of L-DOPA treated cells induced an
increased uptake of this metabolite, I tested whether this metabolite could influence
neuronal metabolism. Therefore, LUHMES cells were treated for 24 h with 400 μM
pyruvate and 800 μM acetate, as measured in incubated medium with L-DOPA. First,
I assayed cell viability to evaluate if acetate is toxic to the cells (Figure 3.13 A), then
I determined uptake rates for glucose, glutamine and pyruvate as well as secretion
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FIGURE 3.12: Effects of L-DOPA on pyruvate and acetate concentrations. LUHMES cells
were treated for 24 h with 200 μM L-DOPA. (A-B): Concentrations of pyruvate and acetate
were measured from media incubated without cells in the presence or absence of L-DOPA.
(C): Uptake and secretion rates of pyruvate and acetate. All were significant by Student t-test,
p-value <0.05
rates for lactate, glutamate and acetate (Figure 3.13 B-G). I found that 800 μM of acetate
did not impair cell viability within a period of 24 h. In addition, glucose, glutamine
and pyruvate uptake did not change upon acetate treatment. I observed no change
of lactate and glutamate secretion rates. Interestingly, following acetate treatment, the
cells did not consume any acetate, but they rather increased its secretion (Figure 3.13
G).
As shown in Figure 3.12 C and Figure 3.13 G, LUHMES cells can either secrete or
consume acetate depending on the conditions. It is synthesized by hydrolysis of acetyl-
CoA by the cytosolic acetyl-CoA hydrolase, with pyruvate as the predominant precur-
sor of acetyl-CoA [191]. Although acetate was only measured following ischemia and
not in healthy brain, it is reported as common metabolite in primary CNS-derived cul-
tures [191].
Upon L-DOPA treatment, LUHMES cells consumed acetate rather than secreting
it. Waniewski et al. reported that only glial cells can metabolize acetate because neu-
ronal cells do not possess the adequate transport system [192]. However, Rae et al.
refuted this by showing that acetate can be transported by neurons through the mono-
carboxylate transporters (MCTs), among which neuronal MCT2 has the highest affinity
for acetate. They also showed that acetate is rapidly incorporated into the lipid fraction
[191]. Once inside the cell, acetate can be metabolized to acetyl-CoA by the acetyl-CoA
synthetase (ACSS2). Acetyl-CoA can then be used to fuel the TCA cycle, for choles-
terol and fatty acid synthesis or for protein and histone acetylation [193]. If LUHMES
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cells are indeed able to use acetate, a rerouting of acetyl-CoA from TCA cycle fuel-
ing to fatty acid synthesis could explain the decreased carbon contribution of pyruvate
to TCA cycle intermediates observed upon L-DOPA treatment in Figure 3.5 F and G,
section 3.1.2.2.
Zhao et al. showed that most enzymes of the central carbon metabolism are acety-
lated. However, the change in enzymatic activity depended on the enzyme considered
[194]. In this case, it seems improbable that the acetate consumed upon L-DOPA treat-
ment goes to protein acetylation. On the other hand, Gu et al. showed that upon H2O2
treatment, the expression of acetyltransferases p300/cAMP-response element binding
protein increased while the expression of histone deacetylases decreased in SH-SY5Y
cells [195]. Acetyl-CoA can also be used to synthesize fatty acids. Ischemic injury in-
duced the degradation of membrane phospholipids and release of free fatty acids. Ul-
loth et al. showed that treatment of PC-12 cells with palmitic and stearic acids induced
cell death. They used concentrations comparable to those measured following trau-
matic brain injuries. The mechanisms involved an early activation of the expression of
the Fas receptor, followed by cell shrinkage and membrane blebbing. In a third step,
the nuclear content condensed and fragmented and finally, the Fas ligand was upreg-
ulated. Treatment with oleic and arachidonic acids did not induce any toxicity [196].
Although the levels of free fatty acids as well as the contribution of acetate to their
synthesis upon L-DOPA treatment is currently unknown, I cannot rule out a potential
toxicity induced by an increase in their concentration.
Finally, I assayed the effect of acetate on the metabolism of pyruvate (Figure 3.13
H). LUHMES cells were incubated with [U-13C3]pyruvate in the presence or absence of
acetate. No difference was observed in the MIDs of citrate, malate and NAA, indicating
that the presence of acetate alone did not modify intracellular fluxes of pyruvate. To as-
sess if LUHMES cells can metabolize acetate, I incubated them with [U-13C2]acetate for
24 h (Figure 3.13 I). MID of NAA, citrate, glutamate, malate and fumarate showed that,
indeed, the neuronal LUHMES cells can metabolize acetate. However, the proportion
of labeling is very low, suggesting that the acetate taken up upon L-DOPA treatment
is used for other purposes. As mentioned in section 3.1.2.1, acetate can be used as
acetyl donor in neurons for membrane repair [160], it is therefore possible that acetate
is directed towards fatty acid synthesis.
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FIGURE 3.13: Effects of acetate on uptake and secretion rates. LUHMES cells were treated
for 24 h with 800 μM acetate. (A): The viability of treated cells was assayed. Uptake rates for
glucose (B), glutamine (C) and pyruvate (D), and secretion rates for lactate (E), glutamate (F)
and acetate (G) were calculated. (H): To evaluate if acetate modified the metabolism of the
cells, they were incubated with [U-13C3]pyruvate (UPyr) in the presence or absence of acetate.
M2 isotopomer for citrate, malate and N-acetyl-aspartate (NAA) are displayed. (I): To evalu-
ate if LUHMES cells can use acetate as carbon source, they were incubated with 800 μM [U-
13C2]Acetate (UAc) for 24 h. M2 isotopomer for NAA, citrate, glutamate, malate and fumarate
are displayed. *: p-value <0.05 by Student t-test
In summary, I observed that L-DOPA treatment induced a decreased glucose and
pyruvate consumption as well as lactate secretion, but increased the lactate over glu-
cose ratio, indicating a decreased glycolytic activity but an increased conversion of glu-
cose to lactate possibly for NAD+ regeneration. While the uptake of glutamine did not
change upon L-DOPA treatment, the concentration of glutamate in extracellular space
highly increased. This increase is rather the result of decreased re-uptake through an
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inhibition of glutamate transporters by ROS and quinones [186]. Increase in glutamate
concentration in the extracellular space has also been associated with SDH inhibition
[155], thus strengthening the idea that L-DOPA toxicity might be mediated through mi-
tochondrial complex II inhibition. Upon L-DOPA treatment, LUHMES cells consumed
acetate produced by the reaction of H2O2 with pyruvate, possibly for fatty acid syn-
thesis. However, when incubated with acetate, LUHMES cells secreted it, indicating it
could be used as carbon source under stress condition.
3.1.5 Effects of L-DOPA on inflammation
The substantia nigra possesses the highest microglial density in the brain. About
12% of the cells in this region are microglia, therefore rendering this brain area highly
sensitive to immune system activation [197]. Microglial cells are of the same myeloid
lineage as macrophages and are the resident immune cells of the brain. Upon activa-
tion, these cells release pro-inflammatory cytokines such as tumour necrosis factor al-
pha (TNFα), interleukine-1 beta (IL-1β), increase the expression of iNOS and the gener-
ation of ROS, which actively trigger apoptosis in neuronal cell culture [198]. Although
the underlying mechanisms of PD are still unknown, it has been hypothesized that the
progressive nature of the disease is caused by chronic neuro-inflammation [199]. In
PD patients, levels of pro-inflammatory cytokines were elevated in peripheral blood
mononuclear cells (PBMCs) [199] and in post-mortem analysis of the substantia nigra
[198]. Moreover, the use of anti-inflammatory drugs has been associated with de-
creased risk of PD [197]. Loss of DJ-1 is associated with dopaminergic neuronal cell
death and development of PD. Silencing of this gene in neurons increased their sus-
ceptibility to oxidative stress, while DJ-1 silencing in microglial BV-2 cells increased
pro-inflammatory-associated markers without further stimulation [144].
The effects of neuromelanin (NM) on microglial cells have been investigated in
vivo and in vitro. Viceconte et al. reported that synthetic NM triggers and inflammatory
reaction in rat brain as well as in BV2 cells [200]. Wilms et al. used primary rat mi-
croglia to demonstrate that human-isolated NM caused an activation of these cells in a
NF-κB-dependent fashion [201]. Bortolanza et al. used rat models of PD to show that
L-DOPA-induced dyskinesia is accompanied by an activation of glial cells. This acti-
vation was characterized by an activation of iNOS. Co-administration of L-DOPA and
nitric oxide synthase (NOS) inhibitor could prevent the dyskinesia, therefore showing
that NO plays a role in this side-effect of L-DOPA treatment [202].
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I showed in section 3.1.1 that mouse immortalized microglial cells BV2 were sen-
sitive to high L-DOPA concentrations. In this section, I investigated whether L-DOPA
triggered an inflammatory response in these cells. Therefore, I treated the cells either
(1) for 24 h with 50 μM L-DOPA alone, (2) 10 ng/mL lipopolysaccharide (LPS) for 6
h or (3) a combination of both where I added LPS 18 h after the L-DOPA treatment
was initiated. I observed that LPS induced a pro-inflammatory response in BV2 cells
as shown by the increase in levels of itaconate and succinate as well as increased gene
expression of TNFα, IL-1β and iNOS (Figure 3.14). Itaconate is a metabolic product de-
rived from the TCA cycle and synthesized in macrophages and microglial cells upon
pro-inflammatory activation. It has antimicrobial effects through inhibition of the gly-
oxylate shunt in bacteria [203]. Succinate accumulation is another marker of inflam-
matory response in macrophages [204]. L-DOPA alone induced a slight non-significant
increase in itaconate and succinate levels, without affecting cytokine gene expression.
A combination of L-DOPA and LPS did not induce a stronger or weaker inflammatory
state than the one generated by LPS alone.
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FIGURE 3.14: Effects of L-DOPA on inflammation. Mouse microglia BV2 cells were treated for
6 h with 10 ng/mL LPS, for 24 h with 50 μM L-DOPA or with a combination of both: cells were
treated with L-DOPA and 18 h later, LPS was added for an additional 6 h. (A): Itaconate levels.
(B): Succinate levels. Inflammation can also be viewed at the gene expression level: TNFα (C),
iNOS (D) and IL-1β (E) are displayed. *: p-value <0.05 by Student t-test, n.s.: not significant
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In summary, I demonstrated that, in our experimental set up, L-DOPA did not
induce an inflammatory response in quiescent cells and that concomitant L-DOPA and
LPS stimulation did not induce a inflammatory profile different than in the case of LPS
stimulation alone.
3.1.6 Summary: Effects of L-DOPA on the metabolism of TH-positive neu-
rons
In this section, I studied the effects of L-DOPA, the most commonly used drug to
treat PD, on the metabolism of the TH-positive neuronal cell model LUHMES. Eluci-
dating the metabolic adaptation of neurons to this compound is of importance in order
to understand the effects of L-DOPA and its derivatives on these cells. We first deter-
mined the effects of L-DOPA on the viability of cell lines of various origins, includ-
ing human LUHMES immortalized mesencephalon, human SH-SY5Y neuroblastoma,
human A549 lung cancer, human CFF-STTG1 astrocytoma, mouse BV2 immortalized
microglia, mouse IMA2.1 immortalized and rat PC-12 pheochromocytoma cells. We
could observe that the LUHMES cells were the most sensitive to this drug. This could
be partly due to the fact that these cells are in a post-mitotic state. The sensitivity of the
different cell lines did not appear to be organism specific: the human CFF-STTG1 cells
did not die upon treatment. I also showed that preventing oxidation using AA, GSH,
NAC or SOD prevented its toxicity. Application of the DOPA enantiomer D-DOPA
did not modify cell viability indicating that the toxicity was independent of enzymatic
action on L-DOPA. Moreover, oxidized L-DOPA was not toxic.
I revealed profound changes in the metabolism of LUHMES cells using a non-
targeted metabolomics approach. The intracellular amounts of essential amino acids
such as valine, leucine, isoleucine, lysine and phenylalanine increased while the
amount of non-essential amino acids including alanine, serine and glycine decreased,
which is indicative of a decreased protein synthesis. Levels of intermediates of the TCA
cycle decreased except for succinate, which showed increased levels upon L-DOPA
treatment. Labeling experiment showed that glucose contribution to lactate, alanine,
serine, glycine and TCA cycle intermediates decreased upon treatment. Carbon contri-
bution from pyruvate increased in lactate and alanine, while carbon contribution from
glutamine increased in TCA cycle intermediates. Flux through the PPP was increased
upon treatment indicating an increased need of NADPH. Fluxes through PDH and PC
decreased as well as the TCA cycling activity, the reductive and oxidative glutamine
metabolism. This indicated a strong reduction in TCA cycle activity.
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The same treatment was performed in the absence of pyruvate to determine
whether this metabolite is necessary for cell survival in the presence of L-DOPA, as it
is the case under H2O2 treatment. Although the absence of pyruvate did not modify
the cell viability upon L-DOPA treatment, it induced a significant increase in glucose
contribution to lactate, but not to alanine. The TCA cycling activity further decreased
and carbon contribution from glucose significantly decreased in citrate, malate and
aspartate, while carbon contribution from glutamine increased in citrate and malate.
Uptake and secretion rates indicated that glucose and pyruvate uptake as well as
lactate secretion decreased upon L-DOPA treatment. However, when calculating the
ratio of lactate over glucose, it appeared that the amount of glucose directed to lactate
production increased, while the carbon contribution from glucose to lactate decreased.
This is due to the fact that although both uptake of glucose and secretion of lactate de-
creased upon treatment, the decrease in glucose uptake was stronger than the decrease
in lactate secretion, leading to an increased ratio. Glutamine uptake was unchanged
and glutamate secretion increased. The really strong secretion of glutamate biased the
difference of glutamine uptake versus glutamate secretion towards a decreased glu-
tamine anaplerosis into the TCA cycle. However, I observed an increased glutamine-
derived carbon contribution to TCA cycle intermediates. These are not exclusive: car-
bon contribution is a relative value. Although the percentage of glutamine-derived
carbon increased in TCA cycle intermediates, the amount of TCA cycle intermediates
decreased (see Figure 3.4). The absolute carbon contribution from glutamine to the
different TCA cycle intermediates can be obtained by multiplying the relative carbon
contribution with the signal intensity for each metabolite. The absolute carbon contri-
bution from glutamine decreased in citrate, malate, fumarate and aspartate Appendix
C.1.
Interestingly, there was an increase in the consumption of acetate, which was pro-
duced by the reaction of pyruvate and H2O2 (issued from L-DOPA auto-oxidation) in
the medium. We could also show that the toxicity was not mediated through glutamate
secretion nor acetate production. Moreover, when the cells were treated with acetate,
they secreted acetate instead of consuming it.
I also profiled cellular metabolism after mitochondrial complex I and GAPDH in-
hibition and could show that none of these reproduced the changes observed upon L-
DOPA treatment. A promising lead to investigate would be a mitochondrial complex
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II inhibition, as shown by increased glutamine contribution to the TCA cycle, accumu-
lation of succinate and increased glutamate secretion.
In the last part of this section, I evaluated whether L-DOPA induces an inflamma-
tory response in mouse microglia BV2 and whether concomitant treatment of L-DOPA
and LPS would induce a different inflammation profile than LPS alone. I showed that
L-DOPA does not induce an inflammatory response in BV2 cells. It is possible that
the increased inflammatory state observed in PD patients is initiated by dying neurons
rather than from the L-DOPA itself.
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FIGURE 3.15: Summary: the effects of L-DOPA. Treatment of LUHMES cells with L-DOPA
induced profound metabolic changes. (1) At the uptake and secretion rate level: a decrease in
glucose, and pyruvate uptake rates, an unchanged uptake rate of glutamine and an increased
uptake rate of acetate. It caused an increased secretion rate of glutamate, as well as a decreased
secretion rate of lactate. Treatment decreased glutamine anaplerosis in the TCA cycle and in-
creased the glucose to lactate conversion. (2) At the metabolic flux level: L-DOPA induced a
decrease in the activity of pyruvate dehydrogenase complex (PDH) and pyruvate carboxylase
(PC), a reduced TCA cycle activity as well as a decrease in oxidative and reductive glutamine
metabolism. (3) At the metabolite abundance level: L-DOPA treatment caused a decrease in the
amounts of TCA cycle intermediates citrate, glutamate, fumarate, malate and aspartate as well
as an increase in the amount of succinate. (4) At the carbon contribution level: in lactate, contribu-
tion of glucose to lactate decreased upon treatment, while contribution of pyruvate increased.
In all TCA cycle intermediates measured, carbon contribution from glucose decreased upon
treatment, while carbon contribution from glutamine increased.
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3.2 Generation of a human dopaminergic cell model
This section focuses on the generation of a human dopamine producing cell sys-
tem. As mentioned in the introduction in section 1.2.4, to date, there exists no cell
culture model of human origin derived from non-cancerous brain cells that produces
DA. Such a system is of crucial importance in the scope of PD: the dopaminergic neu-
rons selectively degenerate with the progression of the disease and DA is known to
increase intracellular oxidative stress [93]. The most widely used systems include hu-
man SH-SY5Y neuroblastoma and rat PC-12 pheochromocytoma cells. The goal of this
project was to use the human immortalized mesencephalon LUHMES cells to obtain
such a model. These cells can be differentiated in post-mitotic neurons and express
TH, the rate-limiting enzyme in the DA synthesis pathway. The first part of this sec-
tion focuses on the comparison of available cell models. Then, in order to induce DA
production in LUHMES and SH-SY5Y cells, I undertook a cloning approach to increase
the expression of genes involved in DA synthesis.
3.2.1 Comparison with available systems
DA is synthesized from tyrosine in a two-step reaction: first, tyrosine is hydrox-
ylated by TH to L-DOPA, which is then decarboxlated by AADC to DA. The activity
of TH depends on the presence of a cofactor, 6R-L-erythro-5,6,7,8-tetrahydrobiopterin
(BH4). The first and rate-limiting enzyme of the synthesis of this cofactor from guano-
sine triphosphate (GTP) is GTP cyclohydrolase 1 (GTPCH). Upon synthesis, DA is
packaged into vesicles by the vesicular monoamine transporter 2 (VMAT2), where it
is stabilized by a lower pH [205].
I first checked gene expression of GTPCH, TH, AADC, VMAT2 in various cell lines.
I compared the iPSC-derived dopaminergic neurons 17608/3 (differentiated by Peter
Barbuti, Clinical and Experimental Neuroscience, LCSB) with LUHMES and SH-SY5Y
cells (Figure 3.16 A-D). Only iPSC-derived dopaminergic neurons expressed all four
genes. SH-SY5Y expressed GTPCH and AADC, but did not express VMAT2 nor TH.
LUHMES cells only expressed TH.
I compared protein synthesis of TH in iPSC-derived dopaminergic 17608/3 and
SNCA3 (a A30P synuclein α (SNCA)-mutation carrier) with LUHMES, SH-SY5Y and
PC-12 (Figure 3.16 E-F). The 17608/3 cells synthesized higher levels of TH than the
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SNCA3 mutants, which produced similar levels to LUHMES cells. SH-SY5Y cells did
not express any TH, while PC-12 cells had the highest expression.
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FIGURE 3.16: Comparison of gene and protein expressions between the iPSC-derived
dopaminergic neurons 17608/3, human LUHMES immortalized TH-positive neurons, hu-
man SH-SY5Y neuroblastoma and rat PC-12 pheochromocytoma cells. Comparison of gene
expression between 17608/3, LUHMES and SH-SY5Y for GTP-cyclohydrolase (GTPCH) (A),
tyrosine hydroxylase (TH) (B), aromatic amino acid decarboxylase (AADC) (C) and vesicular
monoamine transporter 2 (VMAT2) (D). (E): Protein expression of TH in 17608/3, iPSC-derived
dopaminergic neurons carrying a α-synuclein mutation SNCA3 and LUHMES. (F): Protein ex-
pression of TH in LUHMES, SH-SY5Y and PC-12 cells. Protein samples from the same box were
loaded on the same membrane.
I measured DA levels in each cell line using a targeted and highly sensitive method
by gas chromatography - mass spectrometry (GC-MS) (Figure 3.17 A). Metabolites were
extracted from fully confluent wells in 12-well plates. I observed significant DA pro-
duction in PC-12 cells and in iPSC-derived dopaminergic neurons 17608/3 cells. The
compound was also detected in the SNCA3 cells, but to a much lesser extend. LUHMES
and SH-SY5Y cells did not produce any detectable amounts of DA. To test whether
AADC was active, I incubated SH-SY5Y and LUHMES cells in the presence of 50 μM
L-DOPA for 2 h (Figure 3.17 B). Only SH-SY5Y produced DA by decarboxylation of
L-DOPA.
In summary, the iPSC-derived dopaminergic cells are fully mature DA-producing
cells. Their gene expression of catecholamine-related genes served as basis for gene
expression in the model to be generated. PC-12 cells possessed the strongest TH ex-
pression and they produced DA. Gene expression for the considered genes was not
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FIGURE 3.17: Dopamine production across cell lines. (A): Rat PC-12 pheochromocytoma,
human LUHMES mesencephalon, human SH-SY5Y neuroblastoma, iPSC-derived dopaminer-
gic neurons 17608/3 and SNCA3 were extracted. Dopamine could only be detected in PC-12
cells and in iPSC-derived dopaminergic neurons. (B): Upon 50 μM L-DOPA stimulation for
2 h on SH-SY5Y and LUHMES cells, only the SH-SY5Y cells produced detectable amounts of
dopamine.
investigated in PC-12 because of primer incompatibility between organisms. In SH-
SY5Y cells, the expressions of AADC and GTPCH were the strongest, but no TH was
detected neither at gene nor at protein levels. The fact that L-DOPA was decarboxy-
lated to DA indicated that AADC is active in SH-SY5Y. In this case, overexpression of
TH may induce endogenous DA production. Finally, in LUHMES cells, only TH was
expressed on both gene and protein levels. Moreover, DA synthesis could neither be
detected with and without L-DOPA supplementation.
As depicted in Figure 3.17 B, LUHMES cells were incubated with L-DOPA to initi-
ate DA production. I applied several other conditions to induce DA production, such
as KCl for depolarization, AA to prevent DA oxidation or culture under 2% oxygen to
better simulate the brain environment. Unfortunately, none of these were successful. I
then engineered TH overexpressing cell lines using lentiviruses as delivery systems.
3.2.2 Genome engineering to increase gene expression in LUHMES and SH-
SY5Y cells
3.2.2.1 TH overexpression in LUHMES and SH-SY5Y cells
SH-SY5Y cells are classically differentiated for 5 days using retinoic acid (RA) and
low fetal bovine serum (FBS) [54]. Lopes et al. reported that the expression of TH is
induced upon 4 days of differentiation, however, we could not detect any synthesis of
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TH after 5 days of differentiation. Therefore, I used proliferating SH-SY5Y cells for the
following experiments.
TH was the only enzyme of the synthesis pathway of DA missing in SH-SY5Y.
Since it is the rate-limiting enzyme in the pathway, I hypothesized that increasing the
expression of this enzyme in both LUHMES and SH-SY5Y cell lines could induce DA
production. Therefore, the overexpression of this gene was introduced using a lentivi-
ral system which integrated the target sequence into the DNA of the host. Transfected
cells were then selected using blasticidine. As a control, I engineered constructs en-
coding the LacZ gene. The expressed proteins were coupled to a V5-tag, which allows
for protein purification and separation of endogenous and overexpressed enzyme by
western blot using a specific antibody. Both TH and LacZ overexpression were un-
der the control of a cytomegalovirus (CMV) promoter. LUHMES and SH-SY5Y were
seeded at the same density and infected with the same amount of viral particles. Cells
overexpressing TH will be referred to as THox and cells overexpressing LacZ will be
referred to as LacZox.
Figure 3.18 A-D presents gene and protein expressions of TH in SH-SY5Y and
LUHMES cells. The expression of both were much stronger in SH-SY5Y compared
to LUHMES cells. DA measurement (Figure 3.18 E) showed that TH overexpression
was sufficient to induce endogenous DA production in SH-SY5Y, but not in LUHMES
cells.
DA is synthesized from L-DOPA, which itself is produced from tyrosine. Tyro-
sine is a non-essential amino acid which, in mammals, can only be produced from
phenylalanine or supplied by the diet [206]. Using the newly engineered SH-SY5Y
THox cells, I characterized the origin of DA depending on substrate availability. I in-
cubated the cells in Advanced DMEM/F12 prepared in house free of tyrosine and phe-
nylalanine. The experiment was divided in four parts: cells were incubated for 24 h in
medium containing (1) unlabeled tyrosine and phenylalanine, (2) [U-13C9]tyrosine and
unlabeled phenylalanine, (3) unlabeled tyrosine and [U-13C9]phenylalanine and (4) [U-
13C9]phenylalanine without tyrosine. This design allowed to evaluate which substrate
is preferred and if phenylalanine can compensate for the absence of tyrosine. I ob-
served that none of the conditions modified the amount of phenylalanine measured in-
tracellularly (Figure 3.19 A). When tyrosine was excluded, the intracellular level of this
metabolite significantly decreased (Figure 3.19 B) without affecting the total amount of
DA produced under this condition (Figure 3.19 C). Figure 3.19 D-F shows the results
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FIGURE 3.18: TH overexpression in SH-SY5Y and LUHMES cells. Tyrosine hydroxylase (TH)
was overexpressed under the control of a CMV promoter. (A): TH gene expression in SH-SY5Y
wild type (WT) and TH overexpressing (THox) cells. The expression of the protein is coupled
to a V5-tag which can also be detected by western blot. A vector expressing LacZ was used as
control and was also coupled to a V5-tag. (B): TH and V5-tag protein levels in SH-SY5Y WT and
THox. (C): TH gene expression in LUHMES WT and THox. (D): TH and V5-tag protein levels
in LUHMES WT and THox. (E): Dopamine signal in WT and THox SH-SY5Y and LUHMES
cells. Protein samples from the same box were loaded on the same membrane.
obtained from following the fate of each of the tracers. In the case where none of the
precursor was labeled, the dopamine produced was totally unlabeled. When phenyl-
alanine was labeled and tyrosine was present in the medium, no labeling in tyrosine
nor DA was observed. When tyrosine was labeled, about 80% of the DA produced was
labeled. Finally, when phenylalanine was labeled and tyrosine was omitted, about 80%
of tyrosine and 75% of DA were labeled.
In SH-SY5Y THox cells, tyrosine was the preferred substrate for DA synthesis. In
the absence of tyrosine, phenylalanine was used as substrate and the total amount of
DA synthesized was the same as in the presence of tyrosine. However, phenylala-
nine did not replenish the total amount of tyrosine. Figure 3.19 G summarizes these
findings. Fernstrom et al. reported that, in PC-12 cells as well as in rat dopaminergic
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FIGURE 3.19: Source of dopamine production. SH-SY5Y cells overexpressing TH were culti-
vated for 24 h without any stable isotope tracer (UN), with [U-13C9]phenylalanine in the pres-
ence of tyrosine in the medium (UPhe), with [U-13C9]tyrosine in the presence of phenylalanine
in the medium (UTyr) or with [U-13C9]phenylalanine in the absence of tyrosine in the medium
(UPhe woTyr). (A-C): Intracellular amounts of phenylalanine, tyrosine and dopamine. (D-F):
Carbon contribution from the different tracers in phenylalanine, tyrosine and dopamine. (F):
From the labeling, the synthesis of dopamine is primarily issued from extracellular tyrosine.
However, in the absence of tyrosine, phenylalanine is used.
neurons issued from the retina, tyrosine is the preferred substrate for L-DOPA synthe-
sis. Phenylalanine was only used in the absence or at low concentrations of tyrosine
[207]. They also tested several combinations of tyrosine and phenylalanine concentra-
tions. They observed that higher tyrosine concentrations exerted a substrate inhibition
on TH, but only at low phenylalanine concentrations [207]. Kaborath et al. reported
that, in rat brain synaptosomes, phenylalanine hydroxylase (PheH) is not expressed.
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This enzyme is responsible for the hydroxylation of phenylalanine to tyrosine and can
be inhibited by D,L-p-chlorophenylalanine. However, this compound had no effect
on the tyrosine synthesis suggesting that phenylalanine is hydroxylated by TH [208].
They also reported that the hydroxylation rate of tyrosine and phenylalanine by TH are
similar [208].
In summary, upon overexpression of TH, SH-SY5Y produced DA. I showed that
these cells use preferentially tyrosine for its synthesis and that phenylalanine can be
used in the absence of tyrosine to produce the same amounts of DA. Both reactions
are probably mediated by TH, which seems to have a higher affinity for tyrosine than
phenylalanine. However, LUHMES cells did not produce any DA upon TH overex-
pression.
3.2.2.2 Time course differentiation of LUHMES cells
In their original description of the LUHMES cells, Scholz et al. reported that, al-
though the LUHMES cells are considered to be mature from day 6 of differentiation,
longer differentiation leads to increased TH expression [58]. I hypothesized that a
longer differentiation of the LUHMES THox cells could increase TH expression and
activity. This experiment was performed with the support of Xiangyi Dong. We dif-
ferentiated LUHMES WT and THox cells for 0, 2, 6, 10 and 15 days and compared the
expression of TH (Figure 3.20 A). As expected, no expression of TH was detected in WT
cells at day 0 and 2 of differentiation. The protein was detected after 6 days of differen-
tiation and its expression increased further after 10 days. However, after 15 days, the
expression of TH started to decrease. Expression of TH in LUHMES THox cells was
already detected after 2 days of differentiation. At day 6, two bands are discernible:
the upper one corresponded to the overexpressed protein coupled to a V5-tag that ren-
dered it slightly heavier, while the lower one corresponded to the endogenous TH.
At day 10, TH expression was further increased. The expression of the TH construct
stayed constant until day 15, while the intensity of the other band, corresponding to the
endogenous TH, decreased. Metabolites were extracted after 10 days of differentiation
in each cell line, but no DA was detected in any of them.
In the same article, Scholz et al. reported that cyclic adenosine monophosphate
(cAMP) is essential to induce endogenous TH expression [58]. Since the overexpression
of TH is under the control of a CMV promoter, I hypothesized that omitting dibutyryl
cAMP (db-cAMP) would result in the exclusive expression of the engineered version
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TH and V5-tag protein expression of LUHMES WT and THox cells differentiated for 6 days in
the presence of absence of cAMP. (C): TH protein expression for LUHMES LacZox cells differ-
entiated for 6 days in the presence or absence of db-cAMP. (D): V5-tag protein expression of
LUHMES cells overexpressing LacZox under the CMV or UbC promoter. Protein samples from
the same box were loaded on the same membrane.
and no expression of endogenous TH. This would be of value to study mutant forms
of TH in LUHMES. In order to test this, LUHMES WT and THox cells were differenti-
ated with and without db-cAMP for 6 days and TH protein levels were assessed (Fig-
ure 3.20 B). For both cell lines, the absence of db-cAMP impaired TH protein synthesis.
Lewis-Truffin et al. reported that cAMP regulates TH expression through activation of
cAMP response element binding protein (CREB) [60]. Upon activation by cAMP, CREB
binds to the cAMP response element (CRE) located at -45 bp in the 5’ flanking region
of TH and activates its transcription [60]. As expected, endogenous production of TH
is absent when db-cAMP was omitted. Intriguingly, however, TH synthesis from the
overexpression construct was affected as well.
Tank et al. and Chen et al. reported that cAMP can regulate TH at the post-
transcriptional level [209, 210]. In their adrenal medulla and midbrain dopaminergic
neuron models, they did not observe any change in TH mRNA levels upon db-cAMP
supplementation. However, they observed increased TH protein levels. They hypothe-
sized that poly-C binding protein (PCBP) is activated by cAMP and binds to the 3’UTR
region of TH mRNA. The PCBP-TH mRNA complex can stabilize the mRNA and/or
increase its association with polyribosomes leading to increased translation [209]. To
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test whether or not TH is targeted for proteasomal degradation because it is not sta-
bilized by PCBP, LUHMES cells overexpressing LacZ were differentiated for 6 days
with or without db-cAMP (Figure 3.20 C). The results showed that the absence of db-
cAMP lead to no expression of LacZ in those cells. As a consequence, I ruled out a
post-translational modification as the reason why TH was not expressed in LUHMES
THox cells.
Interestingly, CMV infections have been associated with neurological disorders in
people with acquired immune deficiency syndrome (AIDS) as well as with impaired
brain growth, mental retardation and progressive motor deficits in infants with con-
genital disorders [211]. Wheeler et al. investigated the mechanisms of CMV production
in the brain and found that the CMV promoter possesses five CREs and that mutation
in those sites cause a decrease in protein expression of 95% [211]. Thus, the induction of
the overexpressed TH is initiated by cAMP at the transcriptional level and is necessary
for its expression.
For all these reasons, the CMV promoter was not the most appropriate promoter
for the selective study of overexpressed TH in LUHMES cells. Another available pro-
moter is the ubiquitin C (UbC) promoter. Dittgen et al. reported that UbC was the best
suited promoter for expression in cultured neurons [212] and Wilhelm et al. found that
the expression of this promoter was specific for neurons [213]. To test this promoter,
the LacZ gene was expressed under the control of the UbC promoter in LUHMES cells
and the cells were selected with blasticidine. Cells were differentiated for 6 days and
protein expression of LacZ using a V5-tag antibody was assessed (Figure 3.20 D). I
could not observe any LacZ expression under the control of the UbC promoter. I can
here rule out any issue with plasmid insertion into the host DNA since the cells were
resistant to blasticidine. However, the gene of interest and the blasticidine-resistance
gene are not controlled by the same promoter: the former is under the UbC promoter,
while the latter is under the control of simian virus 40 (SV40) promoter (see Figure B.3).
Therefore, it seems that the UbC promoter is not expressed in LUHMES cells. The rea-
son for the low expression of the CMV promoter and the absence of expression of the
UbC promoter in LUHMES cells could be due to promoter methylation. Herbst et al.
studied the expression of green fluorescent protein (GFP) under the control of differ-
ent promoters during the differentiation of cardiomyocytes [214]. Although the CMV
promoter was expressed at all stages of differentiation, they observed a significant de-
crease of its expression due to heavy DNA methylation [214].
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In the context of SH-SY5Y, the effects of cAMP on the cells are completely different.
Cho et al. reported that 500 μM of db-cAMP increased cell proliferation rate in SH-
SY5Y [215]. The CMV promoter can be activated by other factors than cAMP. Activator
protein 1 (AP-1), which also regulates TH expression, has binding sites on the CMV
promoter and can therefore activate it [216]. Moreover, Li et al. reported a cell type-
specific expression of different promoters [217].
In summary, as demonstrated by Scholz et al., the expression of TH in LUHMES
cells depend on cAMP and its expression increased with longer differentiation [58].
I observed that TH expression was at maximum after 10 days of differentiation and
decreased after day 15. When I overexpressed TH in LUHMES cells under the control of
a CMV promoter, I already observed TH synthesis after 2 days of differentiation. As for
the endogenous TH, I observed a maximal expression after day 10, but the expression of
the construct did not decrease at day 15. Both, the endogenous TH and the engineered
construct, depended on cAMP for their expression since both promoters possess CREs.
Using a UbC promoter to control gene expression did not lead to any expression in the
LUHMES cells although it was reported to be specific to neurons [212, 213].
3.2.2.3 LUHMES: AADC overexpression
As I demonstrated in Figure 3.16 C, LUHMES cells expressed really low levels of
AADC. I also showed that, although TH is the rate-limiting enzyme in the DA synthesis
pathway, increasing its expression did not lead to any DA production. I thus generated
a LUHMES cell line overexpressing AADC, referred to as LUHMES AADCox.
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Figure 3.21 A and B show significant increase in gene expression and protein of
AADC in LUHMES AADCox cells as compared to LUHMES WT. However, no DA sig-
nal was detected after metabolite extraction in these cells. To ascertain that the enzyme
is active, I incubated LUHMES AADCox cells for 2 h with 50 μM L-DOPA (Figure 3.21
C). In that case, DA was detected in LUHMES AADCox cells, but not in LUHMES WT,
indicating that the enzyme is active.
To further evaluate the activity of the enzyme, I incubated LUHMES AADCox with
50 μM L-DOPA for up to 6 h (Figure 3.22 A). DA could be detected as early as after five
minutes of incubation and within one hour, the maximal DA production was reached.
After four hours, the DA levels decreased slightly. There are several reasons which
could explain this plateau. First, the DA synthesis reaches equilibrium with the rate
of the enzymes degrading it, thus preventing any further accumulation. Second, the
DA produced is secreted and this activates the dopamine receptors. This is supported
by Berry et al. who reported that AADC activity is increased by dopamine receptor
antagonists and its activity is decreased by dopamine receptor agonists [66]. It is highly
unlikely that the amount of DA remained constant because of a lack of substrate. At
the concentration of 50 μM in 1 mL of medium, this corresponded to a total of 50 nmol
of L-DOPA in the medium at the beginning of the experiment, about a thousand-fold
higher than the amount of DA intracellularly measured. In order to test whether the
amount of DA obtained was the highest that could be produced, I treated LUHMES
AADCox cells for 1 h (corresponding to the beginning of the plateau) with a range
of L-DOPA concentrations from 50 to 600 μM (Figure 3.22 B). The fact that I obtained
higher amounts of DA in this case, suggested that none of the previous hypothesis were
correct. Increasing DA in function of L-DOPA concentrations could suggest a feed-
forward stimulation: when the substrate concentration was high, the enzyme activity
was high as well.
Since AADC is not the rate-limiting enzyme in the CA synthesis pathway, it has
been considered as unregulated for a long time [65]. However, Berry et al. suggested
that the enzyme can be phosphorylated which increases its activity [66]. It is therefore
possible that increasing L-DOPA concentrations induce phosphorylation of AADC and
increase its activity.
Chapter 3. Results and discussion 119
D
op
am
in
e 
am
ou
nt
 (p
m
ol
)
0
5
10
15
20
Time (min)
0 50 100 150 200 250 300 350 400
A B
D
op
am
in
e 
am
ou
nt
 (p
m
ol
)
0
20
40
60
80
100
120
140
L-DOPA concentration (μM)
0 100 200 300 400 500 600 700
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LUHMES AADCox were treated with 50 μM L-DOPA for 0 to 350 min. (B): LUHMES AADCox
cells were treated for 1 h with different L-DOPA concentrations.
In summary, I observed that although AADC expression did not induce endoge-
nous DA production, LUHMES AADCox cells produced DA upon L-DOPA supple-
mentation. The amounts of DA produced were time- and concentration-dependent
and reached saturation for longer incubation times and concentrations.
3.2.3 L-DOPA transport in LUHMES cells
The transport of L-DOPA across the blood brain barrier (BBB) has been widely
studied [218, 219]. It is mediated by the large amino acid transporter (LAT)1 which
transports branched-chain and aromatic amino acids [218]. The expression of LAT1 is
restricted to certain tissues such as the brain, placenta or testis [220]. In order to be ac-
tive, it forms a heterodimeric complex with the heavy chain of 4F2 cell surface antigen
(4F2hc) [218] and functions as antiport by exporting glutamine and importing large
amino acids [221]. Aside from the BBB, L-DOPA has been shown to be transported via
the LAT1 in a porcine renal tubule epithelial cell line [44], teratocarcinoma cells [222]
and in human bladder carcinoma cells [220]. However, L-DOPA transport in neurons
has been poorly studied. On the one hand, studies have been performed in vivo, which
makes it difficult to study transport in a particular cell type. On the other hand, the
study of L-DOPA in vitro has focused on the toxicity of the compound and not on its
transport [223]. Sampiao-Maia et al. reported that LAT1 is responsible for L-DOPA
transport in the mouse neuroblastoma Neuro2A cells [223].
Dopamine transporter (DAT) is responsible for regulating the duration and inten-
sity of DA neurotransmission by rapid re-uptake of DA from the synaptic cleft. Jones
et al. reported that loss of DAT is associated with a 95% reduction in DA content in
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the striatum as well as with a 75% reduction in its release. However, extracellular DA
levels increased five times due to lack of clearance system [224]. This shows that DAT
indirectly regulates intracellular DA levels.
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5 μM GBR12909, 1 mM leucine or a combination of both or with 25 μM L-DOPA with or without
leucine. (B): Gene expression of the DAT in iPSC-derived dopaminergic 17608/3 cells, SH-SY5Y
cells and LUHMES cells after 6 and 10 days of differentiation.
The LUHMES AADCox cells are a good model to study L-DOPA uptake and the
response of inhibitors on the metabolism of DA: having a functional AADC, the pro-
duction of DA can easily be monitored. Therefore, I used these cells to improve our
knowledge of L-DOPA transport in LUHMES cells. The uptake of L-DOPA through
the LAT1 can be inhibited by substrate competition using 1 mM L-leucine [44]. In rat
fetal midbrain neurons, DAT can be inhibited by 5 μM of GBR12909 [225]. I incubated
LUHMES AADCox cells for 1 h with (1) 50 μM D-DOPA, (2) 25 μM L-DOPA supple-
mented or not with 1 mM leucine, (3) 50 μM L-DOPA supplemented with 1 mM leucine,
5 μM GBR12909 or a combination of both (Figure 3.23 A). The supplementation with
D-DOPA served as control, since this L-DOPA enantiomer cannot be enzymatically
processed. In agreement with Shindo et al., I did not observe DA production from D-
DOPA [146]. However, treatment with 25 μM L-DOPA induced DA production, which
was completely prevented by competitive inhibition of LAT1 with 1 mM leucine. When
the cells were treated with 50 μM L-DOPA, leucine supplementation induced a 50% de-
crease in DA production. The levels of intracellular DA measured upon DAT inhibition
by GBR12909 were decreased by 30%. The combination of leucine and GBR12909 was
not additive and the levels of DA measured were the same as those measured upon
leucine treatment alone.
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These data confirmed the observation made by Sampaio-Maia et al. in Neuro2A
cells [223] that L-DOPA is transported into LUHMES via the LAT1 transporter. I also
observed that 1 mM leucine is enough to completely prevent DA synthesis in medium
containing 25 μM L-DOPA and that the same concentration of leucine decreased DA
production by a factor of two in cells treated with 50 μM L-DOPA. DAT is selective for
DA, but can also participate in the transport of synthetic and natural analogues, such
as MPP+, its pyridine derivatives, isoquinoline derivatives or β-carbinoline derivatives
[74]. It is a symporter that translocates one molecule of DA, two sodium and one
chloride ions across the membrane. Its major physiological role is to terminate neu-
rotransmission by re-uptake of DA from the synaptic cleft [74]. In mammalian cells,
DAT expression is restricted to dopaminergic neurons [74]. It is highly expressed in
LUHMES cells at day 6 of differentiation, but its expression decreased at day 10 of dif-
ferentiation. iPSC-derived dopaminergic neurons and SH-SY5Y did not express DAT at
all (Figure 3.23 B). The decreased DA levels observed upon GBR12909 treatment could
be due to a decreased re-uptake of DA rather than a decreased uptake of L-DOPA. The
decreased re-uptake of DA could have been evaluated by extracting DA from medium.
Moreover, loss of DAT has been linked to ageing: the decline of striatal DAT is about
6-7% per decade. DAT neuroimaging is used in the context of PD to evaluate the loss
of dopaminergic neurons [226], therefore highlighting its importance. The importance
of DAT in the context of PD is not fully elucidated yet: Nutt et al. reported that treating
PD patients with a DAT inhibitor prolonged the effects of co-administered L-DOPA.
However, it also prolonged the duration of dyskinesia [227].
Interestingly, the effects of LAT1 and DAT inhibitions were not additive. One hy-
pothesis could be that upon inhibition of L-DOPA transport by leucine, the amounts of
DA produced are not sufficient to induce an active re-uptake by DAT. Therefore, the
inactivation of this transport does not change the intracellular levels of DA. This could
be verified by treating LUHMES AADCox cells with 25 μM L-DOPA in combination
with GBR12909. If the levels of DA do not change, this would confirm our hypothesis.
In summary, in contrary to iPSC-derived dopaminergic neurons and SH-SY5Y
cells, LUHMES cells express the DAT. Its expression was the highest after 6 days of
differentiation and decreased after 10 days. DA production from supplemented L-
DOPA was inhibited by competitive inhibition of LAT1 using leucine, confirming that
L-DOPA transport is carried through the LAT1. I could also confirm that the DAT is
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active in LUHMES cells since its inhibition using GBR12909 caused a decrease in intra-
cellular amounts of DA.
3.2.4 L-DOPA toxicity on dopamine producing cells and upon L-DOPA up-
take inhibition
In section 3.1.1, we evaluated the toxicity of L-DOPA in LUHMES WT cells. The
LUHMES AADCox produced DA upon L-DOPA supplementation. In the brain, upon
synthesis, DA is packaged into synaptic vesicles. These vesicles have a pH of 5.5, which
stabilizes DA and therefore prevents its auto-oxidation. We showed in section 3.1.1 that
the effects of L-DOPA are due to its auto-oxidation in the extracellular space. In order
to strengthen this affirmation, I first tested whether the production of DA from L-DOPA
modified their sensitivity to L-DOPA. If the effect is intracellular, the fact that L-DOPA
can be decarboxylated to DA could trigger its packaging and therefore decrease its
toxicity. Therefore, I treated LUHMES WT and AADCox cells for 24 h with different
L-DOPA concentrations (Figure 3.24 A). The sensitivity to L-DOPA was identical in
both cell lines, indicating that DA did not play a role in the L-DOPA-mediated toxicity.
However, in this case, I cannot rule out the fact that DA also auto-oxidizes in the cells
since LUHMES cells did not express VMAT2.
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FIGURE 3.24: Effects of L-DOPA on LUHMES AADCox and on LUHMES WT under inhibi-
tion of L-DOPA uptake. (A): LUHMES WT and AADCox cells were treated for 24 h with vari-
ous L-DOPA concentrations and cell viability was assayed. (B): LUHMES WT cells were treated
for 24 h with various L-DOPA concentrations alone or supplemented with 5 μM GBR12909, 1
mM leucine or a combination of both and cell viability was assayed.
I performed a final assay to ascertain extracellular effects of L-DOPA. If the ef-
fects are extracellular, preventing or reducing L-DOPA uptake should not modify the
sensitivity to the treatment. I demonstrated in section 3.2.3 that uptake of L-DOPA
can be reduced by 1 mM leucine. I also observed that GBR12909 decreased DA levels
intracellularly, potentially by preventing its re-uptake. Therefore, I treated LUHMES
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WT cells for 24 h with different concentrations of L-DOPA and with 1 mM leucine,
5 μM GBR12909 or a combination of both (Figure 3.24 B). As expected, the inhibition
of GBR12909 did not lead to any change in cell viability: in those cells, AADC is not
active, thus L-DOPA is not converted to DA. I could also observe that preventing L-
DOPA entry into the cells did not protect against L-DOPA toxicity. As seen in 3.23 A,
incubation of 25 μM L-DOPA in combination with 1mM leucine (to inhibit L-DOPA up-
take through LAT) did not lead to any detectable amounts of DA in LUHMES AADCox
cells, indicating that its uptake is almost completely inhibited. Therefore, preventing
or decreasing L-DOPA uptake did not lead to any change in the sensitivity to L-DOPA-
mediated toxicity.
In summary, neither the capacity to process L-DOPA to DA nor the decreased ca-
pacity to take up L-DOPA lead to any change in sensitivity to L-DOPA treatment. These
data strongly support the idea that L-DOPA-mediated toxicity is not due to L-DOPA
itself, but rather to its degradation products from oxidation in the extracellular matrix.
3.2.5 Co-factor supplementation
TH is assumed to be the rate-limiting enzyme in the DA synthesis pathway. Rat
brain synaptosomes do not express PheH while TH, which hydroxylates tyrosine to
L-DOPA, has been reported to also hydroxylate phenylalanine to tyrosine [208]. Tyro-
sine is more stable than L-DOPA and thus can be measured in a more accurate way.
I therefore applied phenylalanine as substrate for this experiment. To test whether
LUHMES WT cells can hydroxylate phenylalanine to tyrosine and therefore evaluate
whether TH is active in these cells, I incubated the cells for 24 h in unlabeled medium
or in medium free of tyrosine and supplemented with [U-13C9]phenylalanine, at twice
the concentration present in Advanced DMEM/F12 (i.e. 430 μM) (Figure 3.25). Levels
of tyrosine and phenylalanine were measured (Figure 3.25 A, B). Levels of phenylala-
nine were higher in the [U-13C9]phenylalanine treated cells, in accordance with the fact
that cells were treated with higher concentrations. Tyrosine levels strongly decreased
in the absence of tyrosine (Figure 3.25 A), as observed in SH-SY5Y cells in Figure 3.19
B. Concerning labeling data, upon treatment with [U-13C9]phenylalanine, almost all
the phenylalanine was labeled (Figure 3.25 C), while none of the tyrosine was labeled
(Figure 3.25 D), suggesting that TH is not active.
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FIGURE 3.25: Tyrosine hydroxylase activity in LUHMES cells. LUHMES WT cells were
treated for 24 h with regular medium (UN) or with medium free of tyrosine and containing [U-
13C9]phenylalanine (UPhe). (A): Intracellular levels of phenylalanine. (B): Intracellular levels of
tyrosine. (C): Carbon contribution in phenylalanine. (D): Carbon contribution of phenylalanine
in tyrosine.
The absence of labeling in tyrosine, indicating that TH is inactive, taken together
with the low GTPCH gene expression (Figure 3.16 A), could indicate that BH4, the co-
factor of TH, is absent. Sawabe et al. reported that sepiapterin, one of the intermediates
in BH4 synthesis, is much more permeable across the cell membrane than BH4. Upon
treatment with sepiapterin or BH4, they observed an accumulation of sepiapterin in
RBL2H3 rat basophilic leukemia cell line, but extremely low levels of BH4 in the cells
[228]. To test whether BH4 is the limiting step in endogenous DA synthesis in LUHMES
AADCox cells, I used sepiapterin for its membrane permeability properties. Once in-
side the cells, it is metabolized to BH4 by sepiapterin reductase (SR) and dihydrofo-
late reductase (DHFR) via the BH4 salvage pathway (see Figure 1.6). I supplemented
LUHMES AADCox cells with various concentrations of sepiapterin (100 to 600 μM) for
5 h and extracted metabolites. If the two enzymes responsible for sepiapterin metabo-
lism are active and BH4 is synthesized, this should lead to activation of TH and DA
production. However, no DA could be measured.
I cannot exclude that SR or DHFR, the enzymes responsible for the conversion
of sepiapterin to BH4, were inactive in LUHMES cells. Harding et al. reported that
BH4 accumulated in primary mouse myotubes and reached a maximum after 30 min
[229]. To evaluate whether direct BH4 supplementation could lead to TH activation
and DA production in LUHMES AADCox cells, I incubated them with the cofactor. I
supplemented LUHMES AADCox cells differentiated for 10 days, corresponding to the
higher TH expression, for 30 min with 100 and 200 μM BH4 and extracted metabolites
for DA measurement. No dopamine could be measured under these conditions.
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In summary, I observed that in LUHMES WT cells, TH did not hydroxylate phe-
nylalanine to tyrosine, suggesting that the enzyme is inactive. As observed in section
3.2.1, the gene expression of GTPCH is very low. In order to bypass this reaction and
to assess whether BH4, the cofactor for TH activity, is missing in LUHMES AADCox,
I supplemented the cells with the cofactor or its precursor. Unfortunately, this did not
lead to an activation of TH and production of DA.
3.2.6 Summary: Generation of a human dopaminergic cell model
This section focused on the generation of a human dopaminergic cell model. Such
a model is of critical importance in the scope of the study of neurodegenerative disease.
Most of the available cell models are of cancer origin or derived from other organisms
than human. Given the organism-specific regulation of enzymes involved in DA syn-
thesis and degradation as well as the proliferative character of cancer cells, such models
are not the best suited to study the metabolism of neurons. Human TH exists in four
isoforms. From these, isoforms 1 and 2 are predominantly expressed in the brain. Other
primates possess two isoforms, while rodents possess only one [205]. The coding re-
gion also slightly differs: rodent TH can be phosphorylated at serine 8, 19, 31 and 40.
However, in human, position 8 contains a threonine, which cannot be phosphorylated,
therefore emphasizing the organism-specific regulation of the enzyme [51].
I focused on the LUHMES cells, derived from the mesencephalon of a eight-week
old foetus and conditionally immortalized using a v-myc vector. I compared gene ex-
pression levels of GTPCH, AADC, TH and VMAT2 with those of human SH-SY5Y neu-
roblastoma and iPSC-derived dopaminergic neurons. iPSC-derived dopaminergic neu-
rons expressed all these genes, while SH-SY5Y expressed neither TH nor VMAT2 and
LUHMES cells only expressed TH. At protein synthesis level, LUHMES, iPSC-derived
dopaminergic neurons and rat PC-12 pheochromocytoma expressed TH while it was
absent in SH-SY5Y cells. DA measurements showed that only PC-12 and iPSC-derived
dopaminergic neurons produced endogenous DA. SH-SY5Y produced DA upon L-
DOPA supplementation, while LUHMES cells did not produce any DA, with or with-
out addition of L-DOPA.
To increase the expression of TH in both SH-SY5Y and LUHMES cells, I engineered
cell lines overexpressing TH. This was sufficient to induce DA production in SH-SY5Y,
but not in LUHMES cells. I then used the SH-SY5Y THox cells to demonstrate that
these cells preferentially use tyrosine for DA synthesis. Furthermore, in the absence of
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tyrosine, they were able to use phenylalanine as substrate. A time course differentiation
of LUHMES WT and THox cells showed that TH expression is maximal after 10 days
of differentiation and that both the endogenous TH as well as the gene overexpressed
under the CMV promoter are under cAMP regulation. The UbC promoter did not lead
to any gene expression in LUHMES cells.
I increased the expression of AADC in LUHMES cells to evaluate whether the
absence of AADC expression is the missing link for DA production in LUHMES. These
cells did not produce any endogenous DA, but produced the neurotransmitter upon
incubation with L-DOPA. In this case, DA production was time- and concentration-
dependent. I then used these cells to characterize L-DOPA transport in LUHMES cells.
I observed that it is LAT1-dependent and that 1 mM of leucine completely abrogated
the production of DA when the cells were incubated with 25 μM L-DOPA. Inhibition
of the DAT also lead to decreased intracellular DA levels through a decreased DA re-
uptake. Interestingly, the effects of LAT1 and DAT inhibition were not additive.
To evaluate whether the capacity of LUHMES AADCox cells to produce DA
from L-DOPA would modify their sensitivity to L-DOPA treatment, LUHMES WT
and AADCox cells were treated with various concentrations of L-DOPA. The results
showed that the ability to degrade L-DOPA to DA did not modify the toxicity of the
compound, suggesting that either DA is as toxic as L-DOPA or that the cell viability
is primarily affected by oxidation products produced in the extracellular space. To
finally confirm this hypothesis, LUHMES WT cells were treated with LAT1 and DAT
inhibitors and the results showed that preventing L-DOPA uptake did not affect cell
viability. This finally ascertained that the toxic effects of L-DOPA are mediated by its
auto-oxidation in extracellular space.
The overexpression of AADC lead to a system able to produce DA upon L-DOPA
supplementation. In order to test whether in this case endogenous TH is active,
LUHMES WT cells were incubated with a phenylalanine tracer in the absence of
tyrosine. PheH has been reported absent in synaptosomes and TH can hydroxylate
tyrosine. Moreover, tyrosine is more stable than L-DOPA. I therefore used this system
to study TH activity. The results showed that there was no hydroxylation of phenyl-
alanine to tyrosine (this hydroxylation was observed in SH-SY5Y THox cells). I thus
supplemented LUHMES AADCox cells with BH4, the cofactor of TH or its precursor,
sepiapterin, to circumvent the low expression levels of GTPCH. None of these lead to
DA production.
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The new LUHMES AADCox cells could be of interest to study the effects of in-
creased AADC expression on the metabolism of neuronal cells. Bankiewicz et al. re-
ported that using an adeno-associated virus to overexpress AADC in monkeys lead to
an improvement in clinical rating scores and decreased L-DOPA requirements as well
as reduced L-DOPA associated side-effects [230]. Mittmeyer et al. launched a phase 1
clinical trial using adeno-associated virus overexpression of AADC and found that the
overexpression persisted over four years and that although the clinical rating improved
over the first twelve months, a slow deterioration was observed over time [231]. This
highlights the need to understand the effects of AADC overexpression on the metabo-
lism of neurons.
It is also interesting to note that the basal forebrain, striatum and cortical areas
contain cell populations of TH-positive neurons that are not expressing AADC and do
not produce CA. However, these cells were not reported to be present in the mesen-
cephalon [36].
To conclude, the expression of TH is not sufficient to obtain a DA-producing cell
system. A summary of the models used as well as the expression and activity of en-
zymes tested and the resulting DA production can be found in Figure 3.26.
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Conclusion and Perspectives
In this work, I first investigated the effects of 2,3-dihydroxy-L-phenylalanine (L-
DOPA) on the metabolism of the human tyrosine hydroxylase (TH)-positive LUHMES
neuronal cells. I demonstrated that this drug, which is commonly used to cope with the
symptoms of Parkinson’s disease (PD), is toxic to these cells and that antioxidant treat-
ment can rescue the toxicity. I also established that L-DOPA induced profound changes
on the metabolism of LUHMES cells. Indeed, glucose contribution to the tricarboxylic
acid (TCA) cycle decreased while glutamine carbon contribution increased upon treat-
ment. Contribution of glucose to lactate decreased, while pyruvate carbon contribu-
tion increased. Pyruvate was not essential for cell survival under L-DOPA treatment.
In addition, I demonstrated that the effect observed was not due to glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) nor mitochondrial complex I inhibition. The
observed accumulation of intracellular succinate, the increase in secretion of glutamate
and the increase in uptake of acetate point towards a mitochondrial complex II inhi-
bition. To test this hypothesis, a further experiment would be to treat LUHMES cells
with 3-nitropropionic acid (3-NP) or malonate, which are inhibitors of mitochondrial
complex II.
It is also interesting to note that LUHMES cells consumed acetate upon L-DOPA
treatment although the literature suggests that acetate is a substrate used by astrocytes.
Upon treatment, acetate is generated through the non-enzymatic and extracellular re-
action of pyruvate with H2O2 derived from L-DOPA auto-oxidation. After its uptake,
acetate can be converted to acetyl-CoA and either be directed towards the TCA cy-
cle or be used for fatty acid synthesis. Given the fact that labeling from pyruvate
was not increased in the TCA cycle, I can conclude that acetate is not used for that
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purpose. It would therefore be interesting to investigate whether acetate is directed
to fatty acid synthesis. This hypothesis could be tested by profiling isotopic enrich-
ment in fatty acids. The measurement of mass isotopomer distributions (MIDs) using
[U-13C3]pyruvate as a tracer together with L-DOPA treatment could indicate whether
pyruvate and acetate are directed to fatty acid synthesis. If this is the case, acetate could
be an additional carbon source supporting the cells upon mitochondrial complex II in-
hibition.
Finally, in a future study, the redox and energy state as well as levels of reduced
L-glutathione (GSH) and glutathione disulfide (GSSG) should be studied in the context
of L-DOPA treatment.
In the second part of this work, I investigated dopamine (DA) metabolism in
various in vitro models. I first compared the expression levels of genes related to
DA synthesis in several cell models including human LUHMES mesencephalon cells,
human SH-SY5Y neuroblastoma cells, rat PC-12 pheochromocytoma cells and iPSC-
derived dopaminergic neurons. TH is responsible for the hydroxylation of tyrosine
to L-DOPA, which is decarboxylated to DA by aromatic amino acid decarboxylase
(AADC). Upon synthesis, DA is packaged into vesicles by vesicular monoamine trans-
porter 2 (VMAT2). Another important enzyme in the context of DA synthesis is GTP
cyclohydrolase 1 (GTPCH), which is the rate-limiting enzyme in the synthesis of 6R-L-
erythro-5,6,7,8-tetrahydrobiopterin (BH4), the cofactor of TH. LUHMES cells expressed
TH, but not GTPCH, AADC, nor VMAT2. SH-SY5Y expressed GTPCH and AADC, but
not TH nor VMAT2. These two cell lines did not produce any endogenous DA. iPSC-
derived dopaminergic neurons expressed GTPCH, TH, AADC and VMAT2. In PC-12,
I only investigated protein expression of TH and showed that these cells express the
protein. Both iPSC-derived dopaminergic neurons and PC-12 produced DA.
In a first attempt to induce DA production in LUHMES cells, I increased TH ex-
pression under cytomegalovirus (CMV) and ubiquitin C (UbC) promoters and ob-
served that only the CMV promoter was expressed. The increased expression of TH
did not lead to endogenous DA production in LUHMES cells. I also observed that the
expression of endogenous and CMV-induced expression of TH was dependent on the
presence of cyclic adenosine monophosphate (cAMP) and the duration of differentia-
tion.
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In SH-SY5Y, among the genes involved in DA synthesis, only TH was missing. TH
overexpression was sufficient to induce endogenous DA production. Using this cell
system, I determined that tyrosine was the preferential substrate for DA synthesis, but
that phenylalanine was used in the absence of tyrosine.
Given the low level of AADC expression in LUHMES cells, this enzyme was over-
expressed in these cells. This did not lead to any endogenous DA production. How-
ever, upon L-DOPA stimulation, DA was detected. Using this cell model, I character-
ized L-DOPA transport in LUHMES cells and established that L-DOPA is taken up via
the large amino acid transporter (LAT).
The expression of GTPCH was also low in LUHMES cells, it is therefore possible
that the activity of TH is impaired due to the low level or absence of its cofactor, BH4.
In order to evaluate this, I supplemented LUHMES AADCox cells with BH4. This did
not lead to any DA synthesis either. This demonstrate that although TH expression has
been considered as a sufficient marker to determine dopaminergic populations, it is not
sufficient for DA production.
Therefore, despite the fact LUHMES cells are a good model to study 1-methyl-4-
phenylpyridinium (MPP+) due to their high expression of dopamine transporter (DAT)
and that the new LUHMES AADCox represents a good model to study L-DOPA up-
take, they are not a suitable model for study of DA metabolism. It would be possible
to co-overexpress AADC and GTPCH in the same cell line, but the fact that neither
BH4 nor its precursor sepiapterin induced activation of TH suggests that this approach
would not give the expected results. It is also possible that the expression of cate-
cholamine (CA)-related genes was turned down with passaged cells. It would therefore
be interesting to measure the original cells.
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A
Isotopic steady state
In order to perform stable isotope-assisted metabolomics, the intracellular fluxes
must be at isotopic steady state. This means that the labeling of metabolite is constant
over time. The isotopic steady state can be established by incubating cells with tracers
of interest and extracting the metabolites at different time point. This experiment was
performed for LUHMES cell using either [U-13C6]glucose or [U-13C5]glutamine and
extracting metabolites after 2, 15, 30 min, 1, 6, 18, 24 and 48 h. I therefore established
that LUHMES cells are at isotopic steady state after 24 h, the incubation time used for
2,3-dihydroxy-L-phenylalanine (L-DOPA) treatment.
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FIGURE A.1: Isotopic steady state. LUHMES cells were incubated for different durations (2,
15, 30 min, 1, 6, 18, 24, 48 h) with either [U-13C6]glucose (UGlc) or [U-13C5]glutamine (UGln).
Mass isotopomer distribution is displayed for citrate, glutamate, malate and fumarate. (A-D):
Kinetic of M0 and M2 isotopologues upon UGlc labeling. (E-H): Kinetic of M0 and M4 (citrate,
malate, fumarate) or M5 (glutamate) isotopologue upon UGln labeling.
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FIGURE A.2: Isotopic steady state. LUHMES cells were incubated for different durations (2,
15, 30 min, 1, 6, 18, 24, 48 h) with either [U-13C6]glucose (UGlc) or [U-13C5]glutamine (UGln).
Mass isotopomer distribution is displayed for aspartate, serine, glycine and lactate. (A): Ki-
netic of M0 and M2 isotopologues upon UGlc labeling in aspartate. (B): Kinetic of M0 and M4
isotopologues upon UGln labeling in aspartate. Kinetic of M0 and M2 (glycine) or M3 (serine,
lactate) upon UGlc labeling in serine (C), glycine (D) and lactate (E).

B
Plasmid maps
This section displays the plasmids used for the cloning of tyrosine hydroxylase
(TH) and aromatic amino acid decarboxylase (AADC) into LUHMES and SH-SY5Y
cells. pDONR207 (Figure B.1) was used to create the entry vector of AADC, while TH
was purchased directly in the entry plasmid. pLenti6.3/TO/V5/DEST (Figure B.2) was
used to produce the expression vector and subsequent lentivirus production. In this
plasmid, the expression of the gene inserted is under the control of the cytomegalovirus
(CMV) promoter. The last plasmid used was pLenti6/UbC/V5-DEST (Figure B.3). It
was also used to produce the expression vector. In this case, the expression of the gene
of interest was under the control of ubiquitin C (UbC) promoter.
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FIGURE B.1: pDONR 207 map
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FIGURE B.2: pLenti 6.3/TO/V5-DEST map
RSV/5 LTR hybrid promoter: bases 1-410
RSV promoter: bases 1-229
HIV-1 5 LTR: bases 230-410
5 splice donor: base 520
HIV-1 psi (y) packaging signal: bases 521-565
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FIGURE B.3: pLenti 6 UbC/TO-DEST map
C
Absolute carbon contribution
The calculation of carbon contribution gives relative information about the con-
tribution of a given carbon source to metabolites. Absolute carbon contribution can
be obtained by multiplying the carbon contributions obtained for each tracer with the
signal intensity of the corresponding metabolites.
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FIGURE C.1: Absolute carbon contributions upon L-DOPA treatment. LUHMES cells
were treated for 24 h with 200 μM L-DOPA and incubated with [U-13C6]glucose (Glc), [U-
13C5]glutamine (Gln) or [U-13C3]pyruvate (Pyr) for the same period. Absolute carbon contri-
bution for citrate (A), succinate (B), malate (C), fumarate (D) and aspartate (E) were calculated
for each tracer.
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D
Loss of DJ-1 impairs antioxidant response by altered
glutamine and serine metabolism
During my PhD thesis, I contributed to the elaboration of a research article pub-
lished in Neurobiology of Disease. This article focused on the effects of loss of DJ-1
on the metabolism of tyrosine hydroxylase (TH)-positive LUHMES cells and BV2 cells.
In LUHMES cells, silencing of DJ-1 lead to an increased sensitivity to oxidative stress.
Data showed that this increased sensitivity was most likely due to a perturbed reduced
L-glutathione (GSH) regeneration. Using stable isotope tracers, we showed that serine
biosynthesis is decreased, while its uptake is increased in the absence of DJ-1. This
metabolite is a precursor of cysteine, the rate-limiting compound in GSH synthesis.
Moreover, we observed that glutamine uptake and its contribution to the tricarboxylic
acid (TCA) cycle decreased. Glutamine can be used for glutamate synthesis, another
component of GSH. Upon treatment with H2O2, the increase in glutathione disulfide
(GSSG)/GSH was stronger in DJ-1-deficient cells, indicating an impaired GSH regen-
eration. In mouse microglia, silencing of DJ-1 induced a weak but constitutive inflam-
matory state. This was evaluated by increased gene expression of Tnfα, Irg1 and iNos
as well as by increased intracellular levels of succinate and itaconate.
In summary, we conclude that it is possible that the combination of (1) the de-
creased anti-oxidant capacity of the neurons as well as (2) the constitutive inflamma-
tory state of microglia contribute to the onset of Parkinson’s disease (PD) in patient
carrying a DJ-1 loss of function mutation.
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Contributions:
In this project, I participated in the generation of the DJ-1 silenced LUHMES cell
lines. I performed the cell viability assay comparing LUHMES shCtrl and shDJ-1 cells
upon 6-hydroxydopamine (6-OHDA) treatment. I also took part in the [U13C6]glucose
and [U13C5]glutamine labeling experiments in LUHMES shDJ-1 and shCtrl cells. In the
same cell lines, I evaluated gene expression of the catalytic and modifier domains of
glutamate cysteine ligase (GCLC and GCLM, respectively). Finally, I compared protein
expression of NRF2 between human A549 lung cancer cells and LUHMES cells.
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The oncogene DJ-1 has been originally identiﬁed as a suppressor of PTEN. Further on, loss-of-function mutations
have been described as a causative factor in Parkinson's disease (PD). DJ-1 has an important function in cellular
antioxidant responses, but its role in central metabolism of neurons is still elusive. We applied stable isotope
assistedmetabolic proﬁling to investigate the effect of a functional loss of DJ-1 and show that DJ-1 deﬁcient neu-
ronal cells exhibit decreased glutamine inﬂux and reduced serine biosynthesis. By providing precursors for GSH
synthesis, these two metabolic pathways are important contributors to cellular antioxidant response. Down-
regulation of these pathways, as a result of loss of DJ-1 leads to an impaired antioxidant response. Furthermore,
DJ-1 deﬁcient mouse microglia showed a weak but constitutive pro-inﬂammatory activation. The combined ef-
fects of altered centralmetabolism and constitutive activation of glia cells raise the susceptibility of dopaminergic
neurons towards degeneration in patients harboring mutated DJ-1. Our work reveals metabolic alterations lead-
ing to increased cellular instability and identiﬁes potential new intervention points that can further be studied in
the light of novel translational medicine approaches.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
DJ-1 (PARK 7) is expressed in different organs throughout the body
and has ﬁrst been identiﬁed as an oncogene together with activated
Ras (Nagakubo et al., 1997). High levels of DJ-1 have been associated
with malignancy of tumor development (Nagakubo et al., 1997;
Davidson et al., 2008; Kim et al., 2005; Yuen et al., 2008).Mechanistical-
ly, DJ-1 has been identiﬁed as a repressor of the phosphatase PTEN,
which itself is a repressor of PKB/AKT (Stambolic et al., 1998; Sun
et al., 1999). In case of DJ-1 overexpression, PKB/AKT is
hyperphosphorylated, promoting cell survival and anaplerotic metabo-
lism needed for proliferation (Kim et al., 2005). In cancer cells, DJ-1 has
been identiﬁed as a positive regulator of NRF2 (Clements et al., 2006), a
master regulator in the antioxidant response. NRF2has also been shown
to inﬂuence central metabolism (Hayes and Dinkova-Kostova, 2014).
However, its role in neuronal metabolism remains to be elucidated.
WhileDJ-1 overexpression provokes oncogenesis, loss of functionmuta-
tions in DJ-1 have been associated with a familial autosomal recessive
form of Parkinson's disease (PD) with an early onset of disease progres-
sion (Bonifati, 2003; Bonifati et al., 2003; Van Duijn et al., 2001). PD
leads to motor and non-motor symptoms with hallmarks such as
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elevated levels of reactive oxygen species (ROS) and speciﬁcally, a decay
of dopaminergic (DAergic) neurons of the substantia nigra pars
compacta (Antony et al., 2013).
Lack of DJ-1 hampers quenching of cellular ROS, affectingmitochon-
drial and cellular integrity (Clements et al., 2006; Ariga et al., 2013;
Irrcher et al., 2010; Kahle et al., 2009; Krebiehl et al., 2010). Within
the brain, DJ-1 is expressed in neuronal as well as non-neuronal cells
(Bader et al., 2005) and is up-regulated with increasing oxidative stress
(Baulac et al., 2009). Oxidation of cysteine residues in DJ-1 leads to a
shift of the isoelectric point (pI) and subsequent relocation of the pro-
tein to the nucleus, as well as the mitochondrial membrane (Canet-
Avilés et al., 2004). ROS production and a concomitant shift of the pI
have also been shown in cells exposed to lipopolysaccharide (LPS), an
inducer of inﬂammatory responses (Mitsumoto and Nakagawa, 2001)
indicating further implications in the context of neuroinﬂammation
and mitochondrial metabolism (Kim et al., 2013; Trudler et al., 2014;
Waak et al., 2009). Activation of microglia has been found to correlate
with the occurrence of neurodegenerative diseases (Brown and Neher,
2010; Meiser et al., 2013).
Although there is evidence that DJ-1 regulates metabolism directly
(Lee et al., 2012) and indirectly (Clements et al., 2006; Aleyasin et al.,
2010; van der Brug et al., 2008), a detailed understanding of its role in
central metabolism, especially in the context of PD, is still missing.
Here, we investigated the impact of a functional loss of DJ-1 on cel-
lular metabolism. Our study demonstrates that loss of DJ-1 affects
central metabolism by decreasing glutamine inﬂux and serine biosyn-
thesis. These two metabolic pathways provide the precursors gluta-
mate, serine and glycine for de novo synthesis of glutathione. In line
with these metabolic ﬂux changes, we observed decreased glutathione
levels in DJ-1 deﬁcient cells.
Additionally, DJ-1 deﬁcient mouse microglia showed a weak but
constitutive pro-inﬂammatory phenotype. We reason that the combi-
nation ofweakpro-inﬂammatory activationwithmetabolic dysfunction
renders DAergic neurons more susceptible for early cell death.
2. Results
2.1. Loss of DJ-1 increases susceptibility to oxidative stress
To investigate the effect of loss of DJ-1 on central metabolism, we
targeted DJ-1 by RNAi in the human tyrosine hydroxylase (TH)-positive
neuronal cell model LUHMES (Scholz et al., 2011) (Fig. 1a and b; S1). As
a control we used non-speciﬁc shRNA and generated shCtrl LUHMES
cells in parallel to the shDJ-1 cells. LUHMES cells are conditionally im-
mortalized and are postmitotic after differentiation (Scholz et al., 2011).
To conﬁrm ourworking hypothesis thatDJ-1 deﬁcient cells aremore
susceptible to oxidative stress (Zhou and Freed, 2005), we ﬁrst per-
formed a viability assay after treating the cells with different concentra-
tions of the ROS-inducing compound 6-hydroxydopamine (6-OHDA)
(Fig. 1c). 6-OHDA treated LUHMES cells lacking DJ-1 showed 30–40%
Fig. 1. Loss ofDJ-1 increases sensitivity to oxidative stress and affects glutathione homeostasis. (a–b)Western blot and qPCR analysis demonstrating DJ-1 knockdown. (c) Viability assay of
LUHMES cells in response to oxidative stress. Cells were treated for six hours with different concentrations of 6-hydroxydopamine (6-OHDA). (d–e) Relative quantiﬁcation of (d) GSH and
(e) GSSG, 20 min after treatment with H2O2. (f) Ratio GSSG/GSH. (g) Gene expression of GR. Error bars represent SEM. Asterisks indicate a signiﬁcant difference to the respective shCtrl
(Welch's t-test, p b 0.05; number of biological replicates: n ≥ 3). See also Supplementary Fig. S1.
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decreased viability (within the range of 10–50 μM 6-OHDA) compared
to shCtrl, conﬁrming that loss of DJ-1 increases sensitivity to oxidative
stress.
To further analyze the cellular response to ROS, we measured the
level of reduced (GSH) and oxidized (GSSG) glutathione after H2O2
treatment by UHPLC–MS (Fig. 1d–f). Already without any additional
perturbation, GSH levels in shDJ-1 cells were lower than in the re-
spective shCtrl cells. With increasing concentrations of H2O2, we de-
tected decreasing GSH levels and a concomitant increase of GSSG and
thus an increase in the GSSG/GSH ratio. The GSSG/GSH ratios were
more increased in shDJ-1 cells, pointing to insufﬁcient GSH regener-
ation from GSSG or a lack of alternative detoxiﬁcation mechanisms.
In line with these observations, we also found decreased gene
expression levels of glutathione reductase (GR) in DJ-1 deﬁcient
cells (Fig. 1g).
Insufﬁcient ROS detoxiﬁcation is likely to affectmitochondrial integ-
rity (Irrcher et al., 2010; Kahle et al., 2009). In neurons, mitochondria
are actively transported through the projections of neuronal cells to di-
rectly satisfy axonal and synaptic energy demands (Saxton and
Hollenbeck, 2012). Therefore, we investigated whether shDJ-1 cells ex-
hibit systematically different mitochondrial motion patterns than shCtrl
cells and whether loss of the gene function would elicit different re-
sponses upon 6-OHDA treatment. To that end, we monitored the global
motion of ﬂuorescence-stained mitochondria in differentiated LUHMES
cells by time-lapse microscopy (Fig. 2, Supplementary Movies and
Fig. S2).Without perturbation, therewas no signiﬁcant difference inmi-
tochondrial movement between the two cell types (Fig. 2C).
Consistentwith the literature (Chen et al., 2008) we observed a gen-
eral deceleration of mitochondrial motion in both cell types, following
6-OHDA treatment (Fig. 2b). Surprisingly, deceleration showed a trend
to be less in shDJ-1 cells compared to shCtrl cells (Fig. 2c and Supple-
mentary movies and Fig. S2), suggesting that the regulation of mito-
chondrial transport in response to 6-OHDA-mediated oxidative stress
might be affected by loss of DJ-1.
Fig. 2. Loss of DJ-1 affects mitochondrial motility in neurons (a) Fluorescence microscopy image of differentiated LUHMES cells stained with TMRM (scale bar = 100 μM) and a 10×
magniﬁcation of a selected area (red square). Stain shows the location of mitochondria in soma and neurites. (b) Representative time-course of global mitochondrial motion analysis
(in this case shDJ-1). Before and after (300 s; grey bar) addition of 200 μM 6-OHDA. Mito motility was reduced due to addition of 6-OHDA (red) compared to control (blue).
(c) Parallel measurement of global mitochondrial motion. Shown values were normalized to the mean velocity measured before treatment with 6-OHDA. Error bars in (c) represent
SD. Asterisks indicate a signiﬁcant difference to the respective shCtrl cells (Student's t-test, p b 0.05 number of biological replicates n= 3). See also Supplementary movies and Fig. S2.
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Together with the observation that the treatment did not lead to a
signiﬁcant drop of the mitochondrial membrane potential in the two
cell types (Supplementary Movies) this may indicate additional effects
of the induced oxidative stress. A direct target would be Ca2+ homeo-
stasis (Guzman et al., 2010) that in turn can inﬂuence mitochondrial
trafﬁcking by Miro1 (Stephen et al., 2015; Nguyen et al., 2014) and
TCA cycle activity by polarization (Krols et al., 2016). Furthermore, DJ-
1 deﬁciency is associated with an impaired microtubule dynamics
(Sheng et al., 2013) leading to modiﬁed cytoskeleton structures that
can affect mitochondrial transport.
2.2. Loss of DJ-1 affects central metabolism
To investigate if the observed moderate changes in mitochondrial
motility may have an impact on the cellular energy pool, we proﬁled
cellularmetabolism by determining uptake and release rates and by an-
alyzing intracellular ﬂuxes using stable isotope labeled tracers. We de-
tected a decrease in alanine release in shDJ-1 cells (Fig. 3a), whereas
differences in glucose, pyruvate and serine consumption and lactate re-
leasewere not statistically different (Fig. 3b, c, d, e). This reduction in al-
anine release of shDJ-1 cells, suggests a lower requirement for nitrogen
excretion in these cells.
Since shDJ-1 cells are more sensitive to oxidative stress, we investi-
gated if the canonical NADPH producing pathways, the pentose phos-
phate pathway and the folate mediated one-carbon metabolism are
affected. To this end, we analyzed gene expression of glycine
dehydrogenase (GLDC), the rate-limiting enzyme of the glycine cleavage
system, of glucose-6-phosphate dehydrogenase (G6PDH), the rate-
limiting enzyme of the PPP and of 5,10-methylene tetrahydrofolate
(THF) dehydrogenase (MTHFD), a key enzyme in folate metabolism.
We did not observe signiﬁcant changes in the expression of GLDC, but
decreased expression of G6PDH, MTHFD1 and MTHFD2 (Fig. 3f–h, S3),
pointing to decreased carbon ﬂux into these pathways and decreased
cellular potential to generate NADPH, needed for antioxidative
activities.
To monitor metabolic ﬂuxes through glycolysis, the serine biosyn-
thesis pathway, glycine cleavage and through PDH, we used uniformly
labeled 13C glucose as a tracer. We found that relative glucose contribu-
tion to serine biosynthesis was decreased in shDJ-1 cells (Fig. 3j), which
is in line with the observed decreased expression of MTHFD1/2. The
trend of increased serine uptake (p-value = 0.084) might be a conse-
quence of the decreased biosynthetic ﬂux from glucose. Furthermore,
based on M2 citrate isotopologues we did not observe any difference
in relative glucose oxidation through PDH (Fig. 3k; 3I for atom transi-
tions), suggesting that not glucose oxidation, but serine and folate me-
tabolism are dependent on DJ-1.
DJ-1 has been shown to stabilize NRF2 in cancer cells (Clements
et al., 2006). NRF2 is a key transcription factor that regulates cellular an-
tioxidant responses also by activating serine ﬂux and folate-mediated
one-carbon metabolism (Mitsuishi et al., 2012). However, by Western
Blottingwewere unable to detect NRF2 in LUHMES cells (Fig. S3f). Con-
cluding from non-detectable NRF2 levels in LUHMES cells, it is possible
Fig. 3.Metabolic proﬁling of DJ-1 silenced LUHMES cells reveals decreased serine biosynthesis ﬂux. (a) Medium consumption and release rates of (a) alanine (release) (b) glucose and
lactate. (c) Ratio lactate release/glucose consumption. (d–e) Consumption rates of (d) pyruvate and (e) serine. (f–h) Gene expression (qPCR) of (f) G6PDH (g) MTHFD1 and
(h) MTHFD2. (i) Schematic of atom transitions in central metabolism using [U-13C]glucose as a tracer. 13C carbons are in green, 12C in black. (j–k) Application of [U-13C]glucose as a
tracer in LUHMES cells for determination of MIDs to infer relative intracellular ﬂuxes. (j) M3 serine isotopologue indicating relative serine biosynthesis ﬂux. (k) M2 citrate
isotopologue indicating relative PDH ﬂux. Error bars represent SEM. Asterisks indicate a signiﬁcant difference to the respective shCtrl (Welch's t-test, p b 0.05; number of biological rep-
licates: n ≥ 3). See also Supplementary Fig. S3.
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that the role of DJ-1 in regulating neuronal metabolism in the context of
cellular antioxidant responses is even more pronounced, compared to
other cell types.
Next, we analyzed TCA cycle ﬂuxes in more detail and we applied
uniformly labeled glutamine as a tracer (Fig. 4a for atom transitions).
Stable isotope labeling revealed decreased glutamine contribution to
the intracellular glutamate pool and to the TCA cycle intermediates
alpha-ketoglutarate (aKG), succinate, fumarate, malate, aspartate (as a
proxy of oxaloacetate) and citrate (Fig. 4b and c). Analysis of glutamine
consumption indicated decreased uptake in shDJ-1 cells (p-value =
0.057) (Fig. 4d). Moreover, we observed decreased gene expression of
glutaminase 2 (GLS2) (Fig. 4e), suggesting decreased glutamine-based
anaplerosis. To evaluate the importance of glutamine as a carbon source,
we calculated its relative carbon contribution to aKG and citrate
(Fig. 4f). Providing 45% of carbon to aKG in shCtrl, glutamine represents
the major precursor of aKG, highlighting the importance of this amino
acid to central metabolism. In shDJ-1, glutamine carbon contribution
to aKG and citrate was signiﬁcantly lower than in shCtrl, which is in
line with our ﬁnding of decreased glutamine uptake in shDJ-1. Interest-
ingly, we found, that not the contribution of glucose, but that of other
carbon sources increased to compensate for the lack of glutamine.
Therefore, we quantiﬁed the consumption of branched chain amino
acids (BCAAs), because their catabolism produces anaplerotic acetyl-
coA and succinyl-coA. We observed that the uptake of these three
amino acids was indeed elevated in shDJ-1 cells compared to shCtrl
(Fig. 4g).
In conclusion, an increased uptake of BCAAs may compensate for the
decreased glutamine carbon contribution, but does not prevent increased
sensitivity to oxidative stress, which therefore, seems to depend more
speciﬁcally on serine metabolism and the supply of cysteine via the
transsulfuration pathway to generate GSH. Moreover, since glutamine
has additional roles inmetabolism such as to provide nitrogen for the syn-
thesis of nucleotides it is possible that lack of glutamine represents an ad-
ditional perturbation to the cell, which makes it more prone to collapse.
Fig. 4.Metabolic proﬁling of DJ-1 silenced LUHMES cells reveals decreased glutamine inﬂux. (a) Schematic of atom transitions in central metabolism using [U-13C]glutamine as a tracer. 13C
carbons are in green, 12C in black. ACO: aconitase; AT: aminotransferase; CS: citrate synthase; GDH: glutamate dehydrogenase; GLS: glutaminase; GS: glutamine synthetase; IDH: isocitrate
dehydrogenase. The dotted line indicates beginning and end of one cycle. (b–c) Application of [U-13C]glutamine as a tracer in LUHMES cells for determination of MIDs to infer relative
intracellular ﬂuxes. (b) MID of glutamate. (c) Relative abundance of M5 aKG, M4 succinate, M4 fumarate, M4 malate, M4 aspartate and M4 citrate. (d) Glutamine consumption from the
medium. (e) Gene expression of GLS2. (f) Carbon contribution of glucose, glutamine and other carbon sources (%) to aKG and citrate. (g) Branched chain amino acid consumption. Error
bars represent SEM. Asterisks indicate a signiﬁcant difference to the respective shCtrl. (Welch's t-test, p b 0.05; number of biological replicates: n ≥ 3). See also Supplementary Fig. S4.
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2.3. Loss of DJ-1 affects mitochondrial metabolism but does not impair TCA
cycle activity
Loss of DJ-1 is often discussed in the context of mitochondrial dys-
function (Clements et al., 2006; Ariga et al., 2013; Irrcher et al., 2010;
Kahle et al., 2009; Krebiehl et al., 2010), but how, andmore importantly,
to what extent this dysfunction manifests on a pathophysiological level
remains to be further speciﬁed. A strong inhibition of oxidative phos-
phorylation (OxPhos) caused by ROS would be detrimental for persons
carrying a loss of function mutation in DJ-1. To analyze this hypothesis
inmore detail, we inspected TCA cycle activity. In case of OxPhos inhibi-
tion, NADH can no longer be oxidized by complex I of the respiration
chain, which results in an increased NADH/NAD+ ratio. This altered
ratio leads to a thermodynamic shift of IDH activity, resulting in in-
creased reductive carboxylation of aKG (Fendt et al., 2013; Mullen
et al., 2014; Wegner et al., 2015). When using [U-13C5]glutamine as a
tracer, this inhibition manifests in increased relative abundance of M5
citrate isotopologues, while the relative abundance of M4 citrate
isotopologues, decreases (Fig. 5A). To test the effect of OxPhos inhibition
and to compare this effect with themetabolic phenotype of shDJ-1 cells,
we treated the cells withMPP+, an inhibitor of complex I of the electron
transport chain, speciﬁcally taken up by DAergic neurons through the
DA transporter (Javitch et al., 1985; Schildknecht et al., 2015).
UponMPP+ treatment, we observed a signiﬁcant increase in fully la-
beled glutamate and M5 citrate in both cell lines (Fig. 5b, c). As expect-
ed, the oxidative route of the TCA cycle was inhibited upon MPP+
treatment, and therefore, relative abundance of M4 citrate was strongly
reduced. Although reductive IDH ﬂux was induced in MPP+-treated
shDJ-1 cells, M5 labeling of citrate and glutamate was lower in shDJ-1,
originating from decreased relative glutamine inﬂux into the TCA
cycle. This decrease was also reﬂected in higher abundances of unla-
beled citrate and glutamate as well as in lower M3 glutamate (Fig. 5b,
c). Interestingly, compared to shDJ-1, we did not observe a decrease in
M0 citrate upon MPP+ treatment in shCtrl cells (Fig. 5c). To normalize
for the decreased glutamine inﬂux we analyzed the ratio of M5 cit-
rate/M5 glutamate, indicating reductive carboxylation of aKG, M4 cit-
rate/M5 glutamate, indicating glutamine oxidation and M5 citrate/M4
citrate, indicating the ratio of reductively to oxidatively derived citrate
from fully labeled glutamine (Fig. 5d–f). These ratios conﬁrmed a strong
induction of reductive IDH ﬂux uponMPP+-treatment in both cell lines.
However, there was no signiﬁcant difference between the two cell
types.
Fig. 5. DJ-1 silenced LUHMES cells show an active TCA cycle but suffer from decreased glutamine contribution. (a) Schematic of atom transitions in central carbon metabolism using
[U-13C]glutamine as a tracer. Shown is reductive carboxylation of M5 aKG to M5 citrate via IDH and ACO. The speciﬁc isoenzyme depends on the compartment and is not further
considered. For abbreviations see Fig. 4. The dotted line indicates end of one route. In case of complex I inhibition at the electron transport chain (ETC), NADH can no longer be
oxidized which leads to a thermodynamic shift in the IDH reaction. (b–c) Application of [U-13C]glutamine as a tracer in LUHMES cells for determination of MIDs to infer relative
intracellular ﬂuxes. (b) MID of glutamate. (c) MID of citrate. (d–f) Ratios of (d) M5 citrate/M5 glutamate, indicating reductive carboxylation of aKG (e), M4 citrate/M5 glutamate,
indicating oxidation of aKG (f), M5 citrate/M4 citrate, indicating the ratio of reductive to oxidative route. LUHMES shDJ-1 and shCtrl cells were treated with 10 μMMPP+ for 6 h. Error
bars represent SEM. Asterisks indicate a signiﬁcant difference to the respective shCtrl (two-way ANOVA, p b 0.05; number of biological replicates: n= 3).
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Analysis of MPP+ treated LUHMES cells leads to the following three
conclusions: (1) Lack of DJ-1 does not result in inhibition of OxPhos.
Therefore, the general potential to produce ATP via NADH oxidation is
still present in DJ-1 deﬁcient cells. (2) The metabolic fate of glutamine
between the oxidative and the reductive route is not different between
the two cell types uponMPP+ treatment. (3) As a consequence of loss of
DJ-1, glutamine inﬂux into the TCA cycle is decreased. Whether or not
this is solely a result of elevated ROS levels in DJ-1 deﬁcient cells, or if
this is rather a mechanistic consequence, needs to be studied further.
2.4. Loss of Dj-1 affects central metabolism in mouse microglia and is sufﬁ-
cient to trigger pro-inﬂammatory activation
Since neuronal integrity in the central nervous system (CNS) also re-
lies on surrounding glia cells, we investigated the effect ofDj-1 silencing
in the mouse microglia cell line BV-2 (Fig. S5) (Blasi et al., 1990; Henn
et al., 2009).
First, wewere interested if the observedmetabolic alteration in neu-
ronal cells also occurs in microglia. We did not observe signiﬁcantly in-
creased glucose consumption but a 20% increase in lactate release
(Fig. 6a–b). Although glutamine uptake seemed to be decreased in DJ-
1 deﬁcient cells, this difference was not signiﬁcant (Fig. 6c). Stable iso-
tope labeling of glutamine revealed decreased glutamate labeling in
shDJ-1 BV-2 cells (Fig. 6d). However, the difference in isotopic enrich-
ment was not as pronounced as in LUHMES cells and was only signiﬁ-
cantly different in the case of malate, aspartate and glutamate
(Fig. 6e). Overall, proliferating BV-2 cells showed similar alterations
than observed in LUHMES cells but less pronounced.
Recently, it has been reported that loss of Dj-1 leads to increased
pro-inﬂammatory (M1) activation of microglia and astrocytes after per-
turbation with activating compounds such as the toll like receptor
Fig. 6. Dj-1 silencing affects glutamine metabolism in the mouse microglia cell model BV-2 and causes pro-inﬂammatory activation. (a–c) Medium consumption and release rates of
(a) glucose, (b) lactate and (c) glutamine. (d–e) Application of [U-13C]glutamine as a tracer in BV-2 cells for determination of MIDs to infer relative intracellular ﬂuxes. (d) MID of
glutamate. (e) Relative abundance of M4 fumarate, M4 malate, M4 aspartate and M4 citrate. (f–h) Intracellular metabolite levels of itaconate (f), succinate (g) and lactate (h) in BV-2
shDJ-1 cells compared to shCtrl. (i) Gene expression analysis of the inﬂammatory marker genes TNFα, Irg1 and iNOS. (j) Intracellular itaconate levels in shDJ-1 and shCtrl cells. shCtrl
cells were treated for 6 h with LPS. Error bars represent SEM. Asterisks indicate a signiﬁcant difference to the respective shCtrl (Welch's t-test, p b 0.05; number of biological replicates:
n= 3). See also Supplementary Fig. S5.
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agonist LPS or the cytokine IFNγ (Kim et al., 2013; Trudler et al., 2014;
Waak et al., 2009). In this study we wanted to investigate if solely the
lack of Dj-1 is already sufﬁcient to trigger M1 polarization, and thus,
could be relevant in the context of neuroinﬂammation. We analyzed
levels of the metabolic M1 markers succinate and itaconate
(Michelucci et al., 2013; Strelko et al., 2011; Tannahill et al., 2013) as
well as expression of TNFα and iNOS. We observed that a lack of Dj-1
function increased itaconate and succinate levels without an additional
perturbation (Fig. 6f, g, S5). Furthermore, we observed increased intra-
cellular lactate levels, most probably a combined result of both, lack of
Dj-1 and M1 polarization (Fig. 6h).
To validate the activation, we analyzed gene expression levels of the
pro-inﬂammatory marker genes Irg1, iNOS and TNFα. Irg1 codes for the
enzyme (Cad) that catalyzes the synthesis of itaconate from cis-
aconitate (Michelucci et al., 2013; Degrandi, 2009; Hall et al., 2013).
The increased level of itaconate correlates with a more than twofold in-
creased Irg1 gene expression in shDJ-1 compared to shCtrl. Moreover,
we observed that TNFα gene expression was increased twofold and
that iNOS was more than three times higher expressed than in shCtrl
(Fig. 6i). To evaluate, how the detected itaconate level in shDJ-1 cells
correlates with different levels of LPS stimulation, we activated the
shCtrl cells with 0.2 ng, 1 ng and 10 ng of LPS (Fig. 6j). We observed
that shDJ-1 BV-2 microglia constitutively synthesize itaconate amounts
corresponding to an activation of shCtrl cells with approximately 1 ng of
LPS. Since we use 10 ng of LPS tomimic a full activation in vitro, we con-
clude that shDJ-1 cells show a moderate but constitutive activation.
2.5. Loss of DJ-1 leads to a metabolic shift in primary human and murine
immune cells
To validate the observed metabolic alterations in primary cells, we
isolated bone marrow-derived cells of Dj-1 knock-out (KO) mice and
differentiated them into macrophages (BMDMs). Since DJ-1 is ubiqui-
tously expressed (Nagakubo et al., 1997), we expected to ﬁnd the ob-
served metabolic changes also in non-CNS cell types. In line with our
previous results in BV-2 cells, BMDMs of Dj-1 KO mice produced more
lactate (Fig. 7a). Moreover, BMDMs of Dj-1 KO mice consumed signiﬁ-
cantly less glutamine compared to wild type (WT) BMDMs (Fig. 7B).
Additionally, we applied [U-13C]glutamine as a tracer and observed
decreased M5 glutamate fractions in Dj-1 KO cells (Fig. 7c). However,
isotopic enrichment in other TCA cycle related metabolites (Fig. 7d)
was not signiﬁcantly different. Compared to LUHMES cells, these differ-
ences in isotopic enrichment might be caused by fundamental differ-
ences in carbon utilization between the two cell types and/or in a
species-speciﬁcmanner. Although each cell type shows also speciﬁc dif-
ferences, overall, the uptake and release rates of glutamine and lactate
point in the same direction when comparing LUHMES, BV-2 and
BMDM cells. It is not surprising that cell type speciﬁc differences lead
to different metabolic phenotypes. However, it is appealing that loss of
DJ-1 shows a similar picture in these various cell types.
To further validate our ﬁndings, we were interested in analyzing
human samples directly originating from patients carrying a DJ-1muta-
tion. We analyzed cellular metabolism of peripheral blood derived
mononuclear cells (PBMCs)-derived CD14+macrophages from four pa-
tients carrying homozygous and heterozygous loss of function muta-
tions (c.192G N C) in the DJ-1 gene (Hering et al., 2004). PBMCs are
relatively easy to access and could therefore be used as a model in sub-
sequent clinical trials. As controls, we analyzed three independent
healthy controls.We applied [U-13C]glucose to provide ﬂux information
for both, glycolysis and TCA cycle. Analysis of isotopic enrichment re-
vealed that serine biosynthesis in CD14+ macrophages was close to
zero (Fig. S6a). However, the labeling pattern of glutamate showed in-
creased relative abundance of M2 isotopologues in patient-derived
macrophages carrying a DJ-1 mutation (Fig. 7e, f, S6b), indicating in-
creased relative glucose carbon contribution to the TCA cycle and to glu-
tamate. This increase can be a consequence of lower glutamine inﬂux,
resulting in higher relative 13C labeling from glucose. We also observed
a relative increase of M2 glutamate in LUHMES shDJ-1 cells compared to
shCtrl (Fig. S6c).
In summary, the analysis of human PBMCs indicated that metabolic
changes initially observed in a cellular model of the CNS might be diag-
nosed from patient-derived primary blood cells. Further analyses will
clarify if the observed ﬂux changes are common for this mutation and
if heterozygous patients show gene-dose dependent effects.
3. Discussion
In this study, we analyzed the metabolic impact of loss of DJ-1. We
demonstrated that loss of DJ-1 affects central metabolism, speciﬁcally
leading to (1) decreased glutamine uptake and decreased glutamine
contribution to the TCA cycle, (2) decreased serine biosynthesis, (3) in-
creased sensitivity to ROS and (4) weakly, but constitutively activated
microglia. These metabolic alterations coincide with decreased cell sur-
vival upon oxidative stress, which may promote early onset of PD. We
speculate that these changes are caused by increased sensitivity to
ROS as a direct result of loss of DJ-1. Unlike cancer cells, we did not de-
tect NRF2 protein in LUHMES wild type cells which leads us to the as-
sumption that DJ-1 has a more fundamental role in neurons,
compared to cancer cells, where NRF2 as a regulator of antioxidant re-
sponses is highly abundant (Clements et al., 2006).We conclude that in-
sufﬁcient ROS quenching in DJ-1 deﬁcient neurons is due to decreased
GSH levels as well as decreased activity of NADP-reducing enzymes
within central metabolism. In line, we observed decreased expression
ofG6PDH, the rate-limiting enzyme of the PPP anddecreased expression
of MTHFD1 and 2, enzymes of the folate cycle and an alternative route
for the generation of NADPH.Moreover, wemeasured decreased GR ex-
pression, which is in line with the lower GSH levels and an increased
GSSG/GSH ratio upon hydrogen peroxide stress. In conclusion, loss of
DJ-1 affects all pathways needed for GSH homeostasis.
DJ-1 has been shown to activate the expression of glutamate cyste-
ine ligase, a key enzyme of GSH synthesis (Zhou and Freed, 2005). How-
ever, based on our gene expression analysis, GCLC andGCLMexpression
was not altered, at least not in LUHMES cells (Fig. S3g, h). We suggest
that decreased levels of the rate limiting amino acid cysteine provoke
the drop in GSH abundance by altering the net ﬂux towards GSH
(Richman and Meister, 1975; Lu, 2013).
Serine can act as a precursor for cysteine and glycine and serves at
the same time as a carbon donor for folate-mediated one-carbonmetab-
olism, which has recently been appreciated for its importance in main-
taining the cellular NADPH pool (Fan et al., 2014). 5,10-methylene-THF
can be oxidized by the NADP-dependent enzymeMTHFD.We observed
a moderate, but signiﬁcantly decreased expression of cytosolicMTHFD1
and a more strongly decreased expression of mitochondrial MTHFD2.
Together with glutamate, cysteine and glycine are the building blocks
for de novo glutathione synthesis. We have demonstrated before that
enzymes of serine and folate metabolism as well as the transsulfuration
pathway are induced in human neurons upon oxidative stress (Krug
et al., 2014). Intriguingly, in the DJ-1 knock-out model, that shows ele-
vated levels of oxidative stress, we observed that serine biosynthesis is
decreased and expression of bothMTHFD1 and 2 are reduced. Therefore,
DJ-1 is likely to have an important regulatory function in serine and fo-
latemetabolism by supporting NADPH and GSH homeostasis. This is es-
pecially pronounced due to our observation of no detectable protein
levels of NRF2 in post-mitotic neuronal cells. However, we do not ex-
clude the possibility that in vivo, neurons are supported by NRF2 medi-
ated protectivemechanisms that are derived from surrounding glia cells
(Kraft et al., 2004).
The third building block of GSH is glutamate, directly derived from
glutamine via glutaminase. We showed that shDJ-1 cells exhibit de-
creasedGLS2 expression and lower glutamine inﬂux. The decreased glu-
tamine inﬂux is furthermore reﬂected in decreased alanine release,
suggesting lower glutamine derived anaplerotic reactions. When less
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glutamate enters the TCA cycle, less nitrogen has to be disposed from
the cell. Previous work in cancer cell models demonstrated that a
knock-down of GLS2 results in decreased GSH levels and increased oxi-
dative stress (Suzuki et al., 2010; Hu et al., 2010). However, Richman
and Meister showed that not glutamate but cysteine is rate limiting to
GSH synthesis (Richman and Meister, 1975). Therefore, we believe
that serine and the adjacent transsulfuration pathwayplay an important
role for the generation of GSH. On top of serine metabolism, decreased
Fig. 7. Stable isotope labeling of BMDMs ofDj-1KOmice and PBMCs-derived CD14+macrophages ofDJ-1 patients indicate decreased glutamine contribution to the TCA cycle. (a) Relative
lactate release of BMDMs. (b) Relative glutamine consumption of BMDMs. (c) MID of glutamate in BMDMs after application of [U-13C]glutamine. (d) Relative abundance of M4 succinate,
M4 fumarate, M4 malate, M4 aspartate and M4 citrate in BMDMs. Error bars represent SEM. Asterisks indicate a signiﬁcant difference to the respective shCtrl (Welch's t-test, p b 0.05;
number of biological replicates: n = 5). (e) Schematic of atom transitions in central carbon metabolism using [U-13C]glucose. Illustrated is how M2 glutamate is generated from
[U-13C]glucose. The dotted line indicates end of one route. (f) Glutamate M2 isotopologue abundance of DJ-1 subjects and non-familial healthy controls (Ctrl). Error bars represent
SEM. The asterisk indicates a signiﬁcant difference to the control (Welch's t-test, p b 0.05; number of individuals: n ≥ 3). (g)Model highlighting the functional role of DJ-1 and summarizing
the affectedmetabolic pathways as a result of DJ-1 deﬁciency. Affectedmetabolites, enzymes or pathways are highlightedwith a red star. Loss of DJ-1 leads to decreased glutamine inﬂux,
decreased serine biosynthesis and decreased MTHFD expression, needed for glutathione (GSH) homeostasis and antioxidant response. Due to lower GSH levels, DJ-1 deﬁcient cells show
increased sensitivity to ROS. Additionally, lower expression ofMTHFD and G6PDH suggests decreased potential to generate NADPH, needed for the reduction of GSSG. In cancer cells, DJ-1
acts as a repressor of PTEN, a negative regulator of AKT. Activated AKT can activate mTORC1. Both AKT and mTOR are important to drive metabolic processes needed for cell survival and
proliferation, among others, glutaminolysis (for further explanation see discussion). Additionally, the transcription factor p53 can act as an activator on PTEN, thereby antagonizing DJ-1
function.Moreover, p53 can repressmTORand introduces apoptosis. However, the relevance of these potential nodes of themetabolic networkhas to be further validated inneuronal cells.
See also Supplementary Fig. S6.
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expression of GLS2 and lower glutamine inﬂux adds an additional per-
turbation to the cell system, which ultimately triggers the observed
physiological effects (Fig. 7g). The defect present in shDJ-1 cells might
not only be the result of elevated oxidative stress levels, but DJ-1
might play a role in additional processes. A possible role could be related
to the described inhibitory function on PTEN (Kim et al., 2005). When
DJ-1 is absent, AKT becomes hypophosphorylated (Aleyasin et al.,
2010; Yang et al., 2005) and mTOR, a master regulator of anaplerosis,
proliferation and cell survival, becomes less active, which could also
favor the activity of p53. The transcription factor p53 is activated upon
oxidative stress and can induce apoptosis (Vousden and Ryan, 2009).
The role of these fundamental metabolic mechanisms is also relevant
during neurogenesis (Rafalski and Brunet, 2011; Vasseur et al., 2009).
However, the mechanistic link between DJ-1 and PTEN in regulating
the AKT pathway is derived from cancer cells (Kim et al., 2005) and
needs additional validation in post-mitotic neurons. Also the interplay
between p53 and DJ-1 as well as the role of p53 in activating PTEN in
neuronal non-proliferating cells needs additional research to gain a
deeper understanding of the metabolic processes that are in place. An-
other potential link to the mTOR pathway is based on the work by
Durán and colleagues (2012) who demonstrated that Rag-mTORC1 sig-
naling is directly regulated by glutaminolysis and that a lack of gluta-
mine results in less mTORC1 phosphorylation and less downstream
activationwithout affecting ATP production (Durán et al., 2012). No dif-
ference in ATP production is also in line with our own results indicating
functional OxPhos, a major pathway for ATP production, especially in
neuronal cells. However, given the example of NRF2 abundance in
LUHMES versus A549 lung cancer cells (Fig. S3f), comparisonswith pro-
liferating cancer cells should be interpreted carefully, since post-mitotic
cells have very different metabolic requirements.
An apparent difference was also reﬂected by the lactate release in
LUHMES cells and proliferating, immortalizedBV-2 cells. In proliferating
cells, increased ROS levels, as present in shDJ-1 cells, can regulate PKM2
and enhance the Warburg effect. In its metabolically active form PKM2
acts as a tetramer. However, at increased ROS levels, PKM2 is post-
translationally modiﬁed, stabilizing its dimeric or monomeric form
(Anastasiou et al., 2011; Gupta and Bamezai, 2010; Lyssiotis et al.,
2012). In this form, PKM2 translocates to the nucleus and inﬂuences
transcriptional regulation to increase lactate release. In contrast to pro-
liferating cells, post-mitotic neurons express theM1 isoformof pyruvate
kinase (Tolle et al., 1976), which is less regulated (Anastasiou et al.,
2012; Chaneton et al., 2012). This explains why we did not observe an
increase in lactate fermentation in LUHMES cells, but increased lactate
release in the proliferating (PKM2 expressing) BV-2 cells.
The reduction of glutamine inﬂux after loss of DJ-1 was weaker in
BV-2 cells than in post-mitotic LUHMES cells because BV-2 cells are im-
mortalized with v-myc/ras (Blasi et al., 1990), which reprograms cellu-
lar metabolism to drive proliferation. A dependency of cancerous and
proliferating cells on glutamine is well known (Wise and Thompson,
2010). Moreover, DJ-1 has been shown to activate ERK signaling, pro-
moting cellular protection against oxidative stress (Gu et al., 2009).
For that reason, immortalization with v-myc, an upstream regulator of
ERK1/2 and AKT, mightmask underlyingmetabolic defects by artiﬁcial-
ly activating the ERK pathway in DJ-1 deﬁcient cells. Thus, the observed
decreased glutamine inﬂux and the known increased activation of PTEN
due to lack of DJ-1 is at least partially overwritten in immortalized BV-2
cells, leading to re-elevated glutamine uptake. In differentiated LUHMES
cells, v-myc expression is absent and is therefore notmasking decreased
glutamine inﬂux (Scholz et al., 2011). Therefore, themetabolic dysfunc-
tion in differentiated, post-mitotic neurons is more pronounced and
represents a clearer phenotype compared to BV-2 cells.
Besides the described effects in neurons, DJ-1 has been shown to
play a role in inﬂammation by regulating cytokine expression and by
interacting with STAT1 signaling (Kim et al., 2013; Trudler et al., 2014;
Waak et al., 2009). Here, we demonstrated that solely the loss of DJ-1 re-
sults in weakly activated microglia. A constitutive, strong activation
would cause immediate detrimental effects in a multicellular environ-
ment. However, a weak activation could be tolerated over a longer peri-
od of time (e.g. several years or decades) but would represent an
additional trigger for PD, increasing the sensitivity of DAergic neurons
over the course of life.
A metabolic reprogramming of immune cells upon M1 polarization
has recently been described (Tannahill et al., 2013; Palsson-McDermott
et al., 2015). M1 polarization in immune cells has been shown to induce
a Warburg-like metabolic phenotype. A PKM2-mediated regulation in
macrophages is possible (Palsson-McDermott et al., 2015). M1 polarized
macrophages increase their rate of glycolysis and increase lactate release.
In the case of loss of DJ-1, this is an additive effect and explains why the
increase in lactate release is more pronounced in BV-2 cells compared
to neurons. The metabolic adaptation to inﬂammation also includes in-
creased glutamine oxidation in the TCA cycle (Tannahill et al., 2013).
Therefore, decreased GLS2 activity in immune cells as a result of DJ-1 de-
ﬁciency can at least be partially overwritten by inﬂammatory activation
and immortalization.
Although TH+-neurons do not proliferate, cellular survival and anti-
oxidant response is even more important since these cells are mostly
matured during embryogenesis and need to be functional over the
whole life span to supply sufﬁcient dopamine to the striatum. Increased
oxidative stress during development can result in a lower absolute
number of dopaminergic neurons in the midbrain (Pham et al., 2010).
In conclusion, it becomes evident that as opposed to cancer therapy,
where SHMT2 ampliﬁcation drives oncogenesis (Kim et al., 2015; Lee
et al., 2014) and where a decrease of glutamine uptake is a strategy to
stop cell proliferation, a lack of glutamine inﬂux and decreased serine
biosynthesis ﬂux seem to be part of the underlying metabolic problem
in PD patients carrying a loss of function mutation in DJ-1.
4. Methods
4.1. Cell culture
Cells were standardwise tested for mycoplasma contamination in a
rhythm of four to eight weeks.
4.2. LUHMES
Cells were kindly provided by the lab of Marcel Leist. Cells were
grown in proliferation medium (Advanced DMEM/F12 + 1xN2 supple-
ment (Invitrogen), 40 ng/ml FGF-2 and 2 mM glutamine) at 37 °C and
5% CO2. Further cultivation and differentiation was performed as de-
scribed in (Krug et al., 2014). For isotopic labeling, medium was re-
placed by differentiation medium containing 2 mM [U-13C5]glutamine
or 17.5 mM [U-13C6]glucose. Cells were extracted at metabolic and iso-
topic steady state (42 h after labeling start). All experiments were per-
formed with differentiated post-mitotic cells.
4.3. BV-2
Cells were kindly provided by the lab of WolfgangWurst. Cells were
grown in DMEM (D5796) (Invitrogen) containing 5 mM glutamine,
25 mM glucose, 10% FBS and 1% P/S at 37 °C and 5% CO2. For isotopic la-
beling medium was replaced by the same medium containing 5 mM
[U-13C]glutamine or 25 mM [U-13C]glucose and dialysed FBS. Cells
were extracted at metabolic and isotopic steady state (24 h after label-
ing start).
4.4. Extraction of intracellular metabolites
Cells were cultivated in 12-well plates andwashedwith 1ml of 0.9%
NaCl and quenchedwith 0.2ml−20 °Cmethanol. After adding an equal
volume of 4 °C cold water, cells were collected with a cell scraper and
transferred to tubes containing 0.2 ml−20 °C chloroform. The extracts
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were shaken at 1400 rpm for 20 min at 4 °C (Thermomixer Eppendorf)
and centrifuged at 16,000 ×g for 5min at 4 °C. 0.2ml of the upper aque-
ous phase was collected in speciﬁc glass vials with micro inserts and
evaporated under vacuum at−4 °C using a refrigerated CentriVap Con-
centrator (Labconco).
4.5. Liquid chromatography–tandem mass spectrometry to measure GSH
and GSSG
Cells were cultured in 12-well plates (500,000 cells per well) and
washed once with 1× PBS before adding 40 μl of 5% TCA, followed by
an equal volume of cold H2O. 2 wells were pooled for one sample to in-
crease abundance of GSSG in the sample. Cells were scraped, transferred
into 1.5 ml Eppendorf tubes and centrifuged for 5 min at 13,000 ×g at
4 °C. Supernatant was transferred into LC–MS glass vials with insert
and stored at−80 °C until measurement. Measurementwas performed
using an Agilent 1290 Series LC coupled to an Agilent 6550 iFunnel Q-
TOF MS system equipped with a Dual Agilent Jet Stream ESI source.
The columns used in this study were a Waters ACQUITY UPLC HSS T3
1.8 μm (length, I.D., particle size: 100 mm × 2.1 mm × 1.8 μm) and a
Phenomenex Kinetex 2.6 μm C18 100 A (length, I.D., particle size:
150 mm × 2.1 mm × 2.6 μm). The autosampler was kept at 4 °C and
the column compartment at constant temperature of 45 °C. The LC con-
ditions were optimized to achieve the best chromatographic parame-
ters for both analytes. The ﬂow rate was set to 0.3 ml/min and the
mobile phases consisted of 0.1% formic acid in water (eluent A) and
0.1% formic acid in 60% methanol (eluent B). The run consisted of a
isocratic delivery of 1% eluent B over 10min, followed by a linear gradi-
ent to 99% eluent B over 2 min, isocratic delivery of 99% eluent B for
7 min, and a re-equilibration phase on starting conditions with 1% elu-
ent B for 5 min. The eluent from the column was only introduced into
the mass spectrometer within the ﬁrst 10 min. The injection volume
was 20 μl.
All the MS experiments were performed using electrospray ioniza-
tion in positive mode (+ESI).
The identity of both GSH and GSSH were conﬁrmed by MS/MS and
standard addition experiments. Full scan spectra were acquired from
m/z 150…1000 (1 spectra/s).
The protonatedmolecules of both GSH and GSSGweremonitored in
high resolution mode with following Q-TOF MS conditions: drying gas
temperature: 225 °C, drying gas ﬂow: 14 l/min (nitrogen), nebulizer:
35 psig, sheath gas temperature: 350 °C, sheath gas ﬂow: 11 l/min,
fragmentor: 400 V, skimmer: 65 V, Oct. RF Vpp: 750 V.
All data were acquired with Agilent MassHunter Workstation Soft-
ware, version B.05.01 and analyzed with Agilent Qualitative Analysis,
version B.06.00. Signal intensities were normalized to cell number.
4.6. Gas chromatography–mass spectrometry
Metabolite derivatization was performed using a Gerstel MPS. Dried
polar metabolites were dissolved in 15 μl of 2% methoxyamine hydro-
chloride in pyridine at 40 °C under shaking. After 60 min an equal vol-
ume of MTBSTFA was added and held for 60 min at 40 °C. 1 μl sample
was injected into an SSL injector at 270 °C in splitlessmode. GC/MS anal-
ysis was performed using an Agilent 7890A GC equipped with a 30 m
DB-35MS + 5 m Duraguard capillary column. Helium was used as car-
rier gas at a ﬂow rate of 1.0 ml/min. The GC oven temperature was
held at 100 °C for 2 min and increased to 300 °C at 10 °C/min. After
3 min, the temperature was increased to 325 °C. The GC was connected
to anAgilent 5975C inert XLMSD, operating under electron ionization at
70 eV. The MS source was held at 230 °C and the quadrupole at 150 °C.
The MS was operated in selected ion monitoring (SIM) (Table S1). The
total run time of one sample was 25.00 min. All GC/MS chromatograms
were processed by using MetaboliteDetector. MIDs were determined
and corrected for natural isotope abundance using MetaboliteDetector
(Hiller et al., 2009).
In case of absolute quantiﬁcation ofmetabolites, a dilution series of a
standardmix containing all relevantmetaboliteswas included in the se-
quence and measured in duplicates.
Measurement of glucose and pyruvate intensities was performed by
derivatization with an equal volume of MSTFA (instead of MTBSTFA)
and held for 30 min at 40 °C under continuous shaking. 1 μl sample
was injected into an SSL injector at 270 °C in split 10 mode. GC oven
temperature was held at 90 °C for 1 min and increased to 300 °C at
15 °C/min for 8 min to 320 °C. The total run time of one sample was
24.3 min.
4.7. Quantiﬁcation of amino acids
Quantiﬁcation of amino acids was performed on an Agilent 1100
HPLC System equipped with a Diode Array Detector. Separation was
carried out on a ZORBAX Amino Acid Analysis Column (150 × 4.6 mm,
5 μm) with a preceding ZORBAX Amino Acid Analysis Guard Cartridge
(Agilent Technologies, Santa Clara, CA, USA) at 40 °C in gradient mode.
The eluents used were 40 mM Na2HPO4 (pH 7.8, eluent A) and a mix-
ture of Acetonitrile, Methanol andWater (45:45:10, eluent B). 0.02% so-
dium azidewas added to eluent A to preventmicrobial growth. Primary
amines were automatically derivatized with ortho-phthalaldehyde
(OPA) in borate buffer (0.4 N in water, pH 10.2) and diluted in eluent
A prior to injection. The resulting OPA-derivatives were subsequently
detected at 338 nm (10 nm bandwidth — reference wavelength:
390 nm, 20 nm bandwidth). All medium samples were diluted 1:1
with the internal standard L-2-aminobutyric acid (ﬁnal concentration:
300 μM) to correct for deviations resulting from the derivatization-
process. External calibration standards as well as reference media with
known concentrations were measured with every run to determine
sample concentrations and ensure stability of the analysis. Gradient
proﬁle: 1.9 min: 0% eluent B; 18.1 min: 57% eluent B; 18.6min: 100% el-
uent B; 22.3 min: 100% eluent B; 23.2 min: 0% eluent B; 26min: 0% elu-
ent B.
4.8. cDNA synthesis and gene expression analysis
cDNA synthesis and qPCR was performed as previously described
(Michelucci et al., 2013). Brieﬂy, RNA was isolated from the interphase
after extraction of metabolites, using the Quiagen RNAeasy Mini Kit.
0.5–1 μg RNA was used for cDNA synthesis using SuperScript III
(Invitrogen), following the manufacturer's instructions. qPCR was per-
formed using iQ SYBR Green Supermix (Bio-Rad) as manufacturer's in-
structions. PCR was carried out on a Light Cycler 480 (Roche). Data
analysiswasperformedusing the Roche analysis software. Gene expres-
sion was normalized to the housekeeping gene L27. Primer sequences
are summarized in Table S2.
4.9. Lentivirus mediated shRNA gene silencing
For gene silencing of LUHMES cells, the destination vectors contain-
ing shRNA were ordered from Thermo Scientiﬁc (http://www.
thermoscientiﬁcbio.com). Plasmids were ampliﬁed and puriﬁed by
maxiprep in Escherichia coli and subsequently used for virus production
in HEK298FT cells according to the manufacturer's protocol. Harvested
virus was ﬁltered using a 45 μM ﬁlter and precipitated with 1/5 volume
of sterile PEG10000 over night at 4 °C. Concentrated virus was aliquoted
in 10 μl and stored at −80 °C. For virus transduction 10 μl virus was
added to 50,000 cells on day 1 and day 2. After medium change on
day 3 cells were selected using 200 ng/ml puromycin. Correct concen-
tration of puromycin was evaluated by a kill curve.
4.10. Western blot
For preparation of whole cell extract, 1 × 106 cells were harvested,
washed with ice cold 1× PBS (Invitrogen/Life Technologies Europe BV
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Belgium), lyzed in 1×M-PER®, Mammalian Protein Extraction Reagent
(Thermo Scientiﬁc, Belgium) completed with 1× protease inhibitor
cocktail (Complete®, Roche, Luxembourg) and further processed ac-
cording to manufactures instructons. Bradford assay was used to mea-
sure the protein concentration (Bio-Rad Protein Assay Dye Reagent,
Bio-Rad, Belgium). Proteins were separated by size using sodium dode-
cyl sulfate polyacrylamide gel elegrophoresis (SDS-PAGE, 15%) and
transferred to an Immobilon-FL PVDF membrane (Merck Millipore)
using the Mini-PROTEAN Tetra Cell and PowerPac Basic Power Supply
(Bio-Rad, Belgium). The membrane was blocked in 5% non-fat milk in
phosphate buffered saline (PBS)-Tween for 1 h at room temperature.
Blots were incubated with primary antibodies: anti DJ-1 XP® Rabbit
mAb (D29E5) (CellSignaling, Bioke, Netherlands) in 5% BSA in PBS-T
(1:1000) for 1 h at room temperature. After incubation with primary
antibody, membrane was washed with PBS-T and incubated for 1 h
at room temperature with anti rabbit-HRP secondary antibody
(1:10,000). For equal loading control of samples monoclonal anti-
GAPDH-HRP (mouse) antibody (G9295, Sigma, Belgium), was probed
in 5% non-fat milk in PBS-T for 1 h at room temperature. Visualization
was done using the ECL Plus Western Blotting Detection System Kit
(GE Healthcare, Netherlands).
4.11. Cell viability assay
Cell viability was assayed using Resazurin (Sigma Aldrich, R7017)
(O'Brien et al., 2000). Brieﬂy, resazurin, blue and non-ﬂuorescent, is re-
duced to resoruﬁn, pink and ﬂuorescent, proportionally to the number
of living cells. After 1 h incubationwith 5 μg/ml resazurin (spiked inme-
dium), ﬂuorescence was measured with a Biotek Synergy Mx micro-
plate reader coupled to the Gen5 software at the excitation
wavelength of 570 nm and emission at 590 nm.
4.12. Cell imaging
Predifferentiated LUHMES cells were seeded at a density of 60 k cells/
well in 96-well plates. After 96 h the cells were post-mitotic and had
formed strongly connected networks. One hour prior to imaging experi-
ments, thewells were carefullywashed and ﬁlledwith 100 μl fresh differ-
entiation medium supplemented with 25 nM tetramethylrhodamine
(TMRM) to ﬂuorescently stain mitochondria. Plates were then incubated
for 30 min at 37 °C, 5% CO2, whereafter the medium was replaced by
TMRM-free solution. Plates were kept for further 30 min at 37 °C, 5%
CO2. Time-lapse images were acquired on a Nikon Ti Eclipse inverted mi-
croscope with motorized stage (Nikon Corporation, Tokyo, Japan) and
high intensity mercury short arc lamp with monochromator (Cairn Re-
search, Kent, UK) enclosed in a bench top incubator. Fluorescence excita-
tion ﬁlter was 540/15 and emission ﬁlter 620/60. Automatic microscope
control, stage programming and acquisitionwere done using OptoMorph
(Cairn Research, Kent, UK).
Two types of experiments were performed: i) longitudinal acquisi-
tion of a single well with one image taken every 2 s for 20 min, and ii)
comparative parallel acquisition by switching between two neighboring
wells using the motorized stage and taking images every 5 s for 30min.
Imaged wells were supplemented with 200 μM 6-OHDA or pure water
for control after 5 min. Images were taken using a 20× air objective
and an EXi Blue camera (Qimaging, Surrey, BC) with an exposure time
of 350 ms and saved as 16-bit grayscale TIFFs in 1392 × 1040 px.
4.13. Global motion analysis
Global motion by particle image velocimetry (PIV) was analyzed,
which quantiﬁes correlations between pairs of time-lapse images and
infers velocities of the image elements that give rise to differences. Mi-
croscopy imageswere contrast-normalized and converted to 8-bit gray-
scale using ImageMagick. Particle image velocimetry was performed
using the OpenPIV toolbox (Taylor et al., 2010) in sliding windows of
16 × 16 px with 8 px overlap in both vertical and horizontal direction.
Statistical analysis of resulting velocity ﬁelds and visualization of results
wasdone inGNUR. Globalmotionwas quantiﬁed by calculatingmedian
velocities over sliding windows spanning six acquisition frames to re-
duce impulse noise corruption from imaging artifacts. Average motion
was assessed in acquisition windows 1 to 100 (pre-treatment) and
401 to 500 (post-treatment) for longitudinal measurements as well as
1 to 40 (pre-treatment) and 301 to 340 (post treatment) for parallel
measurements. Signiﬁcance of difference in motility reduction was
assessed by pooling average velocities before and after treatment from
all time-lapse experiments (n= 3) and performing Student's t-test on
relative velocities, i.e., normalized to untreated control. Propagation of
uncertainty when normalizing velocities was taken into account.
4.14. BMDM isolation, cultivation and differentiation
4.14.1. Animals
For bone marrow-derived macrophages cultures, C57BL/6 DJ-1 KO
and age-matched C57BL/6 WT mice were obtained from the Helmholtz
Zentrum München (Germany) from Dr. Daniela Vogt-Weisenhorn and
Prof. Dr. Wolfgang Wurst. Per group, 5 mice were analyzed and from
each mouse three independent samples were obtained. All animal
work in Munichwas carried out in accordance with the European Com-
munities' Council Directive 2010/63/EU. All efforts were made to mini-
mize animal suffering during the work. All protocols involving animal
handling were approved by the committee for the Care and Use of Lab-
oratory animals of the Government of Upper Bavaria, Germany. C57BL/6
mice (obtained from Charles River Germany) were group housed in in-
dividually ventilated type IIL cages (fourmice per cage) andmaintained
on a 12 h/12 h light/dark cycle with food andwater available ad libitum.
All animal procedures in Luxembourg, such as handling and euthanasia,
have been performed according to the Federation of European Laborato-
ry Animal Science Associations (FELASA) guidelines for the use of
animals in research, and were institutionally approved by the
Luxembourg Centre for System Biomedicine animal user committee
and authorized by the local governmental agencies (Ministry of Health,
Ministry of Agriculture, chief veterinarian of the Luxembourg
government).
4.14.2. Bone marrow-derived macrophages
Mice were deeply anesthetized by intraperitoneal injection of
50 mg/kg of ketamine hydrochloride and 5 mg/kg xylazine hydrochlo-
ride and bone marrows were isolated and cultured as previously de-
scribed by Zhang and colleagues (Zhang et al., 2008). Brieﬂy, bone
marrow was ﬂushed from femurs and tibias of ﬁve C57BL/6 DJ-1 KO
and ﬁve age-matched C57BL/6 WT mice and the resultant cell suspen-
sion was passed through a 70 μm ﬁlter (Greiner Bio-One). After a
10 min centrifugation step at 250 ×g, supernatant was discarded and
pellet re-suspended in 2 ml hypotonic solution (170 mM NH4Cl) for
5 min to allow lysis of any remaining extracellular red blood cells.
Bone marrow-derived cells were ﬁnally plated in 12-well plates
(Greiner Bio-One) at 5 × 105 cells per well. Cells were cultured for
6 days in complete macrophage medium (Dulbecco modiﬁed Eagle's
minimal essential medium DMEM) (Invitrogen) supplemented with
10% fetal bovine serum (FBS) (Invitrogen), 20% conditioned medium
from macrophage-colony stimulating factor-secreting L929 ﬁbroblasts
and 1% penicillin/streptomycin (Invitrogen) at 37 °C. After 6 days in cul-
ture, adherent cells were approximately 95% pure macrophages and
cells were used for experiments. Stable isotope tracers were added for
24 h prior extraction of intracellular metabolites.
Per genotype 5 individualmicewere sacriﬁced and fromeachmouse
three replicates of BMDMs were used for the analysis.
4.14.3. PBMC derived CD14+ macrophages
The fourDJ-1 patientswere brothers of one family (onehomozygous
and three heterozygous). The samples were analyzed in a blinded
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study; patient samples were given numbers and were identiﬁed after
the results were completely analyzed. The controls were non-family
members with different genetic background (two male, one genotype
unknown (blood donation from the red cross)). The CD14+ cells were
isolated by a positive selection method using the magnetic activated
cell sorting (MACS) method: Blood samples of the patients were sepa-
rated in 50ml Leucosept tubes (Greiner) through Ficoll-Paque Premium
(GEHealthcare) density gradient centrifugation (1000×g) for 10min at
room temperature, using no break. After 30min incubation at 4 °C with
2 μl of CD14+ beads (Miltenyi biotech) per 107 PBMCs, the CD14+ cells
got puriﬁed using a positive LS column (Miltenyi Biotech). The puriﬁed
CD14+ cells were incubated for 24 h at 37 °C and 5% CO2 in DMEM
D5030 medium (Sigma) containing 11 mM [U-13C6]glucose and 5 mM
glutamine for metabolite extraction. Cells were extracted at metabolic
and isotopic steady state (24 h after labeling start, (tested before with
other blood donations)). Heterozygous and homozygous patients
were male, two healthy controls were male, the status of the third
healthy control is unknown (blood donation of the red cross).
4.14.4. Statistical analyses
To analyze a signiﬁcant difference between two groups, theWelch's
t-test or two-way ANOVAwas applied. The level of p b 0.05was consid-
ered as signiﬁcant different. Signiﬁcance of difference in motility reduc-
tion was assessed by pooling average velocities before and after
treatment from all time-lapse experiments (n = 3) and performing
Student's t-test on relative velocities, i.e., normalized to untreated con-
trol. Propagation of uncertainty when normalizing velocities was
taken into account.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.nbd.2016.01.019.
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